Inducible	O
resistance	O
to	O
Fas-mediated	O
apoptosis	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Apoptosis	O
produced	O
in	O
B	B-cell_type
cells	I-cell_type
through	O
Fas	B-protein
(	O
APO-1	B-protein
,	O
CD95	B-protein
)	O
triggering	O
is	O
regulated	O
by	O
signals	O
derived	O
from	O
other	O
surface	O
receptors	O
:	O
CD40	O
engagement	O
produces	O
upregulation	O
of	O
Fas	B-protein
expression	O
and	O
marked	O
susceptibility	O
to	O
Fas	B-protein
-induced	O
cell	O
death	O
,	O
whereas	O
antigen	O
receptor	O
engagement	O
,	O
or	O
IL-4R	O
engagement	O
,	O
inhibits	O
Fas	B-protein
killing	O
and	O
in	O
so	O
doing	O
induces	O
a	O
state	O
of	O
Fas	B-protein
-resistance	O
,	O
even	O
in	O
otherwise	O
sensitive	O
,	O
CD40	B-protein
-stimulated	O
targets	O
.	O

Surface	B-protein
immunoglobulin	I-protein
and	O
IL-4R	B-protein
utilize	O
at	O
least	O
partially	O
distinct	O
pathways	O
to	O
produce	O
Fas	B-protein
-resistance	O
that	O
differentially	O
depend	O
on	O
PKC	B-protein
and	O
STAT6	B-protein
,	O
respectively	O
.	O

Further	O
,	O
surface	O
immunoglobulin	O
signaling	O
for	O
inducible	O
Fas	B-protein
-resistance	O
bypasses	O
Btk	B-protein
,	O
requires	O
NF-kappaB	B-protein
,	O
and	O
entails	O
new	O
macromolecular	O
synthesis	O
.	O

Terminal	O
effectors	O
of	O
B	B-cell_type
cell	I-cell_type
Fas	B-protein
-resistance	O
include	O
the	O
known	O
anti-apoptotic	B-protein
gene	I-protein
products	I-protein
,	O
Bcl-xL	B-protein
and	O
FLIP	B-protein
,	O
and	O
a	O
novel	O
anti-apoptotic	B-DNA
gene	I-DNA
that	O
encodes	O
FAIM	B-protein
(	O
Fas	B-protein
Apoptosis	I-protein
Inhibitory	I-protein
Molecule	I-protein
)	O
.	O

faim	B-protein
was	O
identified	O
by	O
differential	O
display	O
and	O
exists	O
in	O
two	O
alternatively	O
spliced	O
forms	O
;	O
faim-S	B-protein
is	O
broadly	O
expressed	O
,	O
but	O
faim-L	O
expression	O
is	O
tissue-specific	O
.	O

The	O
FAIM	B-DNA
sequence	I-DNA
is	O
highly	O
evolu-	O
tionarily	O
conserved	O
,	O
suggesting	O
an	O
important	O
role	O
for	O
this	O
molecule	O
throughout	O
phylogeny	O
.	O

Inducible	O
resistance	O
to	O
Fas	B-protein
killing	O
is	O
hypothesized	O
to	O
protect	O
foreign	O
antigen-specific	O
B	B-cell_type
cells	I-cell_type
during	O
potentially	O
hazardous	O
interactions	O
with	O
FasL-bearing	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
whereas	O
autoreactive	B-cell_type
B	I-cell_type
cells	I-cell_type
fail	O
to	O
become	O
Fas	B-protein
-resistant	O
and	O
are	O
deleted	O
via	O
Fas	B-protein
-dependent	O
cytotoxicity	O
.	O

Inadvertent	O
or	O
aberrant	O
acquisition	O
of	O
Fas	B-protein
-resistance	O
may	O
permit	O
autoreactive	B-cell_type
B	I-cell_type
cells	I-cell_type
to	O
escape	O
Fas	B-protein
deletion	O
,	O
and	O
malignant	B-cell_type
lymphocytes	I-cell_type
to	O
impede	O
anti-tumor	O
immunity	O
.	O

REVIEW	NULL
Cell	NULL
Research	NULL
(	NULL
2000	NULL
)	NULL
,	NULL
10	NULL
,	NULL
245-266	NULL
Inducible	NULL
resistance	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
in	NULL
B	NULL
cells	NULL
RotHstEm	NULL
THomas	NULL
L	NULL
Departments	NULL
of	NULL
Medicine	NULL
and	NULL
Microbiology	NULL
,	NULL
and	NULL
the	NULL
Evans	NULL
Memorial	NULL
Department	NULL
of	NULL
Clinical	NULL
Research	NULL
,	NULL
Boston	NULL
University	NULL
Medical	NULL
Center	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
,	NULL
USA	NULL
ABSTRACT	NULL
Apoptosis	NULL
produced	NULL
in	NULL
B	NULL
cells	NULL
through	NULL
Fas	NULL
(	NULL
APO-1	NULL
,	NULL
CD95	NULL
)	NULL
triggering	NULL
is	NULL
regulated	NULL
by	NULL
signals	NULL
derived	NULL
from	NULL
other	NULL
surface	NULL
receptors	NULL
:	NULL
CD40	NULL
engagement	NULL
produces	NULL
upregulation	NULL
of	NULL
Fas	NULL
expression	NULL
and	NULL
marked	NULL
susceptibility	NULL
to	NULL
Fas-induced	NULL
cell	NULL
death	NULL
,	NULL
whereas	NULL
antigen	NULL
receptor	NULL
engagement	NULL
,	NULL
or	NULL
IL-4R	NULL
engagement	NULL
,	NULL
inhibits	NULL
Fas	NULL
killing	NULL
and	NULL
in	NULL
so	NULL
doing	NULL
induces	NULL
a	NULL
state	NULL
of	NULL
Fas-resistance	NULL
,	NULL
even	NULL
in	NULL
otherwise	NULL
sensitive	NULL
,	NULL
CD40-stimulated	NULL
targets	NULL
.	NULL

Surface	NULL
immunoglobulin	NULL
and	NULL
IL-4R	NULL
utilize	NULL
at	NULL
least	NULL
partially	NULL
distinct	NULL
pathways	NULL
to	NULL
produce	NULL
Fas-resistance	NULL
that	NULL
differentially	NULL
depend	NULL
on	NULL
PKC	NULL
and	NULL
STAT6	NULL
,	NULL
respectively	NULL
.	NULL

Further	NULL
,	NULL
surface	NULL
immunoglobulin	NULL
signaling	NULL
for	NULL
inducible	NULL
Fas-resistance	NULL
bypasses	NULL
Btk	NULL
,	NULL
requires	NULL
NF-	NULL
Â«	NULL
B	NULL
,	NULL
and	NULL
entails	NULL
new	NULL
macromolecular	NULL
synthesis	NULL
.	NULL

Terminal	NULL
effectors	NULL
of	NULL
B	NULL
cell	NULL
Fasg-resistance	NULL
include	NULL
the	NULL
known	NULL
anti-apoptotic	NULL
gene	NULL
products	NULL
,	NULL
Bel-xL	NULL
and	NULL
FLIP	NULL
,	NULL
and	NULL
a	NULL
novel	NULL
anti-apoptotic	NULL
gene	NULL
that	NULL
encodes	NULL
FAIM	NULL
(	NULL
Fas	NULL
Apoptosis	NULL
Inhibitory	NULL
Molecule	NULL
)	NULL
.	NULL

faim	NULL
was	NULL
identified	NULL
by	NULL
differential	NULL
display	NULL
and	NULL
exists	NULL
in	NULL
two	NULL
alter	NULL
Abbreviations	NULL
:	NULL
AICD	NULL
,	NULL
activation-induced	NULL
cell	NULL
death	NULL
;	NULL
ALPS	NULL
,	NULL
autoimmune	NULL
lymphoproliferation	NULL
syndrome	NULL
;	NULL
CARD	NULL
,	NULL
caspase	NULL
recruitment	NULL
domain	NULL
;	NULL
CK	NULL
,	NULL
casein	NULL
kinase	NULL
;	NULL
CMC	NULL
,	NULL
cell-mediated	NULL
cytotoxicity	NULL
;	NULL
DISC	NULL
,	NULL
death-inducing	NULL
signaling	NULL
complex	NULL
;	NULL
EST	NULL
,	NULL
expressed	NULL
sequence	NULL
tag	NULL
;	NULL
FADD	NULL
,	NULL
Fas-associating	NULL
protein	NULL
with	NULL
death	NULL
domain	NULL
;	NULL
FAIM	NULL
,	NULL
Fas	NULL
apoptosis	NULL
inhibitory	NULL
molecule	NULL
;	NULL
FISH	NULL
,	NULL
fluorescence	NULL
in	NULL
situ	NULL
hybridization	NULL
;	NULL
FLICE	NULL
,	NULL
FADD-like	NULL
ICE	NULL
;	NULL
FLIP	NULL
,	NULL
FLICE	NULL
inhibitory	NULL
protein	NULL
;	NULL
HEL	NULL
,	NULL
hen	NULL
egg	NULL
lysozyme	NULL
;	NULL
ICE	NULL
,	NULL
interleukin-1	NULL
$	NULL
-converting	NULL
enzyme	NULL
;	NULL
IFN	NULL
,	NULL
interferon	NULL
;	NULL
KO	NULL
,	NULL
knock-out	NULL
;	NULL
LPS	NULL
,	NULL
lipopolysaccharide	NULL
;	NULL
PARP	NULL
,	NULL
poly-ADP	NULL
ribose	NULL
polymerase	NULL
;	NULL
PCR	NULL
,	NULL
polymerase	NULL
chain	NULL
reaction	NULL
;	NULL
PH	NULL
,	NULL
pleckstrin	NULL
homology	NULL
;	NULL
PKC	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
;	NULL
RT	NULL
,	NULL
reverse	NULL
transcription	NULL
;	NULL
TNFR	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
#	NULL
Correspondence	NULL
to	NULL
:	NULL
Thomas	NULL
L.	NULL
Rothstein	NULL
,	NULL
Immunobiology	NULL
Unit	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
EBRC-437	NULL
,	NULL
Boston	NULL
Medical	NULL
Center	NULL
,	NULL
650	NULL
Albany	NULL
Street	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02118	NULL
USA	NULL
Fax	NULL
:	NULL
617-638-7140	NULL
,	NULL
E-mail	NULL
:	NULL
trothstein	NULL
@	NULL
med-med1.bu.edu	NULL
Inducible	NULL
Fas-resistance	NULL
in	NULL
B	NULL
cells	NULL
natively	NULL
spliced	NULL
forms	NULL
;	NULL
faim-S	NULL
is	NULL
broadly	NULL
expressed	NULL
,	NULL
but	NULL
faim-L	NULL
expression	NULL
is	NULL
tissue-specific	NULL
.	NULL

The	NULL
FAIM	NULL
sequence	NULL
is	NULL
highly	NULL
evo-lutionarily	NULL
conserved	NULL
,	NULL
suggesting	NULL
an	NULL
important	NULL
role	NULL
for	NULL
this	NULL
molecule	NULL
throughout	NULL
phylogeny	NULL
.	NULL

Inducible	NULL
resistance	NULL
to	NULL
Fas	NULL
killing	NULL
is	NULL
hypothesized	NULL
to	NULL
protect	NULL
foreign	NULL
antigen-specific	NULL
B	NULL
cells	NULL
during	NULL
potentially	NULL
hazardous	NULL
interactions	NULL
with	NULL
FasL-bearing	NULL
T	NULL
cells	NULL
,	NULL
whereas	NULL
autoreactive	NULL
B	NULL
cells	NULL
fail	NULL
to	NULL
become	NULL
Fas-resistant	NULL
and	NULL
are	NULL
deleted	NULL
via	NULL
Fas-dependent	NULL
cytotoxicity	NULL
.	NULL

Inadvertent	NULL
or	NULL
aberrant	NULL
acquisition	NULL
of	NULL
Fas-resistance	NULL
may	NULL
permit	NULL
autoreactive	NULL
B	NULL
cells	NULL
to	NULL
escape	NULL
Fas	NULL
deletion	NULL
,	NULL
and	NULL
malignant	NULL
lymphocytes	NULL
to	NULL
impede	NULL
anti-tumor	NULL
immunity	NULL
.	NULL

key	NULL
words	NULL
:	NULL
Apoptosis	NULL
,	NULL
Fas	NULL
,	NULL
B	NULL
lymphocytes	NULL
,	NULL
FAIM	NULL
,	NULL
FLIP	NULL
,	NULL
Bel-xi	NULL
,	NULL
surface	NULL
immunoglobulin	NULL
,	NULL
IL-4R	NULL
,	NULL
CD40	NULL
,	NULL
autoreactivity	NULL
.	NULL

INRODUCTION	NULL
Fas/APO-1	NULL
(	NULL
CD95	NULL
)	NULL
is	NULL
a	NULL
death	NULL
receptor	NULL
of	NULL
the	NULL
TNF	NULL
receptor	NULL
(	NULL
TNFR	NULL
)	NULL
family	NULL
,	NULL
and	NULL
shares	NULL
with	NULL
death	NULL
receptors	NULL
TNFR1	NULL
,	NULL
DR3	NULL
(	NULL
TRAMP	NULL
,	NULL
Wsl	NULL
,	NULL
APO-3	NULL
)	NULL
,	NULL
DR4	NULL
(	NULL
TRAIL-R1	NULL
)	NULL
and	NULL
DR5	NULL
(	NULL
TRAIL-R2	NULL
)	NULL
extracellular	NULL
cysteine-rich	NULL
pseudorepeats	NULL
,	NULL
intracellular	NULL
C-terminal	NULL
death	NULL
domains	NULL
,	NULL
and	NULL
reliance	NULL
on	NULL
FADD	NULL
as	NULL
a	NULL
critical	NULL
early	NULL
mediator	NULL
of	NULL
signaling	NULL
for	NULL
cell	NULL
death	NULL
(	NULL
although	NULL
FADD-dependence	NULL
has	NULL
been	NULL
questioned	NULL
for	NULL
DR4	NULL
)	NULL
[	NULL
1-7	NULL
]	NULL
.	NULL

The	NULL
cognate	NULL
ligand	NULL
for	NULL
Fas	NULL
(	NULL
FasL	NULL
)	NULL
is	NULL
an	NULL
activation	NULL
antigen	NULL
expressed	NULL
by	NULL
CD4+	NULL
Th1	NULL
effector	NULL
cells	NULL
and	NULL
CD8	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
,	NULL
(	NULL
although	NULL
its	NULL
activity	NULL
in	NULL
the	NULL
latter	NULL
is	NULL
frequently	NULL
masked	NULL
by	NULL
the	NULL
more	NULL
substantial	NULL
destructive	NULL
power	NULL
of	NULL
the	NULL
perforin-granzyme	NULL
system	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
natural	NULL
killer	NULL
cells	NULL
[	NULL
8-13	NULL
]	NULL
.	NULL

The	NULL
congenital	NULL
loss	NULL
of	NULL
Fas	NULL
(	NULL
as	NULL
in	NULL
lpr/lpr	NULL
mice	NULL
and	NULL
Fas	NULL
null	NULL
mice	NULL
,	NULL
and	NULL
in	NULL
human	NULL
Autoimmune	NULL
Lymphoproliferation	NULL
Syndrome	NULL
)	NULL
or	NULL
of	NULL
its	NULL
ligand	NULL
(	NULL
as	NULL
in	NULL
gld/gld	NULL
mice	NULL
)	NULL
is	NULL
accompanied	NULL
by	NULL
severely	NULL
elevated	NULL
levels	NULL
of	NULL
serum	NULL
autoantibodies	NULL
associated	NULL
with	NULL
frank	NULL
autoimmunity	NULL
[	NULL
14-24	NULL
]	NULL
;	NULL
for	NULL
this	NULL
reason	NULL
Fas	NULL
is	NULL
thought	NULL
to	NULL
play	NULL
a	NULL
key	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
B	NULL
cells	NULL
,	NULL
particularly	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
autoreactive	NULL
B	NULL
cells	NULL
.	NULL

These	NULL
observations	NULL
are	NULL
supported	NULL
and	NULL
refined	NULL
by	NULL
additional	NULL
experiments	NULL
,	NULL
carried	NULL
out	NULL
over	NULL
the	NULL
last	NULL
dozen	NULL
years	NULL
,	NULL
that	NULL
more	NULL
clearly	NULL
document	NULL
abnormal	NULL
B	NULL
cell	NULL
function	NULL
in	NULL
Fas-deficient	NULL
animals	NULL
and	NULL
distinguish	NULL
B	NULL
cell	NULL
defects	NULL
from	NULL
abnormalities	NULL
in	NULL
the	NULL
T	NULL
cell	NULL
population	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
both	NULL
mixed	NULL
radiation	NULL
chimeras	NULL
and	NULL
tetraparental	NULL
chimeras	NULL
,	NULL
autoimmune	NULL
immunoglobulin	NULL
was	NULL
derived	NULL
solely	NULL
from	NULL
lpr	NULL
B	NULL
cells	NULL
and	NULL
not	NULL
from	NULL
co-existing	NULL
phenotypically	NULL
normal	NULL
B	NULL
cells	NULL
that	NULL
were	NULL
simultaneously	NULL
exposed	NULL
to	NULL
abnormal	NULL
lpr	NULL
T	NULL
cells	NULL
[	NULL
25-27	NULL
]	NULL
.	NULL

Moreover	NULL
,	NULL
autoantibody	NULL
production	NULL
was	NULL
present	NULL
and	NULL
undiminished	NULL
when	NULL
Fas	NULL
deficiency	NULL
was	NULL
restricted	NULL
to	NULL
B	NULL
cells	NULL
through	NULL
production	NULL
of	NULL
transgenic	NULL
MRL	NULL
-	NULL
lpr	NULL
mice	NULL
246	NULL
Rothstein	NULL
TL	NULL
that	NULL
express	NULL
Fas	NULL
within	NULL
the	NULL
thymocyte	NULL
and	NULL
peripheral	NULL
T	NULL
cell	NULL
populations	NULL
by	NULL
use	NULL
of	NULL
the	NULL
murine	NULL
Ick	NULL
promoter	NULL
,	NULL
in	NULL
comparison	NULL
to	NULL
unmanipulated	NULL
MRL	NULL
mice	NULL
[	NULL
28	NULL
]	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
a	NULL
block	NULL
in	NULL
the	NULL
Fas	NULL
death	NULL
pathway	NULL
leads	NULL
to	NULL
dysregulation	NULL
of	NULL
B	NULL
cells	NULL
that	NULL
express	NULL
self-recognizing	NULL
specificities	NULL
,	NULL
suggesting	NULL
that	NULL
under	NULL
normal	NULL
circumstance	NULL
Fas	NULL
functions	NULL
to	NULL
delete	NULL
such	NULL
autoreactive	NULL
B	NULL
cells	NULL
.	NULL

In	NULL
lpr	NULL
and	NULL
Fas	NULL
null	NULL
B	NULL
cells	NULL
,	NULL
Fas-induced	NULL
cell	NULL
death	NULL
is	NULL
blocked	NULL
congenitally	NULL
by	NULL
loss	NULL
of	NULL
surface	NULL
Fas	NULL
expression	NULL
.	NULL

However	NULL
,	NULL
this	NULL
is	NULL
a	NULL
somewhat	NULL
artificial	NULL
,	NULL
certainly	NULL
non-physiological	NULL
,	NULL
way	NULL
of	NULL
thwarting	NULL
Fas	NULL
killing	NULL
.	NULL

In	NULL
view	NULL
of	NULL
the	NULL
very	NULL
severe	NULL
immune	NULL
dyscrasias	NULL
attendant	NULL
to	NULL
genetic	NULL
interference	NULL
with	NULL
Fas	NULL
signaling	NULL
for	NULL
cell	NULL
death	NULL
,	NULL
the	NULL
question	NULL
arose	NULL
as	NULL
to	NULL
whether	NULL
Fas-mediated	NULL
cell	NULL
death	NULL
is	NULL
ever	NULL
blocked	NULL
during	NULL
normal	NULL
immune	NULL
cell	NULL
activity	NULL
,	NULL
because	NULL
if	NULL
that	NULL
would	NULL
happen	NULL
,	NULL
it	NULL
might	NULL
contribute	NULL
to	NULL
autoimmune	NULL
B	NULL
cell	NULL
activity	NULL
.	NULL

More	NULL
generally	NULL
,	NULL
it	NULL
was	NULL
unclear	NULL
to	NULL
what	NULL
extent	NULL
the	NULL
outcome	NULL
of	NULL
Fas	NULL
signaling	NULL
is	NULL
modulated	NULL
by	NULL
other	NULL
influences	NULL
,	NULL
particularly	NULL
receptor-specific	NULL
ones	NULL
.	NULL

Although	NULL
it	NULL
was	NULL
known	NULL
that	NULL
B	NULL
cell	NULL
activation	NULL
,	NULL
as	NULL
with	NULL
lipopolysaccharide	NULL
,	NULL
was	NULL
associated	NULL
with	NULL
Fas	NULL
expression	NULL
and	NULL
sensitivity	NULL
to	NULL
Fas	NULL
signaling	NULL
for	NULL
cell	NULL
death	NULL
that	NULL
greatly	NULL
exceed	NULL
the	NULL
low	NULL
levels	NULL
present	NULL
in	NULL
naive	NULL
B	NULL
cells	NULL
[	NULL
29-33	NULL
]	NULL
,	NULL
we	NULL
pursued	NULL
this	NULL
issue	NULL
further	NULL
,	NULL
by	NULL
evaluating	NULL
the	NULL
effect	NULL
of	NULL
triggering	NULL
certain	NULL
surface	NULL
receptors	NULL
in	NULL
primary	NULL
B	NULL
cells	NULL
.	NULL

Early	NULL
on	NULL
it	NULL
was	NULL
found	NULL
that	NULL
B	NULL
cell	NULL
stimulation	NULL
through	NULL
CD40	NULL
for	NULL
1-3	NULL
d	NULL
markedly	NULL
upregulated	NULL
both	NULL
surface	NULL
Fas	NULL
expression	NULL
,	NULL
and	NULL
sensitivity	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
.	NULL

In	NULL
direct	NULL
contrast	NULL
,	NULL
B	NULL
cell	NULL
stimulation	NULL
through	NULL
surface	NULL
immunoglobulin	NULL
(	NULL
slg	NULL
)	NULL
failed	NULL
to	NULL
enhance	NULL
susceptibility	NULL
to	NULL
Fas	NULL
killing	NULL
at	NULL
all	NULL
.	NULL

Thus	NULL
,	NULL
these	NULL
two	NULL
mitogenic	NULL
receptor-	NULL
mediated	NULL
signals	NULL
differ	NULL
markedly	NULL
in	NULL
their	NULL
capacity	NULL
to	NULL
increase	NULL
the	NULL
sensitivity	NULL
of	NULL
B	NULL
cell	NULL
targets	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
[	NULL
34	NULL
]	NULL
.	NULL

We	NULL
then	NULL
evaluated	NULL
whether	NULL
the	NULL
failure	NULL
of	NULL
slg	NULL
engagement	NULL
to	NULL
induce	NULL
Fas-sensitivity	NULL
resulted	NULL
from	NULL
a	NULL
passive	NULL
process	NULL
,	NULL
due	NULL
to	NULL
inadequate	NULL
signaling	NULL
for	NULL
this	NULL
outcome	NULL
,	NULL
or	NULL
a	NULL
dominant	NULL
process	NULL
,	NULL
due	NULL
to	NULL
active	NULL
suppression	NULL
of	NULL
cytotoxicity	NULL
.	NULL

To	NULL
address	NULL
this	NULL
issue	NULL
,	NULL
primary	NULL
B	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
CD4O0L	NULL
in	NULL
combination	NULL
with	NULL
,	NULL
or	NULL
sequentially	NULL
with	NULL
,	NULL
anti-Ig	NULL
,	NULL
and	NULL
then	NULL
examined	NULL
for	NULL
susceptibility	NULL
to	NULL
apoptosis	NULL
in	NULL
the	NULL
form	NULL
of	NULL
FasL-depen-dent	NULL
Th1-cell	NULL
mediated	NULL
cytotoxicity	NULL
(	NULL
Th1-CMC	NULL
)	NULL
.	NULL

B	NULL
cells	NULL
stimulated	NULL
by	NULL
CD4OL	NULL
plus	NULL
anti-Ig	NULL
expressed	NULL
increased	NULL
levels	NULL
of	NULL
surface	NULL
Fas	NULL
comparable	NULL
in	NULL
magnitude	NULL
to	NULL
the	NULL
elevated	NULL
levels	NULL
present	NULL
in	NULL
B	NULL
cells	NULL
stimulated	NULL
by	NULL
CD40L	NULL
alone	NULL
;	NULL
however	NULL
,	NULL
the	NULL
susceptibility	NULL
of	NULL
dual-stimulated	NULL
B	NULL
cells	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
was	NULL
much	NULL
reduced	NULL
in	NULL
comparison	NULL
to	NULL
B	NULL
cells	NULL
stimulated	NULL
only	NULL
by	NULL
CD40L	NULL
[	NULL
34	NULL
]	NULL
,	NULL
[	NULL
35	NULL
]	NULL
.	NULL

Whereas	NULL
the	NULL
percent	NULL
specific	NULL
lysis	NULL
produced	NULL
during	NULL
a	NULL
4	NULL
h	NULL
``	NULL
Cr	NULL
release	NULL
assay	NULL
of	NULL
B	NULL
cells	NULL
stimulated	NULL
by	NULL
CD4O0L	NULL
alone	NULL
typically	NULL
ranged	NULL
from	NULL
40-60	NULL
%	NULL
at	NULL
the	NULL
highest	NULL
Th1	NULL
effector	NULL
:	NULL
B	NULL
cell	NULL
target	NULL
ratio	NULL
tested	NULL
(	NULL
9:1	NULL
)	NULL
,	NULL
the	NULL
corresponding	NULL
percent	NULL
specific	NULL
lysis	NULL
for	NULL
B	NULL
cells	NULL
stimulated	NULL
by	NULL
both	NULL
CD4OL	NULL
and	NULL
anti-Ig	NULL
was	NULL
only	NULL
0-15	NULL
%	NULL
.	NULL

Considering	NULL
a	NULL
large	NULL
number	NULL
of	NULL
experiments	NULL
,	NULL
the	NULL
mean	NULL
level	NULL
of	NULL
protection	NULL
against	NULL
Fas	NULL
killing	NULL
produced	NULL
by	NULL
slg	NULL
signaling	NULL
amounted	NULL
to	NULL
more	NULL
than	NULL
20-fold	NULL
,	NULL
meaning	NULL
that	NULL
a	NULL
greater	NULL
than	NULL
20-fold	NULL
higher	NULL
Th1	NULL
effector	NULL
:	NULL
B	NULL
cell	NULL
target	NULL
ratio	NULL
was	NULL
needed	NULL
to	NULL
produce	NULL
comparable	NULL
levels	NULL
of	NULL
apoptosis	NULL
in	NULL
B	NULL
cells	NULL
stimulated	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
CD4O0L	NULL
plus	NULL
anti-Ig	NULL
as	NULL
in	NULL
B	NULL
cells	NULL
stimulated	NULL
by	NULL
CD4O0L	NULL
alone	NULL
[	NULL
35	NULL
]	NULL
.	NULL

Thus	NULL
,	NULL
anti-Ig-induced	NULL
sIg	NULL
crosslinking	NULL
established	NULL
a	NULL
state	NULL
of	NULL
resistance	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
,	NULL
or	NULL
Fas-resistance	NULL
.	NULL

Moreover	NULL
,	NULL
slg	NULL
247	NULL
Inducible	NULL
Fas-resistance	NULL
in	NULL
B	NULL
cells	NULL
engagement	NULL
by	NULL
specific	NULL
antigen	NULL
similarly	NULL
produced	NULL
Fas-resistance	NULL
,	NULL
in	NULL
experiments	NULL
in	NULL
which	NULL
B	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
transgenic	NULL
animals	NULL
expressing	NULL
either	NULL
B	NULL
cell	NULL
receptors	NULL
that	NULL
recognize	NULL
H-2K**	NULL
,	NULL
or	NULL
B	NULL
cell	NULL
receptors	NULL
that	NULL
recognize	NULL
HEL	NULL
,	NULL
demonstrating	NULL
that	NULL
sIg-induced	NULL
Fas-resistance	NULL
is	NULL
a	NULL
physiologic	NULL
process	NULL
and	NULL
is	NULL
not	NULL
dependent	NULL
on	NULL
the	NULL
use	NULL
of	NULL
crosslinking	NULL
anti-Ig	NULL
antibody	NULL
[	NULL
34	NULL
]	NULL
,	NULL
[	NULL
86	NULL
]	NULL
.	NULL

The	NULL
opposing	NULL
effects	NULL
of	NULL
CD40	NULL
and	NULL
slg	NULL
engagement	NULL
on	NULL
Fas	NULL
signaling	NULL
for	NULL
cell	NULL
death	NULL
raised	NULL
the	NULL
question	NULL
of	NULL
whether	NULL
engagement	NULL
of	NULL
other	NULL
surface	NULL
receptors	NULL
might	NULL
similarly	NULL
alter	NULL
susceptibility	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
.	NULL

To	NULL
address	NULL
this	NULL
issue	NULL
,	NULL
various	NULL
ligands	NULL
were	NULL
tested	NULL
in	NULL
conjunction	NULL
with	NULL
CD4O0L	NULL
stimulation	NULL
prior	NULL
to	NULL
evaluating	NULL
sensitivity	NULL
to	NULL
Th1	NULL
cell-mediated	NULL
cytotoxicity	NULL
.	NULL

Through	NULL
this	NULL
effort	NULL
IL-4	NULL
,	NULL
alone	NULL
among	NULL
the	NULL
cytokines	NULL
examined	NULL
,	NULL
was	NULL
found	NULL
to	NULL
produce	NULL
Fas-resistance	NULL
[	NULL
37	NULL
]	NULL
.	NULL

As	NULL
with	NULL
anti-Ig	NULL
,	NULL
IL-4	NULL
produced	NULL
Fas-resistance	NULL
when	NULL
added	NULL
either	NULL
concurrently	NULL
,	NULL
or	NULL
sequentially	NULL
,	NULL
with	NULL
CD4O0L	NULL
,	NULL
and	NULL
did	NULL
so	NULL
without	NULL
any	NULL
change	NULL
in	NULL
the	NULL
elevated	NULL
level	NULL
of	NULL
Fas	NULL
expression	NULL
produced	NULL
by	NULL
CD40	NULL
signaling	NULL
;	NULL
however	NULL
,	NULL
IL-4	NULL
in	NULL
optimal	NULL
doses	NULL
was	NULL
less	NULL
effective	NULL
than	NULL
anti-Ig	NULL
,	NULL
providing	NULL
a	NULL
level	NULL
of	NULL
protection	NULL
against	NULL
Fas-mediated	NULL
apoptosis	NULL
that	NULL
averaged	NULL
about	NULL
10-fold	NULL
[	NULL
37	NULL
]	NULL
.	NULL

These	NULL
results	NULL
with	NULL
anti-Ig	NULL
and	NULL
IL-4	NULL
indicate	NULL
that	NULL
in	NULL
normal	NULL
B	NULL
cells	NULL
,	NULL
Fas-mediated	NULL
apoptosis	NULL
can	NULL
be	NULL
suppressed	NULL
through	NULL
inducible	NULL
receptor-triggered	NULL
mechanisms	NULL
completely	NULL
distinct	NULL
from	NULL
genetic	NULL
alteration	NULL
of	NULL
Fas	NULL
.	NULL

This	NULL
paradigm	NULL
is	NULL
supported	NULL
by	NULL
subsequent	NULL
reports	NULL
of	NULL
in	NULL
vitro	NULL
experiments	NULL
in	NULL
the	NULL
human	NULL
system	NULL
,	NULL
and	NULL
of	NULL
in	NULL
vivo	NULL
experiments	NULL
in	NULL
the	NULL
murine	NULL
system	NULL
[	NULL
38-41	NULL
]	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
outcome	NULL
of	NULL
B	NULL
cell	NULL
stimulation	NULL
with	NULL
respect	NULL
to	NULL
Fas	NULL
signaling	NULL
is	NULL
regulated	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
particular	NULL
environmental	NULL
cues	NULL
as	NULL
interpreted	NULL
by	NULL
specific	NULL
receptor	NULL
binding	NULL
.	NULL

In	NULL
the	NULL
experiments	NULL
described	NULL
above	NULL
,	NULL
Fas-mediated	NULL
apoptosis	NULL
was	NULL
initiated	NULL
by	NULL
Th1	NULL
cell	NULL
membrane-bound	NULL
FasL	NULL
,	NULL
and	NULL
Fas-resistance	NULL
was	NULL
observed	NULL
in	NULL
B	NULL
cells	NULL
stimulated	NULL
by	NULL
CD40L	NULL
plus	NULL
anti-Ig	NULL
,	NULL
or	NULL
by	NULL
CD4O0L	NULL
plus	NULL
IL-4	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
recombinant	NULL
,	NULL
soluble	NULL
FasL	NULL
[	NULL
35	NULL
]	NULL
.	NULL

Surprisingly	NULL
though	NULL
,	NULL
a	NULL
different	NULL
outcome	NULL
appeared	NULL
when	NULL
Fas	NULL
killing	NULL
was	NULL
triggered	NULL
by	NULL
soluble	NULL
Jo-2	NULL
monoclonal	NULL
anti-Fas	NULL
antibody	NULL
,	NULL
in	NULL
which	NULL
case	NULL
the	NULL
level	NULL
of	NULL
protection	NULL
against	NULL
Fas-mediated	NULL
apoptosis	NULL
was	NULL
much	NULL
reduced	NULL
in	NULL
comparison	NULL
to	NULL
that	NULL
which	NULL
was	NULL
apparent	NULL
with	NULL
Th1	NULL
effector	NULL
cells	NULL
,	NULL
to	NULL
the	NULL
point	NULL
that	NULL
Fas-resistance	NULL
was	NULL
not	NULL
always	NULL
evident	NULL
.	NULL

The	NULL
failure	NULL
to	NULL
observe	NULL
Fas-resistance	NULL
in	NULL
antibody-treated	NULL
B	NULL
cells	NULL
suggests	NULL
that	NULL
Jo-2	NULL
produces	NULL
a	NULL
super-physiological	NULL
stimulus	NULL
that	NULL
overwhelms	NULL
receptor-driven	NULL
Fas-resistance	NULL
.	NULL

The	NULL
reason	NULL
for	NULL
this	NULL
might	NULL
be	NULL
that	NULL
B	NULL
cell	NULL
FcR	NULL
crosslinking	NULL
of	NULL
whole	NULL
anti-Fas	NULL
antibody	NULL
produces	NULL
more	NULL
efficient	NULL
Fas	NULL
engagement	NULL
,	NULL
inasmuch	NULL
as	NULL
Jo-2-induced	NULL
Fas	NULL
killing	NULL
was	NULL
blocked	NULL
by	NULL
2.4G2	NULL
anti-FcR	NULL
antibody	NULL
,	NULL
or	NULL
it	NULL
might	NULL
be	NULL
that	NULL
the	NULL
anti-Fas	NULL
antibody	NULL
binds	NULL
an	NULL
epitope	NULL
distinct	NULL
from	NULL
that	NULL
engaged	NULL
by	NULL
FasL	NULL
,	NULL
inasmuch	NULL
as	NULL
soluble	NULL
FasL	NULL
did	NULL
not	NULL
block	NULL
the	NULL
ability	NULL
of	NULL
Jo-2	NULL
to	NULL
produce	NULL
apoptosis	NULL
in	NULL
Fas-resistant	NULL
B	NULL
cells	NULL
treated	NULL
with	NULL
CD4O0L	NULL
plus	NULL
anti-Ig	NULL
[	NULL
35	NULL
]	NULL
(	NULL
and	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

Regardless	NULL
of	NULL
the	NULL
mechanism	NULL
,	NULL
however	NULL
,	NULL
the	NULL
results	NULL
with	NULL
Jo-2	NULL
indicate	NULL
that	NULL
sIg-	NULL
and	NULL
IL-4R-induced	NULL
protection	NULL
against	NULL
Fas-mediated	NULL
apoptosis	NULL
is	NULL
relative	NULL
rather	NULL
than	NULL
absolute	NULL
,	NULL
and	NULL
can	NULL
be	NULL
overcome	NULL
by	NULL
especially	NULL
strong	NULL
apoptotic	NULL
signals	NULL
derived	NULL
from	NULL
Fas	NULL
,	NULL
including	NULL
those	NULL
produced	NULL
by	NULL
particularly	NULL
high	NULL
Th1	NULL
effector	NULL
cell	NULL
:	NULL
B	NULL
cell	NULL
target	NULL
cell	NULL
ratios	NULL
.	NULL

248	NULL
Rothstein	NULL
TL	NULL
Receptor	NULL
signaling	NULL
for	NULL
Fas-resistance	NULL
Although	NULL
the	NULL
outcomes	NULL
of	NULL
engaging	NULL
sIg	NULL
and	NULL
IL-4R	NULL
in	NULL
terms	NULL
of	NULL
inducible	NULL
resistance	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
are	NULL
similar	NULL
,	NULL
the	NULL
pathways	NULL
utilized	NULL
to	NULL
bring	NULL
this	NULL
about	NULL
differ	NULL
,	NULL
as	NULL
evidenced	NULL
by	NULL
the	NULL
reliance	NULL
of	NULL
Fas-resistance	NULL
induction	NULL
on	NULL
specific	NULL
signaling	NULL
mediators	NULL
.	NULL

Thus	NULL
,	NULL
inhibition	NULL
of	NULL
PKC	NULL
by	NULL
cell-permeant	NULL
H7	NULL
,	NULL
or	NULL
depletion	NULL
of	NULL
PKC	NULL
by	NULL
prolonged	NULL
exposure	NULL
to	NULL
PMA	NULL
,	NULL
blocked	NULL
induction	NULL
of	NULL
Fas-resistance	NULL
by	NULL
anti-Ig	NULL
but	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
IL-4R-induced	NULL
Fas-resistance	NULL
[	NULL
35	NULL
]	NULL
.	NULL

Conversely	NULL
,	NULL
the	NULL
loss	NULL
of	NULL
STATS	NULL
(	NULL
in	NULL
B	NULL
cells	NULL
obtained	NULL
from	NULL
STAT6-deficient	NULL
mice	NULL
)	NULL
blocked	NULL
induction	NULL
of	NULL
Fasg-resistance	NULL
by	NULL
IL-4	NULL
but	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
slg-induced	NULL
Fas-resistance	NULL
[	NULL
42	NULL
]	NULL
.	NULL

(	NULL
Of	NULL
interest	NULL
,	NULL
sIg	NULL
engagement	NULL
was	NULL
recently	NULL
shown	NULL
to	NULL
trigger	NULL
STATE	NULL
activation	NULL
[	NULL
43	NULL
]	NULL
,	NULL
which	NULL
raised	NULL
the	NULL
possibility	NULL
that	NULL
STAT6	NULL
might	NULL
form	NULL
the	NULL
basis	NULL
of	NULL
a	NULL
common	NULL
pathway	NULL
leading	NULL
both	NULL
from	NULL
slg	NULL
and	NULL
from	NULL
IL-4R	NULL
to	NULL
inducible	NULL
Fas-resistance	NULL
;	NULL
however	NULL
,	NULL
the	NULL
results	NULL
discussed	NULL
above	NULL
negate	NULL
this	NULL
possibility	NULL
)	NULL
.	NULL

Further	NULL
,	NULL
the	NULL
relative	NULL
speed	NULL
with	NULL
which	NULL
Fas-resistance	NULL
was	NULL
established	NULL
also	NULL
differed	NULL
for	NULL
anti-Ig	NULL
and	NULL
IL-4	NULL
.	NULL

Whereas	NULL
anti-Ig	NULL
acted	NULL
rapidly	NULL
to	NULL
produce	NULL
Fas-resistance	NULL
that	NULL
was	NULL
apparent	NULL
at	NULL
3	NULL
h	NULL
,	NULL
and	NULL
maximal	NULL
after	NULL
12	NULL
h	NULL
,	NULL
IL-4-induced	NULL
Fas-resistance	NULL
developed	NULL
much	NULL
more	NULL
slowly	NULL
and	NULL
only	NULL
reached	NULL
a	NULL
maximum	NULL
after	NULL
24	NULL
h	NULL
of	NULL
exposure	NULL
[	NULL
35	NULL
]	NULL
,	NULL
[	NULL
87	NULL
]	NULL
.	NULL

These	NULL
results	NULL
taken	NULL
together	NULL
indicate	NULL
that	NULL
sIg	NULL
and	NULL
IL-4	NULL
receptors	NULL
utilize	NULL
at	NULL
least	NULL
partially	NULL
non-overlapping	NULL
intracellular	NULL
signaling	NULL
pathways	NULL
to	NULL
bring	NULL
about	NULL
Fas-resistance	NULL
.	NULL

The	NULL
timecourse	NULL
experiments	NULL
were	NULL
carried	NULL
out	NULL
by	NULL
stimulating	NULL
B	NULL
cells	NULL
with	NULL
CD4O0L	NULL
for	NULL
a	NULL
total	NULL
of	NULL
48	NULL
h	NULL
,	NULL
and	NULL
adding	NULL
anti-Ig	NULL
or	NULL
IL-4	NULL
at	NULL
various	NULL
times	NULL
before	NULL
the	NULL
end	NULL
of	NULL
the	NULL
culture	NULL
period	NULL
.	NULL

Because	NULL
B	NULL
cell	NULL
treatment	NULL
with	NULL
CD40L	NULL
for	NULL
24	NULL
h	NULL
was	NULL
sufficient	NULL
to	NULL
induce	NULL
Fas-sensitivity	NULL
,	NULL
the	NULL
capacity	NULL
of	NULL
anti-Ig	NULL
and	NULL
IL-4	NULL
to	NULL
produce	NULL
maximal	NULL
Fas-resistance	NULL
when	NULL
added	NULL
24	NULL
h	NULL
before	NULL
the	NULL
end	NULL
of	NULL
48	NULL
h	NULL
culture	NULL
periods	NULL
with	NULL
CD40L	NULL
means	NULL
that	NULL
these	NULL
reagents	NULL
do	NULL
not	NULL
simply	NULL
prevent	NULL
the	NULL
development	NULL
of	NULL
Fas-sensitivity	NULL
in	NULL
response	NULL
to	NULL
CD40	NULL
engagement	NULL
but	NULL
actually	NULL
reverse	NULL
susceptibility	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
that	NULL
has	NULL
already	NULL
been	NULL
established	NULL
.	NULL

Additional	NULL
work	NULL
on	NULL
metabolic	NULL
pathways	NULL
has	NULL
focused	NULL
on	NULL
sIg-induced	NULL
Fas-resistance	NULL
.	NULL

In	NULL
view	NULL
of	NULL
the	NULL
PKC	NULL
requirement	NULL
for	NULL
Fasg-resistance	NULL
produced	NULL
by	NULL
anti-Ig	NULL
,	NULL
the	NULL
capacity	NULL
of	NULL
PKC-activating	NULL
phorbol	NULL
ester	NULL
treatment	NULL
to	NULL
induce	NULL
Fas-resistance	NULL
was	NULL
examined	NULL
.	NULL

Phorbol	NULL
ester	NULL
produced	NULL
only	NULL
partial	NULL
protection	NULL
against	NULL
Fas-mediated	NULL
apoptosis	NULL
,	NULL
whereas	NULL
the	NULL
combination	NULL
of	NULL
a	NULL
phorbol	NULL
ester	NULL
plus	NULL
a	NULL
calcium	NULL
ionophore	NULL
brought	NULL
about	NULL
virtually	NULL
complete	NULL
Fas-resistance	NULL
,	NULL
the	NULL
level	NULL
of	NULL
which	NULL
was	NULL
as	NULL
high	NULL
or	NULL
higher	NULL
than	NULL
that	NULL
associated	NULL
with	NULL
anti-Ig	NULL
[	NULL
35	NULL
]	NULL
.	NULL

This	NULL
recapitulates	NULL
results	NULL
with	NULL
cell	NULL
cycle	NULL
progression	NULL
as	NULL
an	NULL
endpoint	NULL
,	NULL
for	NULL
which	NULL
only	NULL
the	NULL
combination	NULL
of	NULL
a	NULL
phorbol	NULL
ester	NULL
and	NULL
a	NULL
calcium	NULL
ionophore	NULL
,	NULL
which	NULL
together	NULL
mimic	NULL
the	NULL
effects	NULL
of	NULL
slg-triggered	NULL
PLC-mediated	NULL
second	NULL
messengers	NULL
,	NULL
produces	NULL
S	NULL
phase	NULL
entry	NULL
[	NULL
44	NULL
]	NULL
,	NULL
[	NULL
45	NULL
]	NULL
.	NULL

Thus	NULL
,	NULL
Fas-resistance	NULL
can	NULL
be	NULL
established	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
specific	NULL
receptor	NULL
engagement	NULL
by	NULL
appropriate	NULL
stimulation	NULL
of	NULL
intracellular	NULL
mediators	NULL
.	NULL

Btk	NULL
is	NULL
an	NULL
indispensable	NULL
intermediary	NULL
in	NULL
the	NULL
slg	NULL
pathway	NULL
leading	NULL
to	NULL
cell	NULL
cycle	NULL
progression	NULL
,	NULL
as	NULL
evidenced	NULL
by	NULL
the	NULL
complete	NULL
failure	NULL
of	NULL
S	NULL
phase	NULL
entry	NULL
in	NULL
B	NULL
cells	NULL
from	NULL
xid	NULL
mice	NULL
,	NULL
in	NULL
which	NULL
Btk	NULL
is	NULL
mutated	NULL
,	NULL
or	NULL
in	NULL
B	NULL
cells	NULL
from	NULL
Btk	NULL
knock-out	NULL
mice	NULL
,	NULL
in	NULL
which	NULL
Btk	NULL
is	NULL
absent	NULL
249	NULL
Inducible	NULL
Fas-resistance	NULL
in	NULL
B	NULL
cells	NULL
[	NULL
46-48	NULL
]	NULL
.	NULL

In	NULL
view	NULL
of	NULL
the	NULL
importance	NULL
of	NULL
Btk	NULL
for	NULL
slg-induced	NULL
proliferation	NULL
,	NULL
the	NULL
role	NULL
of	NULL
Btk	NULL
in	NULL
slg	NULL
signaling	NULL
for	NULL
Fas-resistance	NULL
was	NULL
examined	NULL
using	NULL
B	NULL
cells	NULL
from	NULL
both	NULL
kinds	NULL
of	NULL
mice	NULL
.	NULL

With	NULL
xid	NULL
B	NULL
cells	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
Fas-sensitivity	NULL
produced	NULL
by	NULL
CD4O0L	NULL
stimulation	NULL
,	NULL
and	NULL
of	NULL
Fas-resistance	NULL
induced	NULL
by	NULL
anti-Ig	NULL
,	NULL
were	NULL
indistinguishable	NULL
from	NULL
results	NULL
obtained	NULL
with	NULL
wild-type	NULL
control	NULL
B	NULL
cells	NULL
.	NULL

With	NULL
Btk	NULL
knock-out	NULL
B	NULL
cells	NULL
,	NULL
CD4O0L	NULL
stimulation	NULL
produced	NULL
Fas-sensitivity	NULL
that	NULL
was	NULL
minimally	NULL
increased	NULL
(	NULL
by	NULL
20-30	NULL
%	NULL
)	NULL
over	NULL
that	NULL
observed	NULL
with	NULL
control	NULL
B	NULL
cells	NULL
;	NULL
however	NULL
,	NULL
there	NULL
was	NULL
no	NULL
difference	NULL
between	NULL
B	NULL
cells	NULL
obtained	NULL
from	NULL
Btk	NULL
knock-out	NULL
and	NULL
from	NULL
wild-type	NULL
control	NULL
mice	NULL
in	NULL
the	NULL
degree	NULL
of	NULL
Fas-resistance	NULL
produced	NULL
by	NULL
anti-Ig	NULL
[	NULL
49	NULL
]	NULL
.	NULL

The	NULL
unexpected	NULL
minor	NULL
increase	NULL
in	NULL
Fas-sensitivity	NULL
in	NULL
Btk	NULL
knock-out	NULL
B	NULL
cells	NULL
may	NULL
relate	NULL
to	NULL
the	NULL
report	NULL
that	NULL
Btk	NULL
binds	NULL
Fas	NULL
and	NULL
interferes	NULL
with	NULL
Fas	NULL
signaling	NULL
for	NULL
cell	NULL
death	NULL
,	NULL
although	NULL
the	NULL
modulation	NULL
of	NULL
Fas-sensitivity	NULL
observed	NULL
here	NULL
in	NULL
murine	NULL
B	NULL
cells	NULL
was	NULL
much	NULL
less	NULL
impressive	NULL
than	NULL
that	NULL
reported	NULL
for	NULL
chicken	NULL
DT4O	NULL
B	NULL
cells	NULL
[	NULL
50	NULL
]	NULL
.	NULL

The	NULL
xid	NULL
and	NULL
Btk	NULL
knock-out	NULL
results	NULL
together	NULL
indicate	NULL
that	NULL
Btk	NULL
plays	NULL
no	NULL
role	NULL
in	NULL
slg	NULL
signaling	NULL
for	NULL
Fas-resistance	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
signaling	NULL
pathway	NULL
that	NULL
leads	NULL
from	NULL
sIg	NULL
to	NULL
Fas-resistance	NULL
differs	NULL
completely	NULL
from	NULL
the	NULL
route	NULL
leading	NULL
from	NULL
slg	NULL
to	NULL
S	NULL
phase	NULL
entry	NULL
,	NULL
in	NULL
that	NULL
Btk	NULL
is	NULL
absolutely	NULL
required	NULL
for	NULL
the	NULL
latter	NULL
but	NULL
not	NULL
at	NULL
all	NULL
for	NULL
the	NULL
former	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
Fas-resistance	NULL
develops	NULL
over	NULL
a	NULL
period	NULL
of	NULL
hours	NULL
following	NULL
anti-Ig	NULL
treatment	NULL
suggested	NULL
that	NULL
new	NULL
gene	NULL
expression	NULL
might	NULL
play	NULL
a	NULL
key	NULL
role	NULL
.	NULL

To	NULL
examine	NULL
this	NULL
possibility	NULL
,	NULL
B	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
inhibitors	NULL
of	NULL
macromolecular	NULL
synthesis	NULL
along	NULL
with	NULL
anti-Ig	NULL
during	NULL
the	NULL
last	NULL
6	NULL
h	NULL
of	NULL
48	NULL
h	NULL
cultures	NULL
with	NULL
CD4O0L	NULL
(	NULL
longer	NULL
periods	NULL
of	NULL
exposure	NULL
being	NULL
precluded	NULL
by	NULL
drug	NULL
toxicity	NULL
)	NULL
;	NULL
the	NULL
addition	NULL
of	NULL
either	NULL
cycloheximide	NULL
or	NULL
actinomycin	NULL
D	NULL
completely	NULL
blocked	NULL
the	NULL
induction	NULL
of	NULL
Fas-resistance	NULL
by	NULL
anti-Ig	NULL
[	NULL
35	NULL
]	NULL
,	NULL
[	NULL
51	NULL
]	NULL
.	NULL

Thus	NULL
,	NULL
Fas-resistance	NULL
induced	NULL
by	NULL
slg	NULL
engagement	NULL
appears	NULL
to	NULL
depend	NULL
on	NULL
new	NULL
gene	NULL
expression	NULL
and	NULL
new	NULL
protein	NULL
synthesis	NULL
.	NULL

These	NULL
results	NULL
also	NULL
indicate	NULL
that	NULL
the	NULL
mechanism	NULL
responsible	NULL
for	NULL
sIg-induced	NULL
Fas-resistance	NULL
in	NULL
primary	NULL
B	NULL
cells	NULL
differs	NULL
from	NULL
that	NULL
reported	NULL
for	NULL
the	NULL
A20	NULL
B	NULL
cell	NULL
line	NULL
,	NULL
which	NULL
is	NULL
not	NULL
interrupted	NULL
by	NULL
cycloheximide	NULL
[	NULL
52	NULL
]	NULL
.	NULL

The	NULL
dependence	NULL
of	NULL
slg-induced	NULL
Fas-resistance	NULL
on	NULL
new	NULL
gene	NULL
expression	NULL
implies	NULL
,	NULL
in	NULL
turn	NULL
,	NULL
a	NULL
role	NULL
for	NULL
factors	NULL
that	NULL
transcriptionally	NULL
activate	NULL
anti-apoptotic	NULL
genes	NULL
.	NULL

A	NULL
candidate	NULL
factor	NULL
might	NULL
be	NULL
NF-	NULL
Â«	NULL
xB	NULL
,	NULL
a	NULL
transactivating	NULL
complex	NULL
that	NULL
is	NULL
developmentally	NULL
regulated	NULL
and	NULL
is	NULL
induced	NULL
as	NULL
a	NULL
result	NULL
of	NULL
slg	NULL
engagement	NULL
,	NULL
inasmuch	NULL
as	NULL
NF-	NULL
Â«	NULL
B	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
regulate	NULL
the	NULL
expression	NULL
of	NULL
some	NULL
anti-apoptotic	NULL
genes	NULL
,	NULL
and	NULL
to	NULL
influence	NULL
the	NULL
Fas-sensitivity	NULL
of	NULL
T	NULL
cell	NULL
lines	NULL
[	NULL
53-61	NULL
]	NULL
.	NULL

To	NULL
evaluate	NULL
the	NULL
role	NULL
of	NULL
NF-cB	NULL
,	NULL
inhibitors	NULL
of	NULL
nuclear	NULL
NF-cB	NULL
translocation	NULL
were	NULL
added	NULL
along	NULL
with	NULL
anti-Ig	NULL
during	NULL
the	NULL
last	NULL
12	NULL
h	NULL
of	NULL
48	NULL
h	NULL
cultures	NULL
with	NULL
CD40L	NULL
;	NULL
the	NULL
proteasome	NULL
inhibitor	NULL
lactacystin	NULL
[	NULL
62	NULL
]	NULL
,	NULL
[	NULL
63	NULL
]	NULL
and	NULL
the	NULL
antioxidant	NULL
pyrrolidinedithiocarbamate	NULL
(	NULL
PDTC	NULL
)	NULL
[	NULL
64	NULL
]	NULL
each	NULL
completely	NULL
blocked	NULL
sIg-induced	NULL
Fas-resistance	NULL
,	NULL
while	NULL
having	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
ability	NULL
of	NULL
CD4O0L	NULL
alone	NULL
to	NULL
upregulate	NULL
Fas	NULL
expression	NULL
and	NULL
to	NULL
produce	NULL
Fas-sengitivity	NULL
.	NULL

As	NULL
an	NULL
important	NULL
corollary	NULL
,	NULL
lactacystin	NULL
and	NULL
PDTC	NULL
also	NULL
inhibited	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
Â«	NULL
xB	NULL
that	NULL
was	NULL
produced	NULL
when	NULL
anti-Ig	NULL
was	NULL
added	NULL
to	NULL
CD40L-stimulated	NULL
B	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
with	NULL
two	NULL
different	NULL
inhibitors	NULL
,	NULL
operating	NULL
through	NULL
two	NULL
different	NULL
mechanisms	NULL
of	NULL
action	NULL
,	NULL
indicate	NULL
that	NULL
slg	NULL
signaling	NULL
for	NULL
Fag-resis-tance	NULL
requires	NULL
NF-	NULL
Â«	NULL
B	NULL
activation	NULL
and	NULL
is	NULL
thus	NULL
NF-	NULL
Â«	NULL
<	NULL
B-dependent	NULL
.	NULL

Notably	NULL
,	NULL
PMA	NULL
induces	NULL
250	NULL
Rothstein	NULL
TL	NULL
vigorous	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-	NULL
Â«	NULL
B	NULL
in	NULL
mature	NULL
B	NULL
cells	NULL
but	NULL
only	NULL
partial	NULL
resistance	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
[	NULL
35	NULL
]	NULL
,	NULL
[	NULL
53	NULL
]	NULL
,	NULL
suggesting	NULL
that	NULL
either	NULL
NF-	NULL
Â«	NULL
B	NULL
induction	NULL
is	NULL
a	NULL
necessary	NULL
but	NULL
not	NULL
sufficient	NULL
condition	NULL
for	NULL
Fas-resistance	NULL
,	NULL
or	NULL
that	NULL
Fas-resistance	NULL
depends	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
sIg-specific	NULL
Â«	NULL
<	NULL
B-binding	NULL
complexes	NULL
.	NULL

Recently	NULL
,	NULL
two	NULL
groups	NULL
reported	NULL
that	NULL
sIg-induced	NULL
NF-	NULL
Â«	NULL
B	NULL
activation	NULL
,	NULL
like	NULL
sIg-induced	NULL
proliferation	NULL
,	NULL
is	NULL
Btk-dependent	NULL
[	NULL
65	NULL
]	NULL
,	NULL
[	NULL
66	NULL
]	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
experiments	NULL
discussed	NULL
above	NULL
indicate	NULL
that	NULL
sIg-induced	NULL
Fas-resistance	NULL
requires	NULL
NF-	NULL
Â«	NULL
B	NULL
yet	NULL
takes	NULL
place	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Btk	NULL
.	NULL

The	NULL
reason	NULL
for	NULL
these	NULL
seemingly	NULL
conflicting	NULL
results	NULL
remains	NULL
unclear	NULL
.	NULL

It	NULL
may	NULL
be	NULL
that	NULL
prior	NULL
CD40L	NULL
stimulation	NULL
establishes	NULL
a	NULL
new	NULL
intracellular	NULL
signaling	NULL
pathway	NULL
through	NULL
which	NULL
slg	NULL
activates	NULL
NF-	NULL
Â«	NULL
B	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Btk	NULL
.	NULL

Or	NULL
it	NULL
may	NULL
be	NULL
that	NULL
induction	NULL
of	NULL
Fas-resistance	NULL
requires	NULL
only	NULL
a	NULL
very	NULL
minimal	NULL
threshold	NULL
level	NULL
of	NULL
NF-	NULL
Â«	NULL
B	NULL
.	NULL

Alternatively	NULL
,	NULL
inhibitors	NULL
of	NULL
NF-	NULL
<	NULL
B	NULL
activation	NULL
may	NULL
at	NULL
the	NULL
same	NULL
time	NULL
inhibit	NULL
another	NULL
signaling	NULL
mediator	NULL
,	NULL
and	NULL
this	NULL
latter	NULL
mediator	NULL
,	NULL
not	NULL
NF-	NULL
Â«	NULL
B	NULL
,	NULL
is	NULL
the	NULL
important	NULL
molecular	NULL
effector	NULL
.	NULL

These	NULL
possibilities	NULL
are	NULL
currently	NULL
being	NULL
tested	NULL
.	NULL

Two	NULL
terminal	NULL
effectors	NULL
of	NULL
Fas-resistance	NULL
:	NULL
Bel-xi	NULL
and	NULL
FLIP	NULL
The	NULL
identity	NULL
of	NULL
gene	NULL
products	NULL
whose	NULL
synthesis	NULL
might	NULL
be	NULL
responsible	NULL
for	NULL
inducible	NULL
Fas-resistance	NULL
was	NULL
sought	NULL
by	NULL
testing	NULL
likely	NULL
prospects	NULL
according	NULL
to	NULL
two	NULL
criteria	NULL
:	NULL
upregulation	NULL
of	NULL
expression	NULL
under	NULL
conditions	NULL
that	NULL
produce	NULL
Fas-resistance	NULL
,	NULL
and	NULL
,	NULL
induction	NULL
of	NULL
Fas-resistance	NULL
by	NULL
upregulated	NULL
expression	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
receptor	NULL
engagement	NULL
.	NULL

Initial	NULL
experiments	NULL
designed	NULL
to	NULL
detect	NULL
such	NULL
molecules	NULL
focused	NULL
on	NULL
members	NULL
of	NULL
the	NULL
Bel-2	NULL
family	NULL
,	NULL
some	NULL
members	NULL
of	NULL
which	NULL
interfere	NULL
with	NULL
mitochondrial	NULL
cytochrome	NULL
c	NULL
release	NULL
[	NULL
67	NULL
]	NULL
.	NULL

A	NULL
number	NULL
of	NULL
Bel-2-	NULL
homologous	NULL
genes	NULL
were	NULL
assayed	NULL
for	NULL
induction	NULL
by	NULL
anti-Ig	NULL
treatment	NULL
of	NULL
CD4O0L-stimulated	NULL
B	NULL
cells	NULL
through	NULL
RT-PCR	NULL
.	NULL

Only	NULL
bel-x1	NULL
was	NULL
upregulated	NULL
.	NULL

Bel-x1	NULL
expression	NULL
was	NULL
strongly	NULL
induced	NULL
at	NULL
the	NULL
RNA	NULL
level	NULL
within	NULL
an	NULL
hour	NULL
of	NULL
anti-Ig	NULL
addition	NULL
,	NULL
and	NULL
at	NULL
the	NULL
protein	NULL
level	NULL
within	NULL
6-12	NULL
h	NULL
[	NULL
68	NULL
]	NULL
.	NULL

B	NULL
cells	NULL
obtained	NULL
from	NULL
Bel-xr-overexpressing	NULL
transgenic	NULL
mice	NULL
were	NULL
then	NULL
tested	NULL
for	NULL
susceptibility	NULL
to	NULL
Thl1	NULL
cell	NULL
mediated	NULL
cytotoxicity	NULL
after	NULL
stimulation	NULL
by	NULL
CD40L	NULL
alone	NULL
,	NULL
in	NULL
order	NULL
to	NULL
determine	NULL
the	NULL
capacity	NULL
of	NULL
Bel-x1	NULL
,	NULL
overexpressed	NULL
in	NULL
isolation	NULL
,	NULL
to	NULL
produce	NULL
Fas-resistance	NULL
.	NULL

These	NULL
B	NULL
cells	NULL
were	NULL
(	NULL
3-fold	NULL
)	NULL
less	NULL
sensitive	NULL
to	NULL
Fas	NULL
killing	NULL
than	NULL
wild-type	NULL
littermate	NULL
control	NULL
B	NULL
cells	NULL
,	NULL
despite	NULL
similar	NULL
levels	NULL
of	NULL
upregulated	NULL
Fas	NULL
expression	NULL
,	NULL
and	NULL
similar	NULL
levels	NULL
of	NULL
activation	NULL
as	NULL
judged	NULL
by	NULL
thymidine	NULL
incorporation	NULL
[	NULL
68	NULL
]	NULL
.	NULL

Thus	NULL
,	NULL
Bel-x1	NULL
appears	NULL
to	NULL
account	NULL
for	NULL
at	NULL
least	NULL
a	NULL
portion	NULL
of	NULL
slg-induced	NULL
Fas-resistance	NULL
because	NULL
,	NULL
expression	NULL
was	NULL
upregulated	NULL
coordinately	NULL
with	NULL
induction	NULL
of	NULL
Fas-resistance	NULL
(	NULL
in	NULL
both	NULL
murine	NULL
and	NULL
human	NULL
B	NULL
cells	NULL
,	NULL
reference	NULL
[	NULL
69	NULL
]	NULL
)	NULL
,	NULL
and	NULL
,	NULL
because	NULL
isolated	NULL
overexpression	NULL
diminished	NULL
B	NULL
cell	NULL
susceptibility	NULL
to	NULL
Fas	NULL
killing	NULL
separate	NULL
and	NULL
apart	NULL
from	NULL
any	NULL
other	NULL
potential	NULL
effects	NULL
of	NULL
slg	NULL
engagement	NULL
(	NULL
although	NULL
in	NULL
connection	NULL
with	NULL
this	NULL
last	NULL
point	NULL
it	NULL
should	NULL
be	NULL
mentioned	NULL
that	NULL
the	NULL
capacity	NULL
of	NULL
Bel-xi	NULL
to	NULL
inhibit	NULL
Fas-mediated	NULL
apoptosis	NULL
in	NULL
B	NULL
cell	NULL
lines	NULL
has	NULL
been	NULL
questioned	NULL
,	NULL
reference	NULL
[	NULL
70	NULL
]	NULL
)	NULL
.	NULL

Further	NULL
,	NULL
the	NULL
reduction	NULL
in	NULL
susceptibility	NULL
to	NULL
Th1-induced	NULL
cytotoxicity	NULL
produced	NULL
by	NULL
Bel-xi	NULL
suggests	NULL
that	NULL
Fas	NULL
death	NULL
signaling	NULL
in	NULL
B	NULL
cells	NULL
involves	NULL
mitochondrial	NULL
cytochrome	NULL
c	NULL
release	NULL
;	NULL
this	NULL
notion	NULL
is	NULL
supported	NULL
by	NULL
our	NULL
observation	NULL
that	NULL
inducibly	NULL
Fas-resistant	NULL
B	NULL
cells	NULL
are	NULL
protected	NULL
against	NULL
apoptosis	NULL
produced	NULL
by	NULL
C2-ceramide	NULL
,	NULL
251	NULL
Inducible	NULL
Fas-resistance	NULL
in	NULL
B	NULL
cells	NULL
the	NULL
cytotoxicity	NULL
of	NULL
which	NULL
has	NULL
been	NULL
associated	NULL
with	NULL
mitochondrial	NULL
damage	NULL
[	NULL
71-75	NULL
]	NULL
[	NULL
71-75	NULL
]	NULL
.	NULL

There	NULL
are	NULL
,	NULL
however	NULL
,	NULL
several	NULL
indications	NULL
that	NULL
Bel-xi	NULL
does	NULL
not	NULL
fully	NULL
account	NULL
for	NULL
Fas-resistance	NULL
produced	NULL
by	NULL
anti-Ig	NULL
:	NULL
1	NULL
)	NULL
the	NULL
loss	NULL
of	NULL
Fas-sensitivity	NULL
in	NULL
(	NULL
CD4OL-stimulated	NULL
)	NULL
Bel-xi-overexpressing	NULL
B	NULL
cells	NULL
was	NULL
incomplete	NULL
,	NULL
and	NULL
was	NULL
less	NULL
dramatic	NULL
than	NULL
the	NULL
loss	NULL
of	NULL
Fas-sensitivity	NULL
observed	NULL
in	NULL
wild-type	NULL
B	NULL
cells	NULL
stimulated	NULL
by	NULL
anti-Ig	NULL
plus	NULL
CD40L	NULL
;	NULL
2	NULL
)	NULL
anti-Ig	NULL
treatment	NULL
of	NULL
(	NULL
CD4O0L-stimulated	NULL
)	NULL
Bel-xr-overexpressing	NULL
B	NULL
cells	NULL
produced	NULL
a	NULL
further	NULL
(	NULL
approximately	NULL
3-fold	NULL
)	NULL
reduction	NULL
in	NULL
the	NULL
already	NULL
muted	NULL
Fas-sensitivity	NULL
of	NULL
these	NULL
B	NULL
cells	NULL
;	NULL
and	NULL
,	NULL
3	NULL
)	NULL
Bel-xi1	NULL
.	NULL
}	NULL

protein	NULL
did	NULL
not	NULL
appear	NULL
in	NULL
normal	NULL
CD40L-stimulated	NULL
B	NULL
cells	NULL
treated	NULL
with	NULL
anti-Ig	NULL
until	NULL
after	NULL
the	NULL
initial	NULL
onset	NULL
of	NULL
diminished	NULL
sensitivity	NULL
to	NULL
Fas	NULL
.	NULL

These	NULL
considerations	NULL
strongly	NULL
suggest	NULL
that	NULL
at	NULL
least	NULL
one	NULL
other	NULL
anti-Ig-responsive	NULL
molecule	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
blocking	NULL
Fas	NULL
killing	NULL
following	NULL
slg	NULL
engagement	NULL
.	NULL

Additional	NULL
experiments	NULL
designed	NULL
to	NULL
elucidate	NULL
the	NULL
identity	NULL
of	NULL
gene	NULL
products	NULL
potentially	NULL
responsible	NULL
for	NULL
sIg-induced	NULL
Fas-resistance	NULL
focused	NULL
on	NULL
evaluation	NULL
of	NULL
FLIP	NULL
.	NULL

FLIP	NULL
is	NULL
a	NULL
FLICE/caspase	NULL
8	NULL
homolog	NULL
that	NULL
lacks	NULL
an	NULL
active	NULL
enzyme	NULL
site	NULL
and	NULL
thus	NULL
competitively	NULL
inhibits	NULL
downstream	NULL
signaling	NULL
that	NULL
normally	NULL
occurs	NULL
following	NULL
FLICE/caspase	NULL
8	NULL
binding	NULL
to	NULL
FADD	NULL
[	NULL
76-79	NULL
]	NULL
.	NULL

Our	NULL
early	NULL
Northern	NULL
blot	NULL
experiments	NULL
suggested	NULL
that	NULL
some	NULL
FLIP	NULL
expression	NULL
was	NULL
induced	NULL
by	NULL
anti-Ig	NULL
treatment	NULL
of	NULL
CD40L-stimulated	NULL
B	NULL
cells	NULL
,	NULL
but	NULL
the	NULL
data	NULL
were	NULL
inconclusive	NULL
owing	NULL
to	NULL
the	NULL
very	NULL
low	NULL
level	NULL
of	NULL
FLIP	NULL
expression	NULL
detected	NULL
.	NULL

However	NULL
,	NULL
definitive	NULL
results	NULL
were	NULL
subsequently	NULL
obtained	NULL
by	NULL
RT-PCR	NULL
,	NULL
which	NULL
showed	NULL
that	NULL
FLIP	NULL
RNA	NULL
expression	NULL
was	NULL
induced	NULL
within	NULL
an	NULL
hour	NULL
of	NULL
adding	NULL
anti-Ig	NULL
to	NULL
CD40L-stimulated	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
that	NULL
FLIP	NULL
protein	NULL
expression	NULL
was	NULL
upregulated	NULL
within	NULL
6	NULL
h.	NULL
These	NULL
results	NULL
were	NULL
recently	NULL
extended	NULL
by	NULL
reports	NULL
indicating	NULL
that	NULL
FLIP	NULL
overexpression	NULL
interferes	NULL
with	NULL
Fas-mediated	NULL
apoptosis	NULL
in	NULL
primary	NULL
B	NULL
cells	NULL
and	NULL
in	NULL
B	NULL
cell	NULL
lines	NULL
[	NULL
80	NULL
]	NULL
,	NULL
[	NULL
81	NULL
]	NULL
.	NULL

These	NULL
studies	NULL
together	NULL
strongly	NULL
suggest	NULL
that	NULL
FLIP	NULL
is	NULL
involved	NULL
in	NULL
bringing	NULL
about	NULL
sIg-induced	NULL
resistance	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
because	NULL
the	NULL
two	NULL
criteria	NULL
discussed	NULL
above	NULL
were	NULL
met	NULL
,	NULL
as	NULL
described	NULL
earlier	NULL
for	NULL
Bel-x1	NULL
:	NULL
FLIP	NULL
expression	NULL
was	NULL
upregulated	NULL
coordinately	NULL
with	NULL
induction	NULL
of	NULL
Fas-resistance	NULL
by	NULL
anti-Ig	NULL
,	NULL
and	NULL
isolated	NULL
FLIP	NULL
overexpression	NULL
diminished	NULL
B	NULL
cell	NULL
susceptibility	NULL
to	NULL
Fas	NULL
signaling	NULL
for	NULL
cell	NULL
death	NULL
.	NULL

(	NULL
In	NULL
these	NULL
studies	NULL
a	NULL
number	NULL
of	NULL
other	NULL
known	NULL
anti-apoptotic	NULL
genes	NULL
screened	NULL
as	NULL
outlined	NULL
above	NULL
failed	NULL
to	NULL
meet	NULL
the	NULL
criterion	NULL
of	NULL
expression	NULL
coincident	NULL
with	NULL
induction	NULL
of	NULL
Fas-resistance	NULL
,	NULL
including	NULL
A1	NULL
,	NULL
A20	NULL
,	NULL
BAG-1	NULL
,	NULL
Bel-2	NULL
,	NULL
IAP-1	NULL
,	NULL
IAP-2	NULL
,	NULL
Ich-18	NULL
,	NULL
IEX-1L	NULL
and	NULL
survivin	NULL
,	NULL
references	NULL
[	NULL
82-90	NULL
]	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
novel	NULL
Fas	NULL
apoptosis	NULL
inhibitory	NULL
molecule	NULL
(	NULL
FAIM	NULL
)	NULL
To	NULL
identify	NULL
additional	NULL
genes	NULL
that	NULL
might	NULL
be	NULL
responsible	NULL
for	NULL
resistance	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
without	NULL
regard	NULL
to	NULL
conserved	NULL
motifs	NULL
or	NULL
known	NULL
properties	NULL
,	NULL
transcripts	NULL
induced	NULL
as	NULL
a	NULL
result	NULL
of	NULL
anti-lg	NULL
treatment	NULL
that	NULL
produces	NULL
Fas-resistance	NULL
were	NULL
detected	NULL
using	NULL
a	NULL
differential	NULL
display	NULL
strategy	NULL
[	NULL
91	NULL
]	NULL
.	NULL

Through	NULL
this	NULL
approach	NULL
,	NULL
a	NULL
completely	NULL
novel	NULL
1.2	NULL
kb	NULL
sequence	NULL
was	NULL
cloned	NULL
that	NULL
contains	NULL
an	NULL
open	NULL
reading	NULL
frame	NULL
encoding	NULL
a	NULL
protein	NULL
product	NULL
of	NULL
179	NULL
amino	NULL
acids	NULL
predicted	NULL
to	NULL
reflect	NULL
a	NULL
stable	NULL
,	NULL
soluble	NULL
,	NULL
B-strand-rich	NULL
molecule	NULL
that	NULL
is	NULL
slightly	NULL
acidic	NULL
[	NULL
51	NULL
]	NULL
.	NULL

The	NULL
function	NULL
of	NULL
this	NULL
gene	NULL
was	NULL
evaluated	NULL
with	NULL
BAL-17	NULL
murine	NULL
B	NULL
lymphoma	NULL
cells	NULL
,	NULL
the	NULL
activation	NULL
responses	NULL
of	NULL
which	NULL
mimic	NULL
those	NULL
of	NULL
primary	NULL
B	NULL
cells	NULL
in	NULL
a	NULL
252	NULL
Rothstein	NULL
TL	NULL
number	NULL
of	NULL
ways	NULL
[	NULL
92	NULL
]	NULL
,	NULL
including	NULL
upregulated	NULL
Fas	NULL
expression	NULL
and	NULL
increased	NULL
sensitivity	NULL
to	NULL
Fas	NULL
killing	NULL
following	NULL
CD40L	NULL
stimulation	NULL
.	NULL

BAL-17	NULL
B	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
gene	NULL
cloned	NULL
in	NULL
pBKCMV	NULL
,	NULL
or	NULL
with	NULL
empty	NULL
vector	NULL
,	NULL
selected	NULL
in	NULL
G418	NULL
,	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
CD40L	NULL
for	NULL
24	NULL
h	NULL
and	NULL
examined	NULL
for	NULL
susceptibility	NULL
to	NULL
Th1	NULL
cell-mediated	NULL
cytotoxicity	NULL
.	NULL

Cytotoxicity	NULL
was	NULL
assessed	NULL
in	NULL
two	NULL
ways	NULL
,	NULL
by	NULL
chromium	NULL
release	NULL
after	NULL
exposure	NULL
of	NULL
transfectants	NULL
to	NULL
FasL-bearing	NULL
Th1	NULL
effector	NULL
cells	NULL
,	NULL
and	NULL
by	NULL
propidium	NULL
iodide-staining	NULL
for	NULL
subdiploid	NULL
DNA	NULL
after	NULL
treatment	NULL
of	NULL
transfectants	NULL
with	NULL
Jo-2	NULL
anti-Fas	NULL
antibody	NULL
.	NULL

Regardless	NULL
of	NULL
the	NULL
means	NULL
by	NULL
which	NULL
Fas	NULL
was	NULL
engaged	NULL
or	NULL
cytotoxicity	NULL
was	NULL
assessed	NULL
,	NULL
Fas-mediated	NULL
apoptosis	NULL
was	NULL
markedly	NULL
reduced	NULL
in	NULL
B	NULL
cells	NULL
expressing	NULL
the	NULL
gene	NULL
of	NULL
interest	NULL
as	NULL
compared	NULL
to	NULL
vector	NULL
transfectants	NULL
,	NULL
using	NULL
both	NULL
G418-resistant	NULL
pools	NULL
and	NULL
stably	NULL
transfected	NULL
lines	NULL
cloned	NULL
by	NULL
limiting	NULL
dilution	NULL
[	NULL
51	NULL
]	NULL
.	NULL

Considering	NULL
the	NULL
dose-response	NULL
curve	NULL
with	NULL
Th1	NULL
effector	NULL
cells	NULL
,	NULL
Fas-resistance	NULL
produced	NULL
by	NULL
the	NULL
gene	NULL
of	NULL
interest	NULL
amounted	NULL
to	NULL
a	NULL
greater	NULL
than	NULL
9-fold	NULL
level	NULL
of	NULL
protection	NULL
against	NULL
Fas-mediated	NULL
apoptosis	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
differentially	NULL
expressed	NULL
gene	NULL
encodes	NULL
a	NULL
Fas	NULL
Apoptosis	NULL
Inhibitory	NULL
Molecule	NULL
,	NULL
which	NULL
we	NULL
termed	NULL
FAIM	NULL
.	NULL

The	NULL
anti-apoptotic	NULL
function	NULL
of	NULL
FAIM	NULL
was	NULL
demonstrated	NULL
further	NULL
at	NULL
a	NULL
biochemical	NULL
level	NULL
by	NULL
evaluating	NULL
cleavage	NULL
products	NULL
of	NULL
poly-ADP	NULL
ribose	NULL
polymerase	NULL
(	NULL
PARP	NULL
)	NULL
that	NULL
result	NULL
from	NULL
caspase	NULL
activation	NULL
[	NULL
93	NULL
,	NULL
94	NULL
]	NULL
.	NULL

PARP	NULL
fragments	NULL
were	NULL
detected	NULL
within	NULL
40	NULL
minutes	NULL
of	NULL
treating	NULL
vector-transfected	NULL
BAL-17	NULL
B	NULL
cells	NULL
with	NULL
Jo-2	NULL
anti-Fas	NULL
antibody	NULL
,	NULL
whereas	NULL
such	NULL
fragments	NULL
were	NULL
not	NULL
observed	NULL
in	NULL
faim-transfected	NULL
BAL-17	NULL
B	NULL
cells	NULL
up	NULL
to	NULL
60	NULL
minutes	NULL
after	NULL
antibody	NULL
treatment	NULL
[	NULL
51	NULL
]	NULL
.	NULL

This	NULL
correlated	NULL
well	NULL
with	NULL
the	NULL
transgenically	NULL
enhanced	NULL
level	NULL
of	NULL
FAIM	NULL
expression	NULL
,	NULL
which	NULL
was	NULL
demonstrated	NULL
by	NULL
Western	NULL
blotting	NULL
to	NULL
be	NULL
greatly	NULL
increased	NULL
over	NULL
the	NULL
endogenous	NULL
levels	NULL
present	NULL
in	NULL
vector-transfected	NULL
controls	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
FAIM	NULL
blocks	NULL
Fas	NULL
killing	NULL
by	NULL
interfering	NULL
with	NULL
a	NULL
step	NULL
prior	NULL
to	NULL
terminal	NULL
caspase	NULL
activity	NULL
.	NULL

As	NULL
might	NULL
be	NULL
expected	NULL
from	NULL
the	NULL
original	NULL
selection	NULL
conditions	NULL
for	NULL
differential	NULL
display	NULL
analysis	NULL
,	NULL
faim	NULL
mRNA	NULL
increased	NULL
within	NULL
an	NULL
hour	NULL
of	NULL
adding	NULL
anti-Ig	NULL
to	NULL
CD4O0L-stimulated	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
expression	NULL
continued	NULL
to	NULL
rise	NULL
over	NULL
the	NULL
next	NULL
5	NULL
h	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
Northern	NULL
blotting	NULL
.	NULL

Along	NULL
the	NULL
same	NULL
lines	NULL
,	NULL
FAIM	NULL
protein	NULL
increased	NULL
within	NULL
6	NULL
h	NULL
of	NULL
treating	NULL
CD4O0L-stimulated	NULL
B	NULL
cells	NULL
with	NULL
anti-Ig	NULL
,	NULL
and	NULL
expression	NULL
continued	NULL
to	NULL
rise	NULL
,	NULL
peaking	NULL
at	NULL
12	NULL
h	NULL
,	NULL
as	NULL
detected	NULL
by	NULL
Western	NULL
blotting	NULL
[	NULL
51	NULL
]	NULL
.	NULL

The	NULL
finding	NULL
of	NULL
substantially	NULL
increased	NULL
FAIM	NULL
expression	NULL
in	NULL
splenocytes	NULL
obtained	NULL
from	NULL
sheep	NULL
red	NULL
blood	NULL
cell-immune	NULL
animals	NULL
,	NULL
as	NULL
compared	NULL
to	NULL
splenocytes	NULL
obtained	NULL
from	NULL
control	NULL
animals	NULL
injected	NULL
with	NULL
saline	NULL
,	NULL
suggests	NULL
that	NULL
these	NULL
in	NULL
vitro	NULL
studies	NULL
of	NULL
inducible	NULL
FAIM	NULL
expression	NULL
bear	NULL
relevance	NULL
for	NULL
physiological	NULL
immune	NULL
responses	NULL
.	NULL

Thus	NULL
,	NULL
upregulation	NULL
of	NULL
FAIM	NULL
expression	NULL
coincides	NULL
with	NULL
B	NULL
cell	NULL
treatment	NULL
by	NULL
Fas-resistance-inducing	NULL
regimens	NULL
in	NULL
vitro	NULL
,	NULL
and	NULL
with	NULL
induction	NULL
of	NULL
foreign	NULL
antigen-specific	NULL
immune	NULL
responses	NULL
in	NULL
vivo	NULL
.	NULL

The	NULL
murine	NULL
faim	NULL
sequence	NULL
contains	NULL
no	NULL
known	NULL
effector	NULL
domains	NULL
;	NULL
that	NULL
is	NULL
,	NULL
it	NULL
lacks	NULL
kinase	NULL
or	NULL
phosphatase	NULL
domains	NULL
,	NULL
caspase	NULL
or	NULL
CARD	NULL
domains	NULL
,	NULL
PH	NULL
or	NULL
SH2	NULL
domains	NULL
,	NULL
and	NULL
so	NULL
forth	NULL
.	NULL

However	NULL
,	NULL
we	NULL
readily	NULL
identified	NULL
highly	NULL
homologous	NULL
faim	NULL
sequences	NULL
in	NULL
other	NULL
species	NULL
,	NULL
indicating	NULL
strong	NULL
evolutionary	NULL
conservation	NULL
[	NULL
51	NULL
]	NULL
.	NULL

Human	NULL
faim	NULL
was	NULL
obtained	NULL
by	NULL
constructing	NULL
a	NULL
consensus	NULL
sequence	NULL
from	NULL
overlapping	NULL
expressed	NULL
sequence	NULL
tag	NULL
(	NULL
EST	NULL
)	NULL
253	NULL
Inducible	NULL
Fas-resistance	NULL
in	NULL
B	NULL
cells	NULL
fragments	NULL
that	NULL
share	NULL
some	NULL
homology	NULL
with	NULL
mouse	NULL
faim	NULL
,	NULL
plus	NULL
direct	NULL
sequencing	NULL
of	NULL
a	NULL
single	NULL
EST	NULL
clone	NULL
that	NULL
completely	NULL
spans	NULL
the	NULL
putative	NULL
human	NULL
transcript	NULL
[	NULL
95	NULL
]	NULL
.	NULL

The	NULL
predicted	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
human	NULL
FAIM	NULL
is	NULL
90	NULL
%	NULL
identical	NULL
to	NULL
the	NULL
predicted	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
mouse	NULL
FAIM	NULL
.	NULL

These	NULL
results	NULL
were	NULL
extended	NULL
by	NULL
Southern	NULL
analysis	NULL
showing	NULL
hybridization	NULL
by	NULL
a	NULL
mouse	NULL
faim	NULL
probe	NULL
to	NULL
genomic	NULL
DNA	NULL
from	NULL
all	NULL
mammalian	NULL
species	NULL
tested	NULL
(	NULL
human	NULL
,	NULL
monkey	NULL
,	NULL
rat	NULL
,	NULL
mouse	NULL
,	NULL
dog	NULL
,	NULL
cow	NULL
,	NULL
and	NULL
rabbit	NULL
)	NULL
(	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

Worm	NULL
faim	NULL
was	NULL
identified	NULL
by	NULL
directly	NULL
sequencing	NULL
cDNA	NULL
amplified	NULL
by	NULL
PCR	NULL
,	NULL
using	NULL
primers	NULL
based	NULL
on	NULL
our	NULL
own	NULL
manual	NULL
analysis	NULL
of	NULL
the	NULL
putative	NULL
exonic	NULL
structure	NULL
of	NULL
a	NULL
C.	NULL
elegans	NULL
genomic	NULL
sequence	NULL
of	NULL
unknown	NULL
function	NULL
that	NULL
contains	NULL
discrete	NULL
regions	NULL
of	NULL
homology	NULL
with	NULL
mouse	NULL
faim	NULL
.	NULL

The	NULL
predicted	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
C.	NULL
elegans	NULL
FAIM	NULL
is	NULL
50	NULL
%	NULL
identical	NULL
to	NULL
the	NULL
predicted	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
mouse	NULL
FAIM	NULL
.	NULL

Fly	NULL
faim	NULL
was	NULL
obtained	NULL
by	NULL
computer-aided	NULL
searching	NULL
of	NULL
the	NULL
recently	NULL
posted	NULL
D.	NULL
melanogaster	NULL
genome	NULL
,	NULL
using	NULL
accepted	NULL
algorithms	NULL
to	NULL
define	NULL
putative	NULL
exon/intron	NULL
structure	NULL
.	NULL

The	NULL
putative	NULL
predicted	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
D.	NULL
melanogaster	NULL
FAIM	NULL
is	NULL
36	NULL
%	NULL
identical	NULL
to	NULL
the	NULL
predicted	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
mouse	NULL
FAIM	NULL
,	NULL
with	NULL
the	NULL
caveat	NULL
that	NULL
the	NULL
fly	NULL
sequence	NULL
has	NULL
not	NULL
been	NULL
amplified	NULL
directly	NULL
from	NULL
cDNA	NULL
[	NULL
96	NULL
]	NULL
.	NULL

Examination	NULL
of	NULL
the	NULL
predicted	NULL
FAIM	NULL
sequences	NULL
from	NULL
these	NULL
4	NULL
species	NULL
indicates	NULL
that	NULL
specific	NULL
regions	NULL
of	NULL
very	NULL
high	NULL
identity	NULL
exist	NULL
within	NULL
the	NULL
amino	NULL
terminal	NULL
region	NULL
that	NULL
likely	NULL
represent	NULL
novel	NULL
anti-apoptotic	NULL
effector	NULL
domains	NULL
or	NULL
domains	NULL
required	NULL
for	NULL
FAIM	NULL
association	NULL
with	NULL
another	NULL
mediator	NULL
or	NULL
modulator	NULL
protein	NULL
.	NULL

Two	NULL
distinct	NULL
short	NULL
stretches	NULL
of	NULL
12	NULL
and	NULL
13	NULL
amino	NULL
acids	NULL
each	NULL
are	NULL
69-75	NULL
%	NULL
identical	NULL
across	NULL
all	NULL
four	NULL
species	NULL
[	NULL
96	NULL
]	NULL
.	NULL

The	NULL
evolutionary	NULL
conservation	NULL
of	NULL
faim	NULL
strongly	NULL
suggests	NULL
that	NULL
the	NULL
faim	NULL
gene	NULL
product	NULL
is	NULL
an	NULL
important	NULL
regulatory	NULL
molecule	NULL
that	NULL
has	NULL
been	NULL
favored	NULL
for	NULL
retention	NULL
throughout	NULL
phylogeny	NULL
,	NULL
and	NULL
thus	NULL
likely	NULL
plays	NULL
a	NULL
key	NULL
role	NULL
in	NULL
cellular	NULL
viability	NULL
or	NULL
other	NULL
processes	NULL
.	NULL

(	NULL
Since	NULL
there	NULL
is	NULL
no	NULL
known	NULL
Fas	NULL
homolog	NULL
in	NULL
C.	NULL
elegans	NULL
or	NULL
D.	NULL
melanogaster	NULL
,	NULL
it	NULL
is	NULL
presumed	NULL
that	NULL
FAIM	NULL
carries	NULL
out	NULL
a	NULL
similar	NULL
,	NULL
but	NULL
possibly	NULL
not	NULL
Fas-specific	NULL
,	NULL
anti-apoptotic	NULL
function	NULL
in	NULL
the	NULL
worm	NULL
and	NULL
the	NULL
fly	NULL
.	NULL
)	NULL

Two	NULL
other	NULL
characteristics	NULL
of	NULL
FAIM	NULL
suggest	NULL
that	NULL
it	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
regulating	NULL
cellular	NULL
processes	NULL
.	NULL

1	NULL
)	NULL
The	NULL
faim	NULL
gene	NULL
is	NULL
broadly	NULL
expressed	NULL
.	NULL

High	NULL
level	NULL
faim	NULL
gene	NULL
expression	NULL
was	NULL
documented	NULL
in	NULL
murine	NULL
brain	NULL
,	NULL
thymus	NULL
,	NULL
kidney	NULL
and	NULL
spleen	NULL
by	NULL
Northern	NULL
blotting	NULL
,	NULL
and	NULL
in	NULL
additional	NULL
normal	NULL
tissues	NULL
by	NULL
RT-PCR	NULL
[	NULL
51	NULL
]	NULL
,	NULL
[	NULL
96	NULL
]	NULL
,	NULL
suggesting	NULL
that	NULL
FAIM	NULL
performs	NULL
an	NULL
essential	NULL
function	NULL
in	NULL
non-lymphoid	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
lymphoid	NULL
,	NULL
cells	NULL
.	NULL

2	NULL
)	NULL
The	NULL
faim	NULL
gene	NULL
localizes	NULL
to	NULL
a	NULL
cytogenetic	NULL
region	NULL
associated	NULL
with	NULL
disease	NULL
.	NULL

Human	NULL
faim	NULL
was	NULL
localized	NULL
to	NULL
chromosome	NULL
3422-25	NULL
by	NULL
fluorescence	NULL
in	NULL
situ	NULL
hybridization	NULL
(	NULL
FISH	NULL
)	NULL
,	NULL
and	NULL
to	NULL
chromosome	NULL
3q25	NULL
by	NULL
radiation	NULL
hybrid	NULL
analysis	NULL
of	NULL
a	NULL
faim-containing	NULL
EST	NULL
[	NULL
96	NULL
]	NULL
.	NULL

This	NULL
region	NULL
contains	NULL
loci	NULL
associated	NULL
with	NULL
B	NULL
cell	NULL
lymphoma	NULL
,	NULL
acute	NULL
non-lymphocytic	NULL
leukemia	NULL
,	NULL
and	NULL
squamous	NULL
cell	NULL
carcinoma	NULL
of	NULL
the	NULL
lung	NULL
[	NULL
97-99	NULL
]	NULL
.	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
mutation	NULL
of	NULL
a	NULL
gene	NULL
that	NULL
blocks	NULL
Th1	NULL
cell-mediated	NULL
cytotoxicity	NULL
might	NULL
inure	NULL
to	NULL
the	NULL
benefit	NULL
of	NULL
malignant	NULL
cells	NULL
is	NULL
speculative	NULL
at	NULL
best	NULL
,	NULL
but	NULL
such	NULL
changes	NULL
might	NULL
increase	NULL
the	NULL
level	NULL
of	NULL
FAIM	NULL
expression	NULL
or	NULL
enhance	NULL
the	NULL
anti-apoptotic	NULL
activity	NULL
of	NULL
FAIM	NULL
.	NULL

Recently	NULL
,	NULL
inhibition	NULL
of	NULL
Fas-mediated	NULL
apoptosis	NULL
by	NULL
overexpression	NULL
of	NULL
FLIP	NULL
was	NULL
shown	NULL
to	NULL
increase	NULL
lymphoma	NULL
tum-origenicity	NULL
[	NULL
100	NULL
]	NULL
,	NULL
[	NULL
101	NULL
]	NULL
,	NULL
supporting	NULL
the	NULL
concept	NULL
that	NULL
modulation	NULL
of	NULL
Fas	NULL
signaling	NULL
for	NULL
cell	NULL
254	NULL
Rothstein	NULL
TL	NULL
death	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
determining	NULL
the	NULL
effectiveness	NULL
of	NULL
anti-tumor	NULL
immunity	NULL
,	NULL
and	NULL
providing	NULL
a	NULL
rationale	NULL
for	NULL
a	NULL
connection	NULL
between	NULL
tumor-associated	NULL
loci	NULL
and	NULL
anti-apoptotic	NULL
genes	NULL
like	NULL
faim	NULL
.	NULL

During	NULL
our	NULL
initial	NULL
cloning	NULL
efforts	NULL
the	NULL
faim	NULL
sequence	NULL
was	NULL
obtained	NULL
from	NULL
two	NULL
sources-a	NULL
mouse	NULL
thymus	NULL
library	NULL
and	NULL
,	NULL
subsequently	NULL
,	NULL
a	NULL
mouse	NULL
brain	NULL
library	NULL
.	NULL

However	NULL
,	NULL
the	NULL
two	NULL
sequences	NULL
differ	NULL
.	NULL

The	NULL
original	NULL
thymus-derived	NULL
FAIM	NULL
sequence	NULL
,	NULL
now	NULL
termed	NULL
FAIM-Short	NULL
(	NULL
FAIM-S	NULL
)	NULL
,	NULL
is	NULL
shorter	NULL
by	NULL
22	NULL
5	NULL
amino	NULL
acids	NULL
in	NULL
comparison	NULL
to	NULL
the	NULL
brain-derived	NULL
sequence	NULL
,	NULL
now	NULL
termed	NULL
FAIM-Long	NULL
(	NULL
FAIM-	NULL
L	NULL
)	NULL
[	NULL
96	NULL
]	NULL
.	NULL

Recently	NULL
we	NULL
identified	NULL
a	NULL
human	NULL
faim-L	NULL
homolog	NULL
among	NULL
publicly	NULL
available	NULL
EST	NULL
fragments	NULL
,	NULL
which	NULL
similarly	NULL
encodes	NULL
22	NULL
additional	NULL
5	NULL
amino	NULL
acids	NULL
,	NULL
21	NULL
of	NULL
which	NULL
are	NULL
identical	NULL
to	NULL
the	NULL
additional	NULL
sequence	NULL
in	NULL
murine	NULL
FAIM-L	NULL
,	NULL
indicating	NULL
a	NULL
high	NULL
degree	NULL
of	NULL
homology	NULL
in	NULL
this	NULL
region	NULL
,	NULL
although	NULL
this	NULL
sequence	NULL
contains	NULL
no	NULL
presently	NULL
recognized	NULL
effector	NULL
motifs	NULL
.	NULL

To	NULL
clarify	NULL
the	NULL
origin	NULL
of	NULL
the	NULL
two	NULL
faim	NULL
sequences	NULL
,	NULL
the	NULL
mouse	NULL
faim	NULL
genomic	NULL
locus	NULL
was	NULL
characterized	NULL
[	NULL
96	NULL
]	NULL
.	NULL

Mouse	NULL
faim	NULL
was	NULL
localized	NULL
to	NULL
a	NULL
region	NULL
(	NULL
9f1	NULL
)	NULL
syntenic	NULL
to	NULL
the	NULL
chromosomal	NULL
location	NULL
of	NULL
human	NULL
faim	NULL
by	NULL
FISH	NULL
analysis	NULL
.	NULL

Three	NULL
BAC	NULL
clones	NULL
containing	NULL
the	NULL
faim	NULL
locus	NULL
were	NULL
obtained	NULL
by	NULL
screening	NULL
a	NULL
murine	NULL
1298y	NULL
genomic	NULL
library	NULL
,	NULL
and	NULL
one	NULL
of	NULL
these	NULL
clones	NULL
was	NULL
used	NULL
as	NULL
a	NULL
template	NULL
for	NULL
analysis	NULL
.	NULL

All	NULL
intron/	NULL
exon	NULL
boundaries	NULL
were	NULL
confirmed	NULL
by	NULL
direct	NULL
sequencing	NULL
[	NULL
102	NULL
]	NULL
.	NULL

The	NULL
murine	NULL
faim	NULL
locus	NULL
was	NULL
shown	NULL
to	NULL
consist	NULL
of	NULL
6	NULL
exons	NULL
.	NULL

Exons	NULL
IV	NULL
and	NULL
VI	NULL
in	NULL
M.	NULL
musculus	NULL
were	NULL
each	NULL
found	NULL
to	NULL
represent	NULL
the	NULL
fusion	NULL
of	NULL
2	NULL
exons	NULL
identified	NULL
in	NULL
C.	NULL
elegans	NULL
,	NULL
so	NULL
that	NULL
the	NULL
intron/exon	NULL
organization	NULL
is	NULL
simplified	NULL
in	NULL
the	NULL
higher	NULL
organism	NULL
,	NULL
which	NULL
although	NULL
unusual	NULL
is	NULL
not	NULL
unprec-	NULL
[	NULL
103-107	NULL
]	NULL
.	NULL

Two	NULL
putative	NULL
translation	NULL
initiation	NULL
sites	NULL
were	NULL
identified	NULL
on	NULL
separate	NULL
exons	NULL
(	NULL
II	NULL
and	NULL
III	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
faim-L	NULL
and	NULL
faim-S	NULL
result	NULL
from	NULL
alternative	NULL
splicing	NULL
.	NULL

Through	NULL
PCR	NULL
amplification	NULL
utilizing	NULL
a	NULL
5Â°	NULL
primer	NULL
that	NULL
corresponds	NULL
to	NULL
the	NULL
5Â°	NULL
untranslated	NULL
region	NULL
,	NULL
faim-L	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
expressed	NULL
in	NULL
primary	NULL
tissue	NULL
,	NULL
although	NULL
among	NULL
multiple	NULL
tissues	NULL
examined	NULL
,	NULL
expression	NULL
of	NULL
faim-L	NULL
was	NULL
extremely	NULL
tissue-specific	NULL
,	NULL
and	NULL
was	NULL
strictly	NULL
limited	NULL
to	NULL
the	NULL
brain	NULL
[	NULL
96	NULL
]	NULL
.	NULL

The	NULL
function	NULL
of	NULL
FAIM-L	NULL
is	NULL
presently	NULL
unknown	NULL
,	NULL
and	NULL
the	NULL
possibility	NULL
that	NULL
FAIM-L	NULL
is	NULL
active	NULL
only	NULL
in	NULL
the	NULL
brain	NULL
,	NULL
or	NULL
that	NULL
FAIM-L	NULL
fulfills	NULL
a	NULL
unique	NULL
role	NULL
in	NULL
the	NULL
brain	NULL
,	NULL
has	NULL
not	NULL
been	NULL
ruled	NULL
out	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
faim	NULL
is	NULL
a	NULL
novel	NULL
gene	NULL
without	NULL
precedent	NULL
in	NULL
publicly	NULL
available	NULL
databases	NULL
,	NULL
whose	NULL
protein	NULL
product	NULL
inhibits	NULL
Fas-mediated	NULL
apoptosis	NULL
,	NULL
and	NULL
whose	NULL
expression	NULL
is	NULL
upregulated	NULL
coordinately	NULL
with	NULL
induction	NULL
of	NULL
Fasg-resistance	NULL
by	NULL
slg	NULL
engagement	NULL
in	NULL
vitro	NULL
and	NULL
during	NULL
antigen-specific	NULL
immune	NULL
responses	NULL
in	NULL
vivo	NULL
.	NULL

These	NULL
features	NULL
suggest	NULL
that	NULL
FAIM	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
physiological	NULL
regulation	NULL
of	NULL
immune	NULL
cell	NULL
activity	NULL
,	NULL
inducibly	NULL
suppressing	NULL
Fas	NULL
signaling	NULL
for	NULL
cell	NULL
death	NULL
along	NULL
with	NULL
and	NULL
FLIP	NULL
.	NULL

The	NULL
multigenic	NULL
nature	NULL
of	NULL
sIg-induced	NULL
Fas-resistance	NULL
suggests	NULL
,	NULL
in	NULL
a	NULL
larger	NULL
sense	NULL
,	NULL
that	NULL
the	NULL
relative	NULL
susceptibility	NULL
of	NULL
B	NULL
cells	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
is	NULL
determined	NULL
by	NULL
the	NULL
balance	NULL
between	NULL
multiple	NULL
pro-	NULL
and	NULL
anti-apoptotic	NULL
molecules	NULL
,	NULL
whose	NULL
expression	NULL
changes	NULL
rapidly	NULL
in	NULL
response	NULL
to	NULL
shifting	NULL
environmental	NULL
conditions	NULL
,	NULL
such	NULL
as	NULL
the	NULL
presence	NULL
of	NULL
antigen	NULL
and/	NULL
or	NULL
T	NULL
cell-derived	NULL
lymphokine	NULL
.	NULL

255	NULL
Inducible	NULL
Fas-resistance	NULL
in	NULL
B	NULL
cells	NULL
Speculative	NULL
role	NULL
for	NULL
Fas-resistance	NULL
T	NULL
cell	NULL
activation	NULL
results	NULL
in	NULL
upregulation	NULL
of	NULL
CD4O0L	NULL
expression	NULL
[	NULL
108-110	NULL
]	NULL
,	NULL
as	NULL
well	NULL
as	NULL
upregulation	NULL
of	NULL
FasL	NULL
expression	NULL
[	NULL
8	NULL
]	NULL
,	NULL
[	NULL
1111-114	NULL
]	NULL
.	NULL

As	NULL
much	NULL
as	NULL
engagement	NULL
of	NULL
(	NULL
constitutively	NULL
expressed	NULL
)	NULL
B	NULL
cell	NULL
CD40	NULL
is	NULL
necessary	NULL
for	NULL
T-dependent	NULL
stimulation	NULL
,	NULL
CD40	NULL
triggering	NULL
also	NULL
upregulates	NULL
Fas	NULL
expression	NULL
,	NULL
and	NULL
engagement	NULL
of	NULL
B	NULL
cell	NULL
Fas	NULL
by	NULL
T	NULL
cell	NULL
FasL	NULL
initiates	NULL
apoptotic	NULL
events	NULL
.	NULL

In	NULL
view	NULL
of	NULL
this	NULL
,	NULL
activated	NULL
T	NULL
cells	NULL
represent	NULL
a	NULL
potential	NULL
threat	NULL
to	NULL
B	NULL
cell	NULL
viability	NULL
,	NULL
and	NULL
this	NULL
may	NULL
well	NULL
be	NULL
the	NULL
point	NULL
at	NULL
which	NULL
inducible	NULL
Fas-resistance	NULL
plays	NULL
a	NULL
key	NULL
role	NULL
,	NULL
by	NULL
protecting	NULL
B	NULL
cells	NULL
against	NULL
FasL	NULL
expressed	NULL
by	NULL
interacting	NULL
Th1	NULL
cells	NULL
and	NULL
thereby	NULL
promoting	NULL
B	NULL
cell	NULL
immune	NULL
responses	NULL
.	NULL

Two	NULL
manifestations	NULL
of	NULL
this	NULL
have	NULL
been	NULL
documented	NULL
.	NULL

1	NULL
)	NULL
Fas-resistant	NULL
B	NULL
cells	NULL
present	NULL
antigen	NULL
more	NULL
effectively	NULL
than	NULL
Fas-sensitive	NULL
B	NULL
cells	NULL
.	NULL

This	NULL
was	NULL
demonstrated	NULL
by	NULL
experiments	NULL
in	NULL
which	NULL
antigen-pulsed	NULL
,	NULL
mitomycin-treated	NULL
Fas-resistant	NULL
B	NULL
cells	NULL
produced	NULL
greater	NULL
proliferation	NULL
of	NULL
antigen-specific	NULL
Th1	NULL
cells	NULL
than	NULL
did	NULL
similarly	NULL
treated	NULL
,	NULL
Fas-sensitive	NULL
B	NULL
cells	NULL
[	NULL
115	NULL
]	NULL
;	NULL
improved	NULL
antigen	NULL
presentation	NULL
presumably	NULL
occurred	NULL
because	NULL
Fas-resistant	NULL
B	NULL
cells	NULL
were	NULL
protected	NULL
against	NULL
the	NULL
threat	NULL
of	NULL
death	NULL
posed	NULL
by	NULL
initially	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
thus	NULL
remained	NULL
viable	NULL
to	NULL
present	NULL
antigen	NULL
to	NULL
another	NULL
round	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

2	NULL
)	NULL
Fas-resistant	NULL
B	NULL
cells	NULL
block	NULL
activation-induced	NULL
cell	NULL
death	NULL
(	NULL
AICD	NULL
)	NULL
of	NULL
T	NULL
cells	NULL
,	NULL
whereas	NULL
Fas-sensitive	NULL
B	NULL
cells	NULL
do	NULL
not	NULL
.	NULL

This	NULL
was	NULL
demonstrated	NULL
by	NULL
experiments	NULL
in	NULL
which	NULL
primed	NULL
T	NULL
cells	NULL
were	NULL
exposed	NULL
a	NULL
second	NULL
time	NULL
to	NULL
antigen	NULL
(	NULL
SEB	NULL
or	NULL
HEL	NULL
)	NULL
presented	NULL
by	NULL
B	NULL
cells	NULL
;	NULL
the	NULL
resulting	NULL
Fas-induced	NULL
cytotoxicity	NULL
(	NULL
AICD	NULL
)	NULL
of	NULL
T	NULL
cells	NULL
was	NULL
markedly	NULL
reduced	NULL
when	NULL
antigen	NULL
was	NULL
presented	NULL
by	NULL
Fas-resistant	NULL
B	NULL
cells	NULL
,	NULL
presumably	NULL
because	NULL
Fas-bearing	NULL
,	NULL
apoptosis-resistant	NULL
B	NULL
cells	NULL
competitively	NULL
inhibited	NULL
T	NULL
cell	NULL
FasL	NULL
,	NULL
preventing	NULL
interaction	NULL
with	NULL
T	NULL
cell	NULL
Fas	NULL
[	NULL
116	NULL
]	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
Fas-resistance	NULL
induced	NULL
in	NULL
B	NULL
cells	NULL
may	NULL
enhance	NULL
and	NULL
perpetuate	NULL
T	NULL
,	NULL
as	NULL
well	NULL
as	NULL
B	NULL
,	NULL
cell	NULL
responses	NULL
.	NULL

The	NULL
idea	NULL
that	NULL
inducible	NULL
Fas-resistance	NULL
modulates	NULL
B	NULL
and	NULL
T	NULL
cell	NULL
deletion	NULL
,	NULL
and	NULL
promotes	NULL
B	NULL
and	NULL
T	NULL
cell	NULL
responses	NULL
,	NULL
is	NULL
further	NULL
supported	NULL
,	NULL
somewhat	NULL
indirectly	NULL
,	NULL
by	NULL
the	NULL
observed	NULL
durability	NULL
of	NULL
the	NULL
receptor-specific	NULL
phenotype	NULL
,	NULL
which	NULL
was	NULL
unchanged	NULL
when	NULL
B	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
re-cultured	NULL
for	NULL
24	NULL
h	NULL
in	NULL
medium	NULL
prior	NULL
to	NULL
assay	NULL
of	NULL
Th1	NULL
cell-mediated	NULL
cytotoxicity	NULL
.	NULL

Fas-resistance	NULL
in	NULL
tolerant	NULL
B	NULL
cells	NULL
The	NULL
model	NULL
described	NULL
above	NULL
,	NULL
which	NULL
suggests	NULL
that	NULL
inducible	NULL
Fas-resistance	NULL
acts	NULL
to	NULL
protect	NULL
B	NULL
cells	NULL
from	NULL
FasL-bearing	NULL
,	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
raises	NULL
the	NULL
issue	NULL
of	NULL
autoreactive	NULL
B	NULL
cells	NULL
,	NULL
the	NULL
very	NULL
B	NULL
cells	NULL
that	NULL
are	NULL
dysregulated	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Fas	NULL
expression	NULL
.	NULL

Inasmuch	NULL
as	NULL
these	NULL
B	NULL
cells	NULL
appear	NULL
to	NULL
be	NULL
eliminated	NULL
in	NULL
a	NULL
Fas-dependent	NULL
fashion	NULL
[	NULL
15	NULL
]	NULL
,	NULL
[	NULL
117-121	NULL
]	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
Fas-resistance	NULL
(	NULL
as	NULL
a	NULL
result	NULL
of	NULL
interaction	NULL
with	NULL
ever	NULL
present	NULL
self	NULL
antigen	NULL
)	NULL
could	NULL
lead	NULL
to	NULL
deleterious	NULL
consequences	NULL
,	NULL
because	NULL
of	NULL
the	NULL
possibility	NULL
that	NULL
normal	NULL
processes	NULL
of	NULL
autoreactive	NULL
B	NULL
cell	NULL
deletion	NULL
might	NULL
be	NULL
thwarted	NULL
.	NULL

It	NULL
would	NULL
seem	NULL
necessary	NULL
for	NULL
the	NULL
rules	NULL
governing	NULL
the	NULL
regulation	NULL
of	NULL
Fas-mediated	NULL
apoptosis	NULL
to	NULL
be	NULL
different	NULL
for	NULL
autoreactive	NULL
B	NULL
cells	NULL
in	NULL
comparison	NULL
to	NULL
normal	NULL
(	NULL
foreign	NULL
antigen-specific	NULL
)	NULL
B	NULL
cells	NULL
.	NULL

To	NULL
address	NULL
this	NULL
issue	NULL
,	NULL
B	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
transgenic	NULL
mice	NULL
expressing	NULL
anti-HEL	NULL
antigen	NULL
receptors	NULL
,	NULL
and	NULL
from	NULL
double	NULL
transgenic	NULL
mice	NULL
that	NULL
express	NULL
both	NULL
the	NULL
anti-HEL	NULL
receptor	NULL
as	NULL
well	NULL
as	NULL
a	NULL
transgene	NULL
encoding	NULL
soluble	NULL
HEL	NULL
(	NULL
anti-HEL/sHEL	NULL
)	NULL
.	NULL

B	NULL
cells	NULL
256	NULL
Rothstein	NULL
TL	NULL
from	NULL
anti-HEL/sHEL	NULL
mice	NULL
are	NULL
continually	NULL
exposed	NULL
to	NULL
what	NULL
is	NULL
,	NULL
for	NULL
them	NULL
,	NULL
autoantigen	NULL
,	NULL
as	NULL
a	NULL
result	NULL
of	NULL
which	NULL
these	NULL
transgenically	NULL
autoreactive	NULL
B	NULL
cells	NULL
are	NULL
tolerant	NULL
,	NULL
and	NULL
thus	NULL
do	NULL
not	NULL
signal	NULL
normally	NULL
through	NULL
sIg	NULL
[	NULL
122-124	NULL
]	NULL
.	NULL

B	NULL
cells	NULL
from	NULL
both	NULL
kinds	NULL
of	NULL
transgenic	NULL
mice	NULL
were	NULL
stimulated	NULL
with	NULL
CD4O0L	NULL
alone	NULL
or	NULL
with	NULL
CD4O0L	NULL
in	NULL
combination	NULL
with	NULL
soluble	NULL
HEL	NULL
,	NULL
and	NULL
tested	NULL
for	NULL
susceptibility	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
soluble	NULL
HEL	NULL
produced	NULL
resistance	NULL
to	NULL
Fas	NULL
killing	NULL
only	NULL
in	NULL
B	NULL
cells	NULL
from	NULL
anti-HEL	NULL
mice	NULL
;	NULL
there	NULL
was	NULL
no	NULL
effect	NULL
of	NULL
sHEL	NULL
on	NULL
the	NULL
Fas-sensitivity	NULL
of	NULL
CD40L-stimulated	NULL
B	NULL
cells	NULL
from	NULL
anti-HEL/sHEL	NULL
mice	NULL
,	NULL
despite	NULL
the	NULL
fact	NULL
that	NULL
upregulated	NULL
levels	NULL
of	NULL
Fas	NULL
expression	NULL
and	NULL
Fas-sensitivity	NULL
produced	NULL
by	NULL
CD4O0L	NULL
were	NULL
similar	NULL
for	NULL
B	NULL
cells	NULL
obtained	NULL
from	NULL
single	NULL
transgenic	NULL
and	NULL
double	NULL
transgenic	NULL
mice	NULL
[	NULL
36	NULL
]	NULL
.	NULL

Thus	NULL
,	NULL
specific	NULL
antigen	NULL
differentially	NULL
induced	NULL
Fas-resistance	NULL
in	NULL
non-autoreactive	NULL
and	NULL
in	NULL
autoreactive	NULL
B	NULL
cells	NULL
,	NULL
succeeding	NULL
in	NULL
the	NULL
former	NULL
but	NULL
failing	NULL
in	NULL
the	NULL
latter	NULL
.	NULL

However	NULL
,	NULL
it	NULL
was	NULL
noted	NULL
that	NULL
anti-Ig	NULL
produced	NULL
similar	NULL
levels	NULL
of	NULL
Fas-resistance	NULL
in	NULL
CD40L-stimulated	NULL
B	NULL
cells	NULL
from	NULL
single	NULL
and	NULL
double	NULL
transgenic	NULL
mice	NULL
,	NULL
suggesting	NULL
that	NULL
autoreactive	NULL
B	NULL
cells	NULL
are	NULL
not	NULL
totally	NULL
intractable	NULL
to	NULL
induction	NULL
of	NULL
Fas-resistance	NULL
through	NULL
sIg	NULL
signaling	NULL
but	NULL
,	NULL
instead	NULL
,	NULL
may	NULL
simply	NULL
require	NULL
a	NULL
higher	NULL
degree	NULL
of	NULL
slg	NULL
crosslinking	NULL
for	NULL
this	NULL
outcome	NULL
.	NULL

To	NULL
examine	NULL
this	NULL
issue	NULL
,	NULL
B	NULL
cells	NULL
from	NULL
anti-HEL/sHEL	NULL
mice	NULL
were	NULL
stimulated	NULL
with	NULL
CD4O0L	NULL
alone	NULL
or	NULL
with	NULL
CD40L	NULL
in	NULL
combination	NULL
with	NULL
biotinylated	NULL
sHEL	NULL
,	NULL
with	NULL
or	NULL
without	NULL
additional	NULL
crosslinking	NULL
imposed	NULL
by	NULL
streptavidin	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
streptavidin	NULL
,	NULL
autoreactive	NULL
B	NULL
cells	NULL
from	NULL
anti-HEL/sHEL	NULL
mice	NULL
acquired	NULL
resistance	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
,	NULL
similar	NULL
in	NULL
magnitude	NULL
to	NULL
that	NULL
produced	NULL
by	NULL
anti-Ig	NULL
[	NULL
36	NULL
]	NULL
.	NULL

These	NULL
results	NULL
strongly	NULL
suggest	NULL
that	NULL
in	NULL
autoreactive	NULL
B	NULL
cells	NULL
an	NULL
elevated	NULL
threshold	NULL
of	NULL
slg	NULL
signaling	NULL
must	NULL
be	NULL
exceeded	NULL
for	NULL
induction	NULL
of	NULL
Fas-resistance	NULL
,	NULL
as	NULL
compared	NULL
to	NULL
the	NULL
degree	NULL
of	NULL
sIg	NULL
signaling	NULL
needed	NULL
for	NULL
induction	NULL
of	NULL
Fas-resistance	NULL
in	NULL
foreign-antigen-specific	NULL
B	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
way	NULL
the	NULL
possibility	NULL
that	NULL
self	NULL
antigen	NULL
might	NULL
induce	NULL
Fas-resistance	NULL
through	NULL
sIg	NULL
signaling	NULL
in	NULL
autoreactive	NULL
B	NULL
cells	NULL
is	NULL
minimized	NULL
,	NULL
and	NULL
sIg-induced	NULL
Fas-resistance	NULL
is	NULL
unlikely	NULL
to	NULL
contribute	NULL
to	NULL
serological	NULL
autoimmunity	NULL
under	NULL
normal	NULL
circumstances	NULL
.	NULL

The	NULL
situation	NULL
with	NULL
IL-4	NULL
is	NULL
very	NULL
different	NULL
.	NULL

Similar	NULL
levels	NULL
of	NULL
Fas-resistance	NULL
were	NULL
produced	NULL
by	NULL
IL-4	NULL
in	NULL
CD4O0L-stimulated	NULL
B	NULL
cells	NULL
obtained	NULL
from	NULL
single	NULL
and	NULL
double	NULL
transgenic	NULL
mice	NULL
[	NULL
36	NULL
]	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
capacity	NULL
of	NULL
IL-4R	NULL
engagement	NULL
to	NULL
produce	NULL
Fas-resistance	NULL
was	NULL
not	NULL
altered	NULL
in	NULL
autoreactive	NULL
B	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
the	NULL
possibility	NULL
that	NULL
autoreactive	NULL
B	NULL
cells	NULL
might	NULL
escape	NULL
Fas-dependent	NULL
deletion	NULL
because	NULL
of	NULL
IL-4R	NULL
signaling	NULL
(	NULL
which	NULL
,	NULL
under	NULL
normal	NULL
circumstances	NULL
,	NULL
would	NULL
be	NULL
averted	NULL
by	NULL
mechanisms	NULL
that	NULL
maintain	NULL
T	NULL
cell	NULL
tolerance	NULL
)	NULL
.	NULL

In	NULL
support	NULL
of	NULL
this	NULL
notion	NULL
,	NULL
serum	NULL
samples	NULL
(	NULL
5	NULL
out	NULL
of	NULL
5	NULL
tested	NULL
)	NULL
obtained	NULL
from	NULL
IL-4-overexpressing	NULL
transgenic	NULL
mice	NULL
[	NULL
125	NULL
]	NULL
were	NULL
found	NULL
to	NULL
contain	NULL
autoantibodies	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
on	NULL
HEp-2	NULL
cells	NULL
[	NULL
37	NULL
]	NULL
.	NULL

HEp-2-staining	NULL
serum	NULL
autoantibodies	NULL
were	NULL
similarly	NULL
reported	NULL
in	NULL
sera	NULL
obtained	NULL
from	NULL
a	NULL
separate	NULL
IL-4	NULL
transgenic	NULL
line	NULL
[	NULL
126	NULL
]	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
the	NULL
role	NULL
of	NULL
IL-4	NULL
has	NULL
been	NULL
examined	NULL
using	NULL
the	NULL
defined	NULL
anti-HEL/sHEL	NULL
system	NULL
by	NULL
breeding	NULL
triple	NULL
transgenic	NULL
(	NULL
anti-HEL/sHEL/IL-4	NULL
)	NULL
animals	NULL
and	NULL
then	NULL
testing	NULL
sera	NULL
for	NULL
anti-HEL	NULL
antibody	NULL
.	NULL

Preliminary	NULL
results	NULL
indicate	NULL
that	NULL
these	NULL
mice	NULL
(	NULL
10	NULL
out	NULL
of	NULL
10	NULL
examined	NULL
)	NULL
produced	NULL
increasing	NULL
amounts	NULL
of	NULL
serum	NULL
anti-HEL	NULL
autoantibody	NULL
with	NULL
increasing	NULL
age	NULL
,	NULL
and	NULL
in	NULL
so	NULL
doing	NULL
broke	NULL
tolerance	NULL
.	NULL

Although	NULL
none	NULL
of	NULL
these	NULL
studies	NULL
precludes	NULL
the	NULL
possibil-	NULL
257	NULL
Inducible	NULL
Fas-resistance	NULL
in	NULL
B	NULL
cells	NULL
ity	NULL
that	NULL
IL-4	NULL
affects	NULL
a	NULL
non-B	NULL
cell	NULL
target	NULL
,	NULL
all	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
ability	NULL
of	NULL
IL-4	NULL
to	NULL
induce	NULL
Fas-resistance	NULL
and	NULL
thereby	NULL
interfere	NULL
with	NULL
the	NULL
known	NULL
Fas-deletional	NULL
pathway	NULL
for	NULL
elimination	NULL
of	NULL
autoreactive	NULL
B	NULL
cells	NULL
.	NULL

This	NULL
conclusion	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
observation	NULL
that	NULL
constitutive	NULL
expression	NULL
of	NULL
B7.2	NULL
led	NULL
to	NULL
a	NULL
breakdown	NULL
in	NULL
tolerance	NULL
in	NULL
anti-HEL/sHEL	NULL
transgenic	NULL
mice	NULL
[	NULL
127	NULL
]	NULL
,	NULL
which	NULL
our	NULL
results	NULL
infer	NULL
was	NULL
due	NULL
to	NULL
complete	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
to	NULL
produce	NULL
IL-4	NULL
which	NULL
in	NULL
turn	NULL
induced	NULL
B	NULL
cell	NULL
Fas-resistance	NULL
.	NULL

The	NULL
results	NULL
discussed	NULL
above	NULL
suggest	NULL
that	NULL
induction	NULL
of	NULL
Fas-resistance	NULL
,	NULL
dysregulation	NULL
of	NULL
autoreactive	NULL
B	NULL
cells	NULL
and	NULL
disruption	NULL
of	NULL
B	NULL
cell	NULL
tolerance	NULL
,	NULL
along	NULL
with	NULL
the	NULL
appearance	NULL
of	NULL
autoantibodies	NULL
,	NULL
could	NULL
result	NULL
either	NULL
from	NULL
slg	NULL
stimulation	NULL
that	NULL
exceeds	NULL
a	NULL
certain	NULL
threshold	NULL
,	NULL
as	NULL
might	NULL
be	NULL
produced	NULL
by	NULL
immune	NULL
complexes	NULL
,	NULL
or	NULL
from	NULL
IL-4R	NULL
engagement	NULL
not	NULL
directly	NULL
related	NULL
to	NULL
cognate	NULL
interactions	NULL
,	NULL
as	NULL
might	NULL
occur	NULL
during	NULL
periods	NULL
of	NULL
heightened	NULL
immuno-logical	NULL
stress	NULL
that	NULL
may	NULL
be	NULL
accompanied	NULL
by	NULL
lymphokine	NULL
overproduction	NULL
[	NULL
128	NULL
]	NULL
.	NULL

SUMMARY	NULL
AND	NULL
DISCUSSION	NULL
The	NULL
most	NULL
important	NULL
conclusion	NULL
to	NULL
be	NULL
drawn	NULL
from	NULL
these	NULL
studies	NULL
is	NULL
that	NULL
B	NULL
cells	NULL
are	NULL
not	NULL
monomorphic	NULL
targets	NULL
for	NULL
Th1	NULL
cell-mediated	NULL
cytotoxicity	NULL
but	NULL
rather	NULL
modulate	NULL
their	NULL
own	NULL
intrinsic	NULL
susceptibility	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
in	NULL
response	NULL
to	NULL
specific	NULL
environmental	NULL
cues	NULL
in	NULL
a	NULL
dynamic	NULL
fashion	NULL
in	NULL
which	NULL
Fas-	NULL
sensitivity	NULL
changes	NULL
rapidly	NULL
as	NULL
a	NULL
result	NULL
of	NULL
specific	NULL
receptor	NULL
binding	NULL
.	NULL

Engagement	NULL
of	NULL
the	NULL
B	NULL
cell	NULL
antigen	NULL
receptor	NULL
or	NULL
the	NULL
IL-4	NULL
receptor	NULL
triggers	NULL
at	NULL
least	NULL
partially	NULL
non-overlapping	NULL
,	NULL
inducible	NULL
pathways	NULL
that	NULL
result	NULL
in	NULL
a	NULL
durable	NULL
state	NULL
of	NULL
Fas-resistance	NULL
that	NULL
is	NULL
mediated	NULL
by	NULL
Bel-xL	NULL
,	NULL
FLIP	NULL
,	NULL
and	NULL
FAIM	NULL
,	NULL
and	NULL
possibly	NULL
other	NULL
molecules	NULL
that	NULL
are	NULL
as	NULL
yet	NULL
unknown	NULL
.	NULL

Fas-resistance	NULL
likely	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
during	NULL
critical	NULL
,	NULL
early	NULL
B	NULL
cell	NULL
:	NULL
T	NULL
cell	NULL
interactions	NULL
,	NULL
protecting	NULL
B	NULL
cells	NULL
from	NULL
the	NULL
inherent	NULL
threat	NULL
to	NULL
survival	NULL
posed	NULL
by	NULL
FasL	NULL
expression	NULL
on	NULL
the	NULL
part	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
way	NULL
inducible	NULL
Fas-resistance	NULL
is	NULL
hypothesized	NULL
to	NULL
enhance	NULL
serological	NULL
immune	NULL
responses	NULL
and	NULL
,	NULL
perhaps	NULL
,	NULL
to	NULL
promote	NULL
T	NULL
cell	NULL
responses	NULL
by	NULL
improving	NULL
antigen	NULL
presentation	NULL
and	NULL
by	NULL
blocking	NULL
AICD	NULL
.	NULL

Notably	NULL
,	NULL
Fas-resistance	NULL
,	NULL
as	NULL
represented	NULL
by	NULL
the	NULL
absence	NULL
of	NULL
functional	NULL
Fas	NULL
expression	NULL
in	NULL
mutant	NULL
mice	NULL
or	NULL
by	NULL
overexpression	NULL
of	NULL
FLIP	NULL
in	NULL
retrovirally	NULL
transduced	NULL
chimeras	NULL
,	NULL
produces	NULL
serological	NULL
autoreactivity	NULL
,	NULL
and	NULL
thus	NULL
may	NULL
constitute	NULL
an	NULL
etiologic	NULL
factor	NULL
in	NULL
clinically	NULL
important	NULL
autoimmunity	NULL
[	NULL
26	NULL
]	NULL
,	NULL
[	NULL
28	NULL
]	NULL
,	NULL
[	NULL
80	NULL
]	NULL
.	NULL

In	NULL
other	NULL
words	NULL
,	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
receptor-induced	NULL
Fas-resistance	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
a	NULL
key	NULL
element	NULL
in	NULL
determining	NULL
the	NULL
usefulness	NULL
or	NULL
aberrance	NULL
of	NULL
real	NULL
world	NULL
immune	NULL
responses	NULL
.	NULL

Modulation	NULL
of	NULL
Fas-sensitivity	NULL
is	NULL
not	NULL
limited	NULL
to	NULL
B	NULL
cells	NULL
.	NULL

T	NULL
cells	NULL
may	NULL
upregulate	NULL
Fas	NULL
expression	NULL
but	NULL
still	NULL
fail	NULL
to	NULL
undergo	NULL
apoptosis	NULL
in	NULL
response	NULL
to	NULL
Fas	NULL
signaling	NULL
.	NULL

This	NULL
occurs	NULL
shortly	NULL
after	NULL
activation	NULL
through	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
in	NULL
vitro	NULL
.	NULL

With	NULL
time	NULL
and	NULL
continued	NULL
stimulation	NULL
,	NULL
the	NULL
Fas-resistant	NULL
phenotype	NULL
reverses	NULL
,	NULL
and	NULL
T	NULL
cells	NULL
become	NULL
Fas-sensitive	NULL
,	NULL
without	NULL
any	NULL
change	NULL
in	NULL
the	NULL
elevated	NULL
level	NULL
of	NULL
Fas	NULL
expression	NULL
,	NULL
perhaps	NULL
as	NULL
a	NULL
result	NULL
of	NULL
IL-2R	NULL
signaling	NULL
and	NULL
alterations	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
Bel-xL	NULL
and	NULL
FLIP	NULL
,	NULL
although	NULL
the	NULL
precise	NULL
mechanism	NULL
remains	NULL
uncertain	NULL
[	NULL
76	NULL
]	NULL
,	NULL
[	NULL
129-133	NULL
]	NULL
.	NULL

Additional	NULL
reports	NULL
suggest	NULL
that	NULL
Fas-sensitivity	NULL
is	NULL
modulated	NULL
in	NULL
anergic	NULL
T	NULL
cells	NULL
,	NULL
memory	NULL
T	NULL
cells	NULL
,	NULL
primed	NULL
T	NULL
cells	NULL
and	NULL
Th2	NULL
cells	NULL
[	NULL
134-139	NULL
]	NULL
.	NULL

258	NULL
Rothstein	NULL
TL	NULL
Thus	NULL
,	NULL
inducible	NULL
changes	NULL
in	NULL
the	NULL
sensitivity	NULL
of	NULL
T	NULL
cells	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
likely	NULL
play	NULL
a	NULL
role	NULL
in	NULL
T	NULL
cell	NULL
homeostasis	NULL
and	NULL
in	NULL
T	NULL
cell	NULL
immune	NULL
responses	NULL
.	NULL

Malignant	NULL
cells	NULL
,	NULL
both	NULL
lymphoid	NULL
and	NULL
non-lymphoid	NULL
,	NULL
manifest	NULL
resistance	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
[	NULL
140-149	NULL
]	NULL
.	NULL

Inasmuch	NULL
as	NULL
inhibition	NULL
of	NULL
Fas	NULL
signaling	NULL
for	NULL
cell	NULL
death	NULL
is	NULL
associated	NULL
with	NULL
tumor	NULL
development	NULL
and	NULL
progression	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
Fas-mediated	NULL
apoptosis	NULL
constitutes	NULL
at	NULL
least	NULL
a	NULL
portion	NULL
of	NULL
anti-tumor	NULL
immunity	NULL
,	NULL
and	NULL
that	NULL
some	NULL
malignancies	NULL
take	NULL
advantage	NULL
of	NULL
mechanisms	NULL
that	NULL
block	NULL
Fas	NULL
killing	NULL
to	NULL
maintain	NULL
viability	NULL
and	NULL
co-exist	NULL
within	NULL
the	NULL
framework	NULL
of	NULL
a	NULL
normal	NULL
immune	NULL
system	NULL
[	NULL
100,101	NULL
]	NULL
,	NULL
[	NULL
150-153	NULL
]	NULL
.	NULL

The	NULL
mechanisms	NULL
utilized	NULL
by	NULL
malignant	NULL
cells	NULL
may	NULL
represent	NULL
perversions	NULL
of	NULL
the	NULL
physiological	NULL
means	NULL
by	NULL
which	NULL
B	NULL
cells	NULL
normally	NULL
inhibit	NULL
susceptibility	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
in	NULL
a	NULL
receptor-specific	NULL
fashion	NULL
.	NULL

If	NULL
true	NULL
,	NULL
molecules	NULL
involved	NULL
in	NULL
establishing	NULL
sIg-induced	NULL
Fas-resistance	NULL
might	NULL
form	NULL
targets	NULL
for	NULL
pharmacologic	NULL
manipulation	NULL
of	NULL
the	NULL
apoptotic	NULL
balance	NULL
between	NULL
host	NULL
and	NULL
tumor	NULL
,	NULL
including	NULL
NF-	NULL
Â«	NULL
B	NULL
,	NULL
Bel-x1	NULL
,	NULL
FLIP	NULL
,	NULL
and/or	NULL
FAIM	NULL
[	NULL
51,56	NULL
,	NULL
68,76,154	NULL
,	NULL
155	NULL
]	NULL
.	NULL

The	NULL
sum	NULL
of	NULL
the	NULL
work	NULL
described	NULL
above	NULL
,	NULL
in	NULL
conjunction	NULL
with	NULL
evidence	NULL
provided	NULL
by	NULL
other	NULL
investigators	NULL
,	NULL
strongly	NULL
suggests	NULL
that	NULL
the	NULL
regulation	NULL
and	NULL
dysregulation	NULL
of	NULL
Fas-mediated	NULL
apoptosis	NULL
contributes	NULL
to	NULL
the	NULL
level	NULL
and	NULL
importance	NULL
of	NULL
normal	NULL
immune	NULL
,	NULL
autoimmune	NULL
,	NULL
and	NULL
tumor-immune	NULL
responses	NULL
.	NULL

New	NULL
insights	NULL
are	NULL
likely	NULL
to	NULL
arise	NULL
from	NULL
further	NULL
study	NULL
of	NULL
the	NULL
inter-relationships	NULL
between	NULL
surface	NULL
receptor	NULL
engagement	NULL
and	NULL
susceptibility	NULL
to	NULL
Fas	NULL
signaling	NULL
,	NULL
and	NULL
of	NULL
mechanisms	NULL
and	NULL
molecules	NULL
responsible	NULL
for	NULL
inducible	NULL
Fas-resistance	NULL
,	NULL
which	NULL
may	NULL
provide	NULL
new	NULL
targets	NULL
for	NULL
influencing	NULL
normal	NULL
and	NULL
abnormal	NULL
immune	NULL
activity	NULL
.	NULL

ACKNOWLEDGEMENTS	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
United	NULL
States	NULL
Public	NULL
Health	NULL
Service	NULL
grants	NULL
AI40181	NULL
and	NULL
AlT45112	NULL
awarded	NULL
by	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
and	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Arthritis	NULL
Foundation	NULL
.	NULL

REFERENCES	NULL
[	NULL
1	NULL
]	NULL
Yonehara	NULL
S	NULL
,	NULL
Ishii	NULL
A	NULL
,	NULL
Yonehara	NULL
M.	NULL
A	NULL
cell-killing	NULL
monoclonal	NULL
antibody	NULL
(	NULL
anti-Fas	NULL
)	NULL
to	NULL
a	NULL
cell	NULL
surface	NULL
antigen	NULL
co-downregulated	NULL
with	NULL
the	NULL
receptor	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1989	NULL
;	NULL
169:1747-56	NULL
.	NULL

[	NULL
2	NULL
]	NULL
Trauth	NULL
BC	NULL
,	NULL
Klas	NULL
C	NULL
,	NULL
Peters	NULL
AM	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Monoclonal	NULL
antibody-	NULL
mediated	NULL
tumor	NULL
regression	NULL
by	NULL
induction	NULL
of	NULL
apoptosis	NULL
.	NULL

Science	NULL
1989	NULL
;	NULL
245:301-5	NULL
.	NULL

[	NULL
3	NULL
]	NULL
Nagata	NULL
S.	NULL
Apoptosis	NULL
by	NULL
death	NULL
factor	NULL
.	NULL

Cell	NULL
1997	NULL
;	NULL
88:355-65	NULL
.	NULL

[	NULL
4	NULL
]	NULL
Chinnaiyan	NULL
AM	NULL
,	NULL
O'Rourke	NULL
K	NULL
,	NULL
Yu	NULL
GL	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Signal	NULL
transduction	NULL
by	NULL
DR3	NULL
,	NULL
a	NULL
death	NULL
domain-containing	NULL
receptor	NULL
related	NULL
to	NULL
TNFR-1	NULL
and	NULL
CD95	NULL
.	NULL

Science	NULL
1996	NULL
;	NULL
,	NULL
B	NULL
.	NULL

274:990-2	NULL
.	NULL

[	NULL
5	NULL
]	NULL
Chaudhary	NULL
PM	NULL
,	NULL
Eby	NULL
M	NULL
,	NULL
Jasmin	NULL
A	NULL
,	NULL
Bookwalter	NULL
A	NULL
,	NULL
Murray	NULL
J	NULL
,	NULL
Hood	NULL
L.	NULL
Death	NULL
receptor	NULL
5	NULL
,	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
TNFR	NULL
family	NULL
,	NULL
and	NULL
DR4	NULL
induce	NULL
FADD-	NULL
dependent	NULL
apoptosis	NULL
and	NULL
activate	NULL
the	NULL
NF-	NULL
x	NULL
B	NULL
pathway	NULL
.	NULL

Immunity	NULL
1997	NULL
;	NULL
7:821-30	NULL
.	NULL

[	NULL
6	NULL
]	NULL
Schneider	NULL
P	NULL
,	NULL
Thome	NULL
M	NULL
,	NULL
Burns	NULL
K	NULL
,	NULL
et	NULL
al	NULL
.	NULL

TRAIL	NULL
receptors	NULL
1	NULL
(	NULL
DR4	NULL
)	NULL
and	NULL
2	NULL
(	NULL
DR5	NULL
)	NULL
signal	NULL
FADD-dependent	NULL
apoptosis	NULL
and	NULL
activate	NULL
NF-	NULL
x	NULL
B	NULL
.	NULL

Immunity	NULL
1997	NULL
;	NULL
7:831-6	NULL
.	NULL

[	NULL
7	NULL
]	NULL
Yeh	NULL
WC	NULL
,	NULL
Pompa	NULL
JL	NULL
,	NULL
McCurrach	NULL
ME	NULL
,	NULL
et	NULL
al	NULL
.	NULL

FADD	NULL
:	NULL
essential	NULL
for	NULL
embryo	NULL
development	NULL
and	NULL
signaling	NULL
from	NULL
some	NULL
,	NULL
but	NULL
not	NULL
all	NULL
,	NULL
inducers	NULL
of	NULL
apoptosis	NULL
.	NULL

Science	NULL
1998	NULL
;	NULL
279:1954-8	NULL
.	NULL

259	NULL
Inducible	NULL
Fas-resistance	NULL
in	NULL
B	NULL
cells	NULL
[	NULL
8	NULL
]	NULL
Suda	NULL
T	NULL
,	NULL
Okazaki	NULL
T	NULL
,	NULL
Naito	NULL
Y	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
Fas	NULL
ligand	NULL
in	NULL
cells	NULL
of	NULL
T	NULL
cell	NULL
lineage	NULL
.	NULL

J	NULL
Immunol	NULL
1995	NULL
;	NULL
154:3806-13	NULL
.	NULL

[	NULL
9	NULL
]	NULL
Smyth	NULL
MJ	NULL
,	NULL
Sutton	NULL
VR	NULL
,	NULL
Kershaw	NULL
MH	NULL
,	NULL
Trapani	NULL
JA	NULL
.	NULL

Xenospecific	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
use	NULL
perforin-and	NULL
Fas-mediated	NULL
lytic	NULL
pathways	NULL
.	NULL

Transplantation	NULL
1996	NULL
;	NULL
62:1529-32	NULL
.	NULL

[	NULL
10	NULL
]	NULL
Hahn	NULL
S	NULL
,	NULL
Gehri	NULL
R	NULL
,	NULL
Erb	NULL
P.	NULL
Mechanism	NULL
and	NULL
biological	NULL
significance	NULL
of	NULL
CD4-mediated	NULL
cytotoxicity	NULL
.	NULL

Immunol	NULL
Rev	NULL
1995	NULL
;	NULL
146:57-79	NULL
.	NULL

[	NULL
11	NULL
]	NULL
Arase	NULL
H	NULL
,	NULL
Arase	NULL
N	NULL
,	NULL
Saito	NULL
T.	NULL
Fas-mediated	NULL
cytotoxicity	NULL
by	NULL
freshly	NULL
isolated	NULL
natural	NULL
killer	NULL
cells	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1995	NULL
;	NULL
181:1235-8	NULL
.	NULL

[	NULL
12	NULL
]	NULL
Montel	NULL
AH	NULL
,	NULL
Bochan	NULL
MR	NULL
,	NULL
Hobbs	NULL
JA	NULL
,	NULL
Lynch	NULL
DH	NULL
,	NULL
Brahmi	NULL
Z.	NULL
Fas	NULL
involvement	NULL
in	NULL
cytotoxicity	NULL
mediated	NULL
by	NULL
human	NULL
NK	NULL
cells	NULL
.	NULL

Cell	NULL
Immunol	NULL
1995	NULL
;	NULL
166:236-46	NULL
.	NULL

[	NULL
13	NULL
]	NULL
Oshimi	NULL
Y	NULL
,	NULL
Oda	NULL
S	NULL
,	NULL
Honda	NULL
Y	NULL
,	NULL
Nagata	NULL
S	NULL
,	NULL
Miyazaki	NULL
S.	NULL
Involvement	NULL
of	NULL
Fas	NULL
ligand	NULL
and	NULL
Fas-mediated	NULL
pathway	NULL
in	NULL
the	NULL
cytotoxicity	NULL
of	NULL
human	NULL
natural	NULL
killer	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
1996	NULL
;	NULL
157:2909-15	NULL
.	NULL

[	NULL
14	NULL
]	NULL
Cohen	NULL
PL	NULL
,	NULL
Eisenberg	NULL
RA	NULL
.	NULL

Lpr	NULL
and	NULL
gld	NULL
:	NULL
single	NULL
gene	NULL
models	NULL
of	NULL
systemic	NULL
autoimmunity	NULL
and	NULL
lymphoproliferative	NULL
disease	NULL
.	NULL

Annu	NULL
Rev	NULL
Immunol	NULL
1991	NULL
;	NULL
9:243-69	NULL
.	NULL

[	NULL
15	NULL
]	NULL
Watanabe-Fukunaga	NULL
R	NULL
,	NULL
Brannan	NULL
CI	NULL
,	NULL
Copeland	NULL
NG	NULL
,	NULL
Jenkins	NULL
NA	NULL
,	NULL
Nagata	NULL
S.	NULL
Lymphoproliferation	NULL
disorder	NULL
in	NULL
mice	NULL
explained	NULL
by	NULL
defects	NULL
in	NULL
Fas	NULL
antigen	NULL
that	NULL
mediates	NULL
apoptosis	NULL
.	NULL

Nature	NULL
1992	NULL
;	NULL
856:314-7	NULL
.	NULL

[	NULL
16	NULL
]	NULL
Takahashi	NULL
T	NULL
,	NULL
Tanaka	NULL
M	NULL
,	NULL
Brannan	NULL
CI	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Generalized	NULL
lymphoproliferative	NULL
disease	NULL
in	NULL
mice	NULL
,	NULL
caused	NULL
by	NULL
a	NULL
point	NULL
mutation	NULL
in	NULL
the	NULL
Fas	NULL
ligand	NULL
.	NULL

Cell	NULL
1994	NULL
;	NULL
76:969-76	NULL
.	NULL

[	NULL
17	NULL
]	NULL
Fisher	NULL
GH	NULL
,	NULL
Rosenberg	NULL
FJ	NULL
,	NULL
Straus	NULL
SE	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Dominant	NULL
interfering	NULL
Fas	NULL
gene	NULL
mutations	NULL
impair	NULL
apoptosis	NULL
in	NULL
a	NULL
human	NULL
autoimmune	NULL
lymphoproliferative	NULL
syndrome	NULL
.	NULL

Cell	NULL
1995	NULL
;	NULL
81:985-46	NULL
.	NULL

[	NULL
18	NULL
]	NULL
Rieux-Laucat	NULL
F	NULL
,	NULL
Le	NULL
Deist	NULL
F	NULL
,	NULL
Hivroz	NULL
C	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Mutations	NULL
in	NULL
Fas	NULL
associated	NULL
with	NULL
human	NULL
lymphoproliferative	NULL
syndrome	NULL
and	NULL
autoimmunity	NULL
.	NULL

Science	NULL
1995	NULL
;	NULL
268:1347-9	NULL
.	NULL

[	NULL
19	NULL
]	NULL
Drappa	NULL
J	NULL
,	NULL
Vaishnaw	NULL
AK	NULL
,	NULL
Sullivan	NULL
KE	NULL
,	NULL
Chu	NULL
JL	NULL
,	NULL
Elkon	NULL
KB	NULL
.	NULL

Fas	NULL
gene	NULL
mutations	NULL
in	NULL
the	NULL
Canale-Smith	NULL
syndrome	NULL
,	NULL
an	NULL
inherited	NULL
lymphoproliferative	NULL
disorder	NULL
associated	NULL
with	NULL
autoimmunity	NULL
[	NULL
see	NULL
comments	NULL
]	NULL
.	NULL

N	NULL
Engl	NULL
J	NULL
Med	NULL
1996	NULL
;	NULL
385:1643-9	NULL
.	NULL

[	NULL
20	NULL
]	NULL
Wu	NULL
J	NULL
,	NULL
Wilson	NULL
J	NULL
,	NULL
He	NULL
J	NULL
,	NULL
Xiang	NULL
L	NULL
,	NULL
Schur	NULL
PH	NULL
,	NULL
Mountz	NULL
JD	NULL
.	NULL

Fas	NULL
ligand	NULL
mutation	NULL
in	NULL
a	NULL
patient	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
and	NULL
lymphoproliferative	NULL
disease	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
1996	NULL
;	NULL
98:1107-13	NULL
.	NULL

[	NULL
21	NULL
]	NULL
Le	NULL
Deist	NULL
F	NULL
,	NULL
Emile	NULL
JF	NULL
,	NULL
Rieux-	NULL
Laucat	NULL
F	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Clinical	NULL
,	NULL
immunological	NULL
,	NULL
and	NULL
pathological	NULL
consequences	NULL
of	NULL
Fas-deficient	NULL
conditions	NULL
.	NULL

Lancet	NULL
1996	NULL
;	NULL
348:719-23	NULL
.	NULL

[	NULL
22	NULL
]	NULL
Wang	NULL
J	NULL
,	NULL
Zheng	NULL
L	NULL
,	NULL
Lobito	NULL
A	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Inherited	NULL
human	NULL
Caspase	NULL
10	NULL
mutations	NULL
underlie	NULL
defective	NULL
lymphocyte	NULL
and	NULL
dendritic	NULL
cell	NULL
apoptosis	NULL
in	NULL
autoimmune	NULL
lymphoproliferative	NULL
syndrome	NULL
type	NULL
II	NULL
.	NULL

Cell	NULL
1999	NULL
;	NULL
98:47-58	NULL
.	NULL

[	NULL
23	NULL
]	NULL
Nagata	NULL
S	NULL
,	NULL
Suda	NULL
T.	NULL
Fas	NULL
and	NULL
Fas	NULL
ligand	NULL
:	NULL
lpr	NULL
and	NULL
gld	NULL
mutations	NULL
.	NULL

Immunol	NULL
Today	NULL
1995	NULL
;	NULL
16:39-43	NULL
.	NULL

[	NULL
24	NULL
]	NULL
Adachi	NULL
M	NULL
,	NULL
SuematsuS	NULL
,	NULL
Suda	NULL
T	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Enhanced	NULL
and	NULL
accelerated	NULL
lymphoproliferation	NULL
in	NULL
Fas-null	NULL
mice	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
1996	NULL
;	NULL
93:2131-6	NULL
.	NULL

[	NULL
25	NULL
]	NULL
Perkins	NULL
DL	NULL
,	NULL
Michaelson	NULL
J	NULL
,	NULL
Glaser	NULL
RM	NULL
,	NULL
Marshak-Rothstein	NULL
A	NULL
.	NULL

Selective	NULL
elimination	NULL
of	NULL
non-	NULL
Ipr	NULL
lymphoid	NULL
cells	NULL
in	NULL
mice	NULL
undergoing	NULL
Ipr-mediated	NULL
graft-vs-host	NULL
disease	NULL
.	NULL

J	NULL
Immunol	NULL
1987	NULL
;	NULL
189:1406-13	NULL
.	NULL

[	NULL
26	NULL
]	NULL
Nemazee	NULL
D	NULL
,	NULL
Guiet	NULL
C	NULL
,	NULL
Buerki	NULL
K	NULL
,	NULL
Marshak-Rothstein	NULL
A	NULL
.	NULL

B	NULL
lymphocytes	NULL
from	NULL
the	NULL
autoimmune-prone	NULL
mouse	NULL
strain	NULL
MLR/	NULL
lpr	NULL
manifest	NULL
an	NULL
intrinsic	NULL
defect	NULL
in	NULL
tetraparental	NULL
MRL/	NULL
lpr	NULL
in	NULL
equilibrium	NULL
DBA/2	NULL
chimeras	NULL
.	NULL

J	NULL
Immunol	NULL
1991	NULL
;	NULL
147:2536-9	NULL
.	NULL

[	NULL
27	NULL
]	NULL
Sobel	NULL
ES	NULL
,	NULL
Kakkaaiah	NULL
VN	NULL
,	NULL
Schiffenbauer	NULL
J	NULL
,	NULL
Reap	NULL
EA	NULL
,	NULL
Cohen	NULL
PL	NULL
,	NULL
Eisenberg	NULL
RA	NULL
.	NULL

Novel	NULL
immunoregulatory	NULL
B	NULL
cell	NULL
pathways	NULL
revealed	NULL
by	NULL
lpr-+	NULL
mixed	NULL
chimeras	NULL
.	NULL

J	NULL
Immunol	NULL
1998	NULL
;	NULL
160:1497-503	NULL
.	NULL

[	NULL
28	NULL
]	NULL
Fukuyama	NULL
H	NULL
,	NULL
Adachi	NULL
M	NULL
,	NULL
Suematsu	NULL
S	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Transgenic	NULL
expression	NULL
of	NULL
Fas	NULL
in	NULL
T	NULL
cells	NULL
blocks	NULL
lymphoproliferation	NULL
but	NULL
not	NULL
autoimmune	NULL
disease	NULL
in	NULL
MRL	NULL
-	NULL
lpr	NULL
mice	NULL
.	NULL

J	NULL
Immunol	NULL
1998	NULL
;	NULL
160:3805-11	NULL
.	NULL

[	NULL
29	NULL
]	NULL
Stalder	NULL
T	NULL
,	NULL
Hahn	NULL
S	NULL
,	NULL
Erb	NULL
P.	NULL
Fas	NULL
antigen	NULL
is	NULL
the	NULL
major	NULL
target	NULL
molecule	NULL
for	NULL
CD4+	NULL
T	NULL
cell-mediated	NULL
cytotoxicity	NULL
.	NULL

J	NULL
Immunol	NULL
1994	NULL
;	NULL
152:1127-33	NULL
.	NULL

[	NULL
30	NULL
]	NULL
Ju	NULL
ST	NULL
,	NULL
Cui	NULL
H	NULL
,	NULL
Panka	NULL
DJ	NULL
,	NULL
Ettinger	NULL
R	NULL
,	NULL
Marshak-Rothstein	NULL
A	NULL
.	NULL

Participation	NULL
of	NULL
target	NULL
Fas	NULL
protein	NULL
in	NULL
apoptosis	NULL
pathway	NULL
induced	NULL
by	NULL
CD4+	NULL
Th1	NULL
and	NULL
CD8+	NULL
cytotoxic	NULL
T	NULL
cells	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sei	NULL
USA	NULL
1994	NULL
;	NULL
91:4185-9	NULL
.	NULL

260	NULL
Rothstein	NULL
TL	NULL
[	NULL
31	NULL
]	NULL
Daniel	NULL
PT	NULL
,	NULL
Krammer	NULL
PH	NULL
.	NULL

Activation	NULL
induces	NULL
sensitivity	NULL
toward	NULL
APO-1	NULL
(	NULL
CD95	NULL
)	NULL
-mediated	NULL
apoptosis	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
1994	NULL
;	NULL
152:5624-32	NULL
.	NULL

[	NULL
32	NULL
]	NULL
Watanabe	NULL
D	NULL
,	NULL
Suda	NULL
T	NULL
,	NULL
Nagata	NULL
S.	NULL
Expression	NULL
of	NULL
Fas	NULL
in	NULL
B	NULL
cells	NULL
of	NULL
the	NULL
mouse	NULL
germinal	NULL
center	NULL
and	NULL
Fas-dependent	NULL
killing	NULL
of	NULL
activated	NULL
B	NULL
cells	NULL
.	NULL

Int	NULL
Immunol	NULL
1995	NULL
;	NULL
7:1949-56	NULL
.	NULL

[	NULL
33	NULL
]	NULL
Onel	NULL
KB	NULL
,	NULL
Tucek-Szabo	NULL
CL	NULL
,	NULL
Ashany	NULL
D	NULL
,	NULL
Lacy	NULL
E	NULL
,	NULL
Nikolic-Zugic	NULL
J	NULL
,	NULL
Elkon	NULL
KB	NULL
.	NULL

Expression	NULL
and	NULL
function	NULL
of	NULL
the	NULL
murine	NULL
CD95/FasR/APO-1	NULL
receptor	NULL
in	NULL
relation	NULL
to	NULL
B	NULL
cell	NULL
ontogeny	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
1995	NULL
;	NULL
25:2940-7	NULL
.	NULL

[	NULL
34	NULL
]	NULL
Rothstein	NULL
TL	NULL
,	NULL
Wang	NULL
JK	NULL
,	NULL
Panka	NULL
DJ	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Protection	NULL
against	NULL
Fas-dependent	NULL
Th1-mediated	NULL
apoptosis	NULL
by	NULL
antigen	NULL
receptor	NULL
engagement	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

Nature	NULL
1995	NULL
;	NULL
874:163-5	NULL
.	NULL

[	NULL
35	NULL
]	NULL
Foote	NULL
LC	NULL
,	NULL
Schneider	NULL
TJ	NULL
,	NULL
Fischer	NULL
GM	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Intracellular	NULL
signaling	NULL
for	NULL
inducible	NULL
antigen	NULL
receptor-mediated	NULL
Fas	NULL
resistance	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
1996	NULL
;	NULL
157:1878-85	NULL
.	NULL

[	NULL
36	NULL
]	NULL
Foote	NULL
LC	NULL
,	NULL
Marshak-Rothstein	NULL
A	NULL
,	NULL
Rothstein	NULL
TL	NULL
.	NULL

Tolerant	NULL
B	NULL
lymphocytes	NULL
acquire	NULL
resistance	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
after	NULL
treatment	NULL
with	NULL
interleukin	NULL
4	NULL
but	NULL
not	NULL
after	NULL
treatment	NULL
with	NULL
specific	NULL
antigen	NULL
unless	NULL
a	NULL
surface	NULL
immunoglobulin	NULL
threshold	NULL
is	NULL
exceeded	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1998	NULL
;	NULL
187:847-53	NULL
.	NULL

[	NULL
37	NULL
]	NULL
Foote	NULL
LC	NULL
,	NULL
Howard	NULL
RG	NULL
,	NULL
Marshak-Rothstein	NULL
A	NULL
,	NULL
Rothstein	NULL
TL	NULL
.	NULL

IL-4	NULL
induces	NULL
Fas	NULL
resistance	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
1996	NULL
;	NULL
157:2749-53	NULL
.	NULL

[	NULL
38	NULL
]	NULL
Schattner	NULL
EJ	NULL
,	NULL
Elkon	NULL
KB	NULL
,	NULL
Yoo	NULL
DH	NULL
,	NULL
et	NULL
al	NULL
.	NULL

CD40	NULL
ligation	NULL
induces	NULL
Apo-	NULL
1/Fas	NULL
expression	NULL
on	NULL
human	NULL
B	NULL
lymphocytes	NULL
and	NULL
facilitates	NULL
apoptosis	NULL
through	NULL
the	NULL
Apo-1/Fas	NULL
pathway	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1995	NULL
;	NULL
182:1557-65	NULL
.	NULL

[	NULL
39	NULL
]	NULL
Garrone	NULL
P	NULL
,	NULL
Neidhardt	NULL
EM	NULL
,	NULL
Garcia	NULL
E	NULL
,	NULL
Galibert	NULL
L	NULL
,	NULL
van	NULL
Kooten	NULL
C	NULL
,	NULL
Banchereau	NULL
J.	NULL
Fas	NULL
ligation	NULL
induces	NULL
apoptosis	NULL
of	NULL
CD40-activated	NULL
human	NULL
B	NULL
lymphocytes	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1995	NULL
;	NULL
182:1265-73	NULL
.	NULL

[	NULL
40	NULL
]	NULL
Lagresle	NULL
C	NULL
,	NULL
Mondiere	NULL
P	NULL
,	NULL
Bella	NULL
C	NULL
,	NULL
Krammer	NULL
PH	NULL
,	NULL
Defrance	NULL
T.	NULL
Concurrent	NULL
engagement	NULL
of	NULL
CD40	NULL
and	NULL
the	NULL
antigen	NULL
receptor	NULL
protects	NULL
naive	NULL
and	NULL
memory	NULL
human	NULL
B	NULL
cells	NULL
from	NULL
APO-1/Fas-mediated	NULL
apoptosis	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1996	NULL
;	NULL
183:1377-88	NULL
.	NULL

[	NULL
41	NULL
]	NULL
Rathmell	NULL
JC	NULL
,	NULL
Townsend	NULL
SE	NULL
,	NULL
Xu	NULL
JC	NULL
,	NULL
Flavell	NULL
RA	NULL
,	NULL
Goodnow	NULL
CC	NULL
.	NULL

Expansion	NULL
or	NULL
elimination	NULL
of	NULL
B	NULL
cells	NULL
in	NULL
vivo	NULL
:	NULL
dual	NULL
roles	NULL
for	NULL
CD4Q0-	NULL
and	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
-ligands	NULL
modulated	NULL
by	NULL
the	NULL
B	NULL
cell	NULL
antigen	NULL
receptor	NULL
.	NULL

Cell	NULL
1996	NULL
;	NULL
87:319-29	NULL
.	NULL

[	NULL
42	NULL
]	NULL
Wurster	NULL
AL	NULL
,	NULL
Rothstein	NULL
TL	NULL
,	NULL
Grusby	NULL
MJ	NULL
.	NULL

IL-4	NULL
protects	NULL
primary	NULL
B	NULL
cells	NULL
from	NULL
apoptosis	NULL
through	NULL
Stat6-dependent	NULL
upregulation	NULL
of	NULL
Bel-xL	NULL
.	NULL

Submitted	NULL
.	NULL

[	NULL
43	NULL
]	NULL
Karras	NULL
JG	NULL
,	NULL
Wang	NULL
Z	NULL
,	NULL
Coniglio	NULL
SJ	NULL
,	NULL
Frank	NULL
DA	NULL
,	NULL
Rothstein	NULL
TL	NULL
.	NULL

Antigen-receptor	NULL
engagement	NULL
in	NULL
B	NULL
cells	NULL
induces	NULL
nuclear	NULL
expression	NULL
of	NULL
STATS	NULL
and	NULL
STAT6	NULL
proteins	NULL
that	NULL
bind	NULL
and	NULL
transactivate	NULL
an	NULL
IFN-	NULL
y	NULL
activation	NULL
site	NULL
.	NULL

J	NULL
Immunol	NULL
1996	NULL
;	NULL
157:39-47	NULL
.	NULL

[	NULL
44	NULL
]	NULL
Klaus	NULL
GG	NULL
,	NULL
O'Garra	NULL
A	NULL
,	NULL
Bijsterbosch	NULL
MK	NULL
,	NULL
Holman	NULL
M.	NULL
Activation	NULL
and	NULL
proliferation	NULL
signals	NULL
in	NULL
mouse	NULL
B	NULL
cells	NULL
.	NULL

VIII	NULL
.	NULL

Induction	NULL
of	NULL
DNA	NULL
synthesis	NULL
in	NULL
B	NULL
cells	NULL
by	NULL
a	NULL
combination	NULL
of	NULL
calcium	NULL
ionophores	NULL
and	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
1986	NULL
;	NULL
16:92-7	NULL
.	NULL

[	NULL
45	NULL
]	NULL
Rothstein	NULL
TL	NULL
,	NULL
Backer	NULL
TR	NULL
,	NULL
Miller	NULL
RA	NULL
,	NULL
Kolber	NULL
DL	NULL
.	NULL

Stimulation	NULL
of	NULL
murine	NULL
B	NULL
cells	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
calcium	NULL
ionophore	NULL
plus	NULL
phorbol	NULL
ester	NULL
.	NULL

Cell	NULL
Immunol	NULL
1986	NULL
;	NULL
102:364-73	NULL
.	NULL

[	NULL
46	NULL
]	NULL
Sieckmann	NULL
DG	NULL
,	NULL
Asofsky	NULL
R	NULL
,	NULL
Mosier	NULL
DE	NULL
,	NULL
Zitron	NULL
IM	NULL
,	NULL
Paul	NULL
.	NULL

Activation	NULL
of	NULL
mouse	NULL
lymphocytes	NULL
by	NULL
anti-immunoglobulin	NULL
.	NULL

L.	NULL
Parameters	NULL
of	NULL
the	NULL
proliferative	NULL
response	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1978	NULL
;	NULL
147:814-29	NULL
.	NULL

[	NULL
47	NULL
]	NULL
Rawlings	NULL
DJ	NULL
,	NULL
Saffran	NULL
DC	NULL
,	NULL
Tsukada	NULL
S	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Mutation	NULL
of	NULL
unique	NULL
region	NULL
of	NULL
Bruton	NULL
'	NULL
s	NULL
tyrosine	NULL
kinase	NULL
in	NULL
immunodeficient	NULL
XID	NULL
mice	NULL
.	NULL

Science	NULL
1998	NULL
;	NULL
261:358-61	NULL
.	NULL

[	NULL
48	NULL
]	NULL
Khan	NULL
WN	NULL
,	NULL
Alt	NULL
FW	NULL
,	NULL
Gerstein	NULL
RM	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Defective	NULL
B	NULL
cell	NULL
development	NULL
and	NULL
function	NULL
in	NULL
Btk-deficient	NULL
mice	NULL
.	NULL

Immunity	NULL
1995	NULL
;	NULL
8:283-99	NULL
.	NULL

[	NULL
49	NULL
]	NULL
Negm	NULL
RS	NULL
,	NULL
Schneider	NULL
TJ	NULL
,	NULL
Colarusso	NULL
TP	NULL
,	NULL
Woodland	NULL
RT	NULL
,	NULL
Rothstein	NULL
TL	NULL
.	NULL

Btk	NULL
does	NULL
not	NULL
regulate	NULL
susceptibility	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
nor	NULL
inducible	NULL
Fas-resistance	NULL
in	NULL
murine	NULL
B	NULL
cells	NULL
.	NULL

In	NULL
preparation	NULL
2000	NULL
;	NULL
.	NULL

[	NULL
50	NULL
]	NULL
Vassilevy	NULL
A	NULL
,	NULL
Ozer	NULL
Z	NULL
,	NULL
Navara	NULL
C	NULL
,	NULL
Mahajan	NULL
S	NULL
,	NULL
Uckun	NULL
FM	NULL
.	NULL

Bruton	NULL
'	NULL
s	NULL
tyrosine	NULL
kinase	NULL
as	NULL
an	NULL
inhibitor	NULL
of	NULL
the	NULL
Fas/CD95	NULL
death-inducing	NULL
signaling	NULL
complex	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
1999	NULL
;	NULL
274:1646-56	NULL
.	NULL

[	NULL
51	NULL
]	NULL
Schneider	NULL
TJ	NULL
,	NULL
Fischer	NULL
GM	NULL
,	NULL
Donohoe	NULL
TJ	NULL
,	NULL
Colarusso	NULL
TP	NULL
,	NULL
Rothstein	NULL
TL	NULL
.	NULL

A	NULL
novel	NULL
gene	NULL
coding	NULL
for	NULL
a	NULL
Fas	NULL
apoptosis	NULL
inhibitory	NULL
molecule	NULL
(	NULL
FAIM	NULL
)	NULL
isolated	NULL
from	NULL
inducibly	NULL
Fas-resistant	NULL
B	NULL
lymphocytes	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1999	NULL
;	NULL
189:949-56	NULL
.	NULL

261	NULL
Inducible	NULL
Fas-resistance	NULL
in	NULL
B	NULL
cells	NULL
[	NULL
52	NULL
]	NULL
Catlett	NULL
IM	NULL
,	NULL
Bishop	NULL
GA	NULL
.	NULL

Cutting	NULL
edge	NULL
:	NULL
a	NULL
novel	NULL
mechanism	NULL
for	NULL
rescue	NULL
of	NULL
B	NULL
cells	NULL
from	NULL
CD95/Fas-mediated	NULL
apoptosis	NULL
.	NULL

J	NULL
Immunol	NULL
1999	NULL
;	NULL
163:2378-81	NULL
.	NULL

[	NULL
53	NULL
]	NULL
Liu	NULL
JL	NULL
,	NULL
Chiles	NULL
TC	NULL
,	NULL
Sen	NULL
RJ	NULL
,	NULL
Rothstein	NULL
TL	NULL
.	NULL

Inducible	NULL
nuclear	NULL
expression	NULL
of	NULL
NF-	NULL
Â«	NULL
B	NULL
in	NULL
primary	NULL
B	NULL
cells	NULL
stimulated	NULL
through	NULL
the	NULL
surface	NULL
Ig	NULL
receptor	NULL
.	NULL

J	NULL
Immunol	NULL
1991	NULL
;	NULL
146:1685-91	NULL
.	NULL

[	NULL
54	NULL
]	NULL
Rooney	NULL
JW	NULL
,	NULL
Dubois	NULL
PM	NULL
,	NULL
Sibley	NULL
CH	NULL
.	NULL

Cross-linking	NULL
of	NULL
surface	NULL
IgM	NULL
activates	NULL
NF-	NULL
x	NULL
B	NULL
in	NULL
B	NULL
lymphocyte	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
1991	NULL
;	NULL
21:2993-8	NULL
.	NULL

[	NULL
55	NULL
]	NULL
Ghosh	NULL
S.	NULL
Regulation	NULL
of	NULL
inducible	NULL
gene	NULL
expression	NULL
by	NULL
the	NULL
transcription	NULL
factor	NULL
NF-	NULL
Â«	NULL
B.	NULL
Immunol	NULL
Res	NULL
1999	NULL
;	NULL
19:183-9	NULL
.	NULL

[	NULL
56	NULL
]	NULL
Jeremias	NULL
I	NULL
,	NULL
Kupatt	NULL
C	NULL
,	NULL
Baumann	NULL
B	NULL
,	NULL
Herr	NULL
I	NULL
,	NULL
Wirth	NULL
T	NULL
,	NULL
Debatin	NULL
KM	NULL
.	NULL

Inhibition	NULL
of	NULL
nuclear	NULL
factor	NULL
Â«	NULL
B	NULL
activation	NULL
attenuates	NULL
apoptosis	NULL
resistance	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

Blood	NULL
1998	NULL
;	NULL
91:4624-31	NULL
.	NULL

[	NULL
57	NULL
]	NULL
Dudley	NULL
E	NULL
,	NULL
Hornung	NULL
F	NULL
,	NULL
Zheng	NULL
L	NULL
,	NULL
Scherer	NULL
D	NULL
,	NULL
Ballard	NULL
D	NULL
,	NULL
Lenardo	NULL
M.	NULL
NF-	NULL
Â«	NULL
B	NULL
regulates	NULL
Fas/APO-1/CD95-and	NULL
TCR-mediated	NULL
apoptosis	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
1999	NULL
;	NULL
29:878-86	NULL
.	NULL

[	NULL
58	NULL
]	NULL
Zong	NULL
WX	NULL
,	NULL
Edelstein	NULL
LC	NULL
,	NULL
Chen	NULL
C	NULL
,	NULL
Bash	NULL
J	NULL
,	NULL
Gelinas	NULL
C.	NULL
The	NULL
prosurvival	NULL
Bel-2	NULL
homolog	NULL
Bfl-1/A1	NULL
is	NULL
a	NULL
direct	NULL
transcriptional	NULL
target	NULL
of	NULL
NF-	NULL
Â«	NULL
B	NULL
that	NULL
blocks	NULL
TNF	NULL
@	NULL
-induced	NULL
apoptosis	NULL
.	NULL

Genes	NULL
Dev	NULL
1999	NULL
;	NULL
13	NULL
:	NULL
382-7	NULL
.	NULL

[	NULL
59	NULL
]	NULL
Grumont	NULL
RJ	NULL
,	NULL
Rourke	NULL
IJ	NULL
,	NULL
Gerondakis	NULL
S.	NULL
Rel-dependent	NULL
induction	NULL
of	NULL
A1	NULL
transcription	NULL
is	NULL
required	NULL
to	NULL
protect	NULL
B	NULL
cells	NULL
from	NULL
antigen	NULL
receptor	NULL
ligation-induced	NULL
apoptosis	NULL
.	NULL

Genes	NULL
Dev	NULL
1999	NULL
;	NULL
13:400-11	NULL
.	NULL

[	NULL
60	NULL
]	NULL
Lee	NULL
HH	NULL
,	NULL
Dadgostar	NULL
H	NULL
,	NULL
Cheng	NULL
Q	NULL
,	NULL
Shu	NULL
J	NULL
,	NULL
Cheng	NULL
G.	NULL
NF-	NULL
x	NULL
B-mediated	NULL
up-regulation	NULL
of	NULL
Bel-x	NULL
and	NULL
Bfl-1/A1	NULL
is	NULL
required	NULL
for	NULL
CD40	NULL
survival	NULL
signaling	NULL
in	NULL
B	NULL
lymphocytes	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
1999	NULL
;	NULL
96:9136-41	NULL
.	NULL

[	NULL
61	NULL
]	NULL
Wang	NULL
CY	NULL
,	NULL
Guttridge	NULL
DC	NULL
,	NULL
Mayo	NULL
MW	NULL
,	NULL
Baldwin	NULL
AS	NULL
,	NULL
Jr.	NULL
NF-	NULL
x	NULL
B	NULL
induces	NULL
expression	NULL
of	NULL
the	NULL
Bel-2	NULL
homologue	NULL
A1/Bfl-1	NULL
to	NULL
preferentially	NULL
suppress	NULL
chemotherapy-induced	NULL
apoptosis	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
1999	NULL
;	NULL
19:5923-9	NULL
.	NULL

[	NULL
62	NULL
]	NULL
)	NULL
Fenteany	NULL
G	NULL
,	NULL
Standaert	NULL
RF	NULL
,	NULL
Lane	NULL
WS	NULL
,	NULL
Choi	NULL
S	NULL
,	NULL
Corey	NULL
EJ	NULL
,	NULL
Schreiber	NULL
SL	NULL
.	NULL

Inhibition	NULL
of	NULL
proteasome	NULL
activities	NULL
and	NULL
subunit-specific	NULL
amino-terminal	NULL
threonine	NULL
modification	NULL
by	NULL
lactacystin	NULL
.	NULL

Science	NULL
1995	NULL
;	NULL
268:726-31	NULL
.	NULL

[	NULL
63	NULL
]	NULL
Matsui	NULL
K	NULL
,	NULL
Omura	NULL
S	NULL
,	NULL
Cui	NULL
H	NULL
,	NULL
Schauer	NULL
SL	NULL
,	NULL
Sonenshein	NULL
GE	NULL
,	NULL
Ju	NULL
ST.	NULL
Proteasome	NULL
regulation	NULL
of	NULL
Fas	NULL
ligand	NULL
cytotoxicity	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
1997	NULL
;	NULL
27:2269-78	NULL
.	NULL

[	NULL
64	NULL
]	NULL
Schreck	NULL
R	NULL
,	NULL
Meier	NULL
B	NULL
,	NULL
Mannel	NULL
DN	NULL
,	NULL
Droge	NULL
W	NULL
,	NULL
Baeuerle	NULL
PA.	NULL
Dithiocarbamates	NULL
as	NULL
potent	NULL
inhibitors	NULL
of	NULL
nuclear	NULL
factor	NULL
Â®	NULL
B	NULL
activation	NULL
in	NULL
intact	NULL
cells	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1992	NULL
;	NULL
175:1181-94	NULL
.	NULL

[	NULL
65	NULL
]	NULL
Bajpai	NULL
UD	NULL
,	NULL
Zhang	NULL
K	NULL
,	NULL
Teutsch	NULL
M	NULL
,	NULL
Sen	NULL
R	NULL
,	NULL
Wortis	NULL
HH	NULL
.	NULL

Bruton	NULL
's	NULL
tyrosine	NULL
kinase	NULL
links	NULL
the	NULL
B	NULL
cell	NULL
receptor	NULL
to	NULL
nuclear	NULL
factor	NULL
Â®	NULL
B	NULL
activation	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
2000	NULL
;	NULL
191:1735-44	NULL
.	NULL

[	NULL
66	NULL
]	NULL
Petro	NULL
JB	NULL
,	NULL
Rahman	NULL
SM	NULL
,	NULL
Ballard	NULL
DW	NULL
,	NULL
Khan	NULL
WN	NULL
.	NULL

Bruton	NULL
's	NULL
tyrosine	NULL
kinase	NULL
is	NULL
required	NULL
for	NULL
activation	NULL
of	NULL
I	NULL
x	NULL
B	NULL
kinase	NULL
and	NULL
nuclear	NULL
factor	NULL
<	NULL
B	NULL
in	NULL
response	NULL
to	NULL
B	NULL
cell	NULL
receptor	NULL
engagement	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
2000	NULL
;	NULL
191	NULL
:	NULL
1745-54	NULL
.	NULL

[	NULL
67	NULL
]	NULL
Yang	NULL
E	NULL
,	NULL
Korsmeyer	NULL
SJ	NULL
.	NULL

Molecular	NULL
thanatopsis	NULL
:	NULL
a	NULL
discourse	NULL
on	NULL
the	NULL
BCL2	NULL
family	NULL
and	NULL
cell	NULL
death	NULL
.	NULL

Blood	NULL
1996	NULL
;	NULL
88:386-401	NULL
.	NULL

[	NULL
68	NULL
]	NULL
Schneider	NULL
TJ	NULL
,	NULL
Grillot	NULL
D	NULL
,	NULL
Foote	NULL
LC	NULL
,	NULL
Nunez	NULL
GE	NULL
,	NULL
Rothstein	NULL
TL	NULL
.	NULL

Bel-x	NULL
protects	NULL
primary	NULL
B	NULL
cells	NULL
against	NULL
Fas-mediated	NULL
apoptosis	NULL
.	NULL

J	NULL
Immunol	NULL
1997	NULL
;	NULL
159:4834-9	NULL
.	NULL

[	NULL
69	NULL
]	NULL
Zhang	NULL
X	NULL
,	NULL
Li	NULL
L	NULL
,	NULL
Choe	NULL
J	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Up-regulation	NULL
of	NULL
Bel-xL	NULL
expression	NULL
protects	NULL
CD4O-activated	NULL
human	NULL
B	NULL
cells	NULL
from	NULL
Fas-mediated	NULL
apoptosis	NULL
.	NULL

Cell	NULL
Immunol	NULL
1996	NULL
;	NULL
178:149-54	NULL
.	NULL

[	NULL
70	NULL
]	NULL
Huang	NULL
DC	NULL
,	NULL
Hahne	NULL
M	NULL
,	NULL
Schroeter	NULL
M	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Activation	NULL
of	NULL
Fas	NULL
by	NULL
FasL	NULL
induces	NULL
apoptosis	NULL
by	NULL
a	NULL
mechanism	NULL
that	NULL
can	NULL
not	NULL
be	NULL
blocked	NULL
by	NULL
Bel-2	NULL
or	NULL
Bel-x	NULL
(	NULL
L	NULL
)	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
1999	NULL
;	NULL
96:14871-6	NULL
.	NULL

[	NULL
71	NULL
]	NULL
Zamzami	NULL
N	NULL
,	NULL
Marchetti	NULL
P	NULL
,	NULL
Castedo	NULL
M	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Sequential	NULL
reduction	NULL
of	NULL
mitochondrial	NULL
transmembrane	NULL
potential	NULL
and	NULL
generation	NULL
of	NULL
reactive	NULL
oxygen	NULL
species	NULL
in	NULL
early	NULL
programmed	NULL
cell	NULL
death	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1995	NULL
;	NULL
182:367-77	NULL
.	NULL

[	NULL
72	NULL
]	NULL
Decaudin	NULL
D	NULL
,	NULL
Geley	NULL
S	NULL
,	NULL
Hirsch	NULL
T	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Bel-2	NULL
and	NULL
Bel-XL	NULL
antagonize	NULL
the	NULL
mitochondrial	NULL
dysfunction	NULL
preceding	NULL
nuclear	NULL
apoptosis	NULL
induced	NULL
by	NULL
chemotherapeutic	NULL
agents	NULL
.	NULL

Cancer	NULL
Res	NULL
1997	NULL
;	NULL
57:62-7	NULL
.	NULL

[	NULL
73	NULL
]	NULL
Arora	NULL
AS	NULL
,	NULL
Jones	NULL
BJ	NULL
,	NULL
Patel	NULL
TC	NULL
,	NULL
Bronk	NULL
SF	NULL
,	NULL
Gores	NULL
GJ	NULL
.	NULL

Ceramide	NULL
induces	NULL
hepatocyte	NULL
cell	NULL
death	NULL
through	NULL
disruption	NULL
of	NULL
mitochondrial	NULL
function	NULL
in	NULL
the	NULL
rat	NULL
.	NULL

Hepatology	NULL
1997	NULL
;	NULL
25:958-63	NULL
.	NULL

262	NULL
Rothstein	NULL
TL	NULL
[	NULL
74	NULL
]	NULL
Gudz	NULL
TI	NULL
,	NULL
Tserng	NULL
KY	NULL
,	NULL
Hoppel	NULL
CL	NULL
.	NULL

Direct	NULL
inhibition	NULL
of	NULL
mitochondrial	NULL
respiratory	NULL
chain	NULL
complex	NULL
III	NULL
by	NULL
cell-permeable	NULL
ceramide	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
1997	NULL
;	NULL
272:24154-8	NULL
.	NULL

[	NULL
75	NULL
]	NULL
Scaffidi	NULL
C	NULL
,	NULL
Schmitz	NULL
I	NULL
,	NULL
Zha	NULL
J	NULL
,	NULL
Korsmeyer	NULL
SJ	NULL
,	NULL
Krammer	NULL
PH	NULL
,	NULL
Peter	NULL
ME	NULL
.	NULL

Differential	NULL
modulation	NULL
of	NULL
apoptosis	NULL
sensitivity	NULL
in	NULL
CD95	NULL
type	NULL
I	NULL
and	NULL
type	NULL
II	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
1999	NULL
;	NULL
274:22582-8	NULL
.	NULL

[	NULL
76	NULL
]	NULL
Irmler	NULL
M	NULL
,	NULL
Thome	NULL
M	NULL
,	NULL
Hahne	NULL
M	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Inhibition	NULL
of	NULL
death	NULL
receptor	NULL
signals	NULL
by	NULL
cellular	NULL
FLIP	NULL
[	NULL
see	NULL
comments	NULL
]	NULL
.	NULL

Nature	NULL
1997	NULL
;	NULL
888:190-5	NULL
.	NULL

[	NULL
77	NULL
}	NULL
Hu	NULL
S	NULL
,	NULL
Vincenz	NULL
C	NULL
,	NULL
Ni	NULL
J	NULL
,	NULL
Gentz	NULL
R	NULL
,	NULL
Dixit	NULL
VM	NULL
.	NULL

I-FLICE	NULL
,	NULL
a	NULL
novel	NULL
inhibitor	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor-1-	NULL
and	NULL
CD-	NULL
95-induced	NULL
apoptosis	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
1997	NULL
;	NULL
272:17255-7	NULL
.	NULL

[	NULL
78	NULL
]	NULL
Srinivasula	NULL
SM	NULL
,	NULL
Ahmad	NULL
M	NULL
,	NULL
Ottilie	NULL
S	NULL
,	NULL
et	NULL
al	NULL
.	NULL

FLAME-1	NULL
,	NULL
a	NULL
novel	NULL
FADD-like	NULL
anti-apoptotic	NULL
molecule	NULL
that	NULL
regulates	NULL
Fas/TNFR1-induced	NULL
apoptosis	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
1997	NULL
;	NULL
272:18542-5	NULL
.	NULL

[	NULL
79	NULL
]	NULL
Goltsevy	NULL
YV	NULL
,	NULL
Kovalenko	NULL
AV	NULL
,	NULL
Arnold	NULL
E	NULL
,	NULL
Varfolomeev	NULL
EE	NULL
,	NULL
Brodianskii	NULL
VM	NULL
,	NULL
Wallach	NULL
D.	NULL
CASH	NULL
,	NULL
a	NULL
novel	NULL
caspase	NULL
homologue	NULL
with	NULL
death	NULL
effector	NULL
domains	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
1997	NULL
;	NULL
272:19641-4	NULL
.	NULL

[	NULL
80	NULL
]	NULL
Van	NULL
Parijs	NULL
L	NULL
,	NULL
Refaeli	NULL
Y	NULL
,	NULL
Abbas	NULL
AK	NULL
,	NULL
Baltimore	NULL
D.	NULL
Autoimmunity	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
retrovirus-mediated	NULL
expression	NULL
of	NULL
C-FLIP	NULL
in	NULL
lymphocytes	NULL
.	NULL

Immunity	NULL
1999	NULL
;	NULL
11:763-70	NULL
.	NULL

[	NULL
81	NULL
]	NULL
Wang	NULL
J	NULL
,	NULL
Lobito	NULL
AA	NULL
,	NULL
Shen	NULL
F	NULL
,	NULL
Hornung	NULL
F	NULL
,	NULL
Winoto	NULL
A	NULL
,	NULL
Lenardo	NULL
MJ	NULL
.	NULL

Inhibition	NULL
of	NULL
Fas-mediated	NULL
apoptosis	NULL
by	NULL
the	NULL
B	NULL
cell	NULL
antigen	NULL
receptor	NULL
through	NULL
c-FLIP	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
2000	NULL
;	NULL
30:155-63	NULL
.	NULL

[	NULL
82	NULL
]	NULL
Lin	NULL
EY	NULL
,	NULL
Orlofsky	NULL
A	NULL
,	NULL
Berger	NULL
MS	NULL
,	NULL
Prystowsky	NULL
MB	NULL
.	NULL

Characterization	NULL
of	NULL
A1	NULL
,	NULL
a	NULL
novel	NULL
hemopoietic-specific	NULL
early-response	NULL
gene	NULL
with	NULL
sequence	NULL
similarity	NULL
to	NULL
bel-2	NULL
.	NULL

J	NULL
Immunol	NULL
1993	NULL
;	NULL
151:1979-88	NULL
.	NULL

[	NULL
83	NULL
]	NULL
Krikos	NULL
A	NULL
,	NULL
Laherty	NULL
CD	NULL
,	NULL
Dixit	NULL
VM	NULL
.	NULL

Transcriptional	NULL
activation	NULL
of	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
Â«	NULL
-inducible	NULL
zinc	NULL
finger	NULL
protein	NULL
,	NULL
A20	NULL
,	NULL
is	NULL
mediated	NULL
by	NULL
Â«	NULL
B	NULL
elements	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
1992	NULL
;	NULL
267:17971-6	NULL
.	NULL

[	NULL
84	NULL
]	NULL
Takayama	NULL
S	NULL
,	NULL
Sato	NULL
T	NULL
,	NULL
Krajewski	NULL
S	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Cloning	NULL
and	NULL
functional	NULL
analysis	NULL
of	NULL
BAG-1	NULL
:	NULL
a	NULL
novel	NULL
Bel-2-binding	NULL
protein	NULL
with	NULL
anti-cell	NULL
death	NULL
activity	NULL
.	NULL

Cell	NULL
1995	NULL
;	NULL
80:279-84	NULL
.	NULL

[	NULL
85	NULL
]	NULL
Pegoraro	NULL
L	NULL
,	NULL
Palumbo	NULL
A	NULL
,	NULL
Erikson	NULL
J	NULL
,	NULL
et	NULL
al	NULL
.	NULL

A	NULL
14	NULL
;	NULL
18	NULL
and	NULL
an	NULL
8	NULL
;	NULL
14	NULL
chromosome	NULL
translocation	NULL
in	NULL
a	NULL
cell	NULL
line	NULL
derived	NULL
from	NULL
an	NULL
acute	NULL
B-cell	NULL
leukemia	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sei	NULL
USA	NULL
1984	NULL
;	NULL
81:7166-70	NULL
.	NULL

[	NULL
86	NULL
]	NULL
Hockenbery	NULL
D	NULL
,	NULL
Nunez	NULL
G	NULL
,	NULL
Milliman	NULL
C	NULL
,	NULL
Schreiber	NULL
RD	NULL
,	NULL
Korsmeyer	NULL
SJ	NULL
.	NULL

Bel-2	NULL
is	NULL
an	NULL
inner	NULL
mitochondrial	NULL
membrane	NULL
protein	NULL
that	NULL
blocks	NULL
programmed	NULL
cell	NULL
death	NULL
.	NULL

Nature	NULL
1990	NULL
;	NULL
348:334-6	NULL
.	NULL

[	NULL
87	NULL
]	NULL
Rothe	NULL
M	NULL
,	NULL
Pan	NULL
MG	NULL
,	NULL
Henzel	NULL
WJ	NULL
,	NULL
Ayres	NULL
TM	NULL
,	NULL
Goeddel	NULL
DV	NULL
.	NULL

The	NULL
TNFR2-TRAF	NULL
signaling	NULL
complex	NULL
contains	NULL
two	NULL
novel	NULL
proteins	NULL
related	NULL
to	NULL
baculoviral	NULL
inhibitor	NULL
of	NULL
apoptosis	NULL
proteins	NULL
.	NULL

Cell	NULL
1995	NULL
;	NULL
83:1248-52	NULL
.	NULL

[	NULL
88	NULL
]	NULL
Wang	NULL
L	NULL
,	NULL
Miura	NULL
M	NULL
,	NULL
Bergeron	NULL
L	NULL
,	NULL
Zhu	NULL
H	NULL
,	NULL
Yuan	NULL
J.	NULL
Ich-1	NULL
,	NULL
an	NULL
Ice/ced-3-related	NULL
gene	NULL
,	NULL
encodes	NULL
both	NULL
positive	NULL
and	NULL
negative	NULL
regulators	NULL
of	NULL
programmed	NULL
cell	NULL
death	NULL
.	NULL

Cell	NULL
1994	NULL
;	NULL
78:7839-50	NULL
.	NULL

[	NULL
89	NULL
]	NULL
Wu	NULL
MX	NULL
,	NULL
Ao	NULL
Z	NULL
,	NULL
Prasad	NULL
KV	NULL
,	NULL
Wu	NULL
R	NULL
,	NULL
Schlossman	NULL
SF	NULL
.	NULL

IEX-1L	NULL
,	NULL
an	NULL
apoptosis	NULL
inhibitor	NULL
involved	NULL
in	NULL
NF-	NULL
$	NULL
\kappa	NULL
$	NULL
B-mediated	NULL
cell	NULL
survival	NULL
.	NULL

Science	NULL
1998	NULL
;	NULL
281:998-1001	NULL
.	NULL

[	NULL
90	NULL
]	NULL
Ambrosini	NULL
G	NULL
,	NULL
Adida	NULL
C	NULL
,	NULL
Altieri	NULL
DC	NULL
.	NULL

A	NULL
novel	NULL
anti-apoptosis	NULL
gene	NULL
,	NULL
survivin	NULL
,	NULL
expressed	NULL
in	NULL
cancer	NULL
and	NULL
lymphoma	NULL
.	NULL

Nat	NULL
Med	NULL
1997	NULL
;	NULL
8:917-21	NULL
.	NULL

[	NULL
91	NULL
]	NULL
Liang	NULL
P	NULL
,	NULL
Pardee	NULL
AB	NULL
.	NULL

Differential	NULL
display	NULL
of	NULL
eukaryotic	NULL
messenger	NULL
RNA	NULL
by	NULL
means	NULL
of	NULL
the	NULL
polymerase	NULL
chain	NULL
reaction	NULL
[	NULL
see	NULL
comments	NULL
]	NULL
.	NULL

Science	NULL
1992	NULL
;	NULL
257:967-71	NULL
.	NULL

[	NULL
92	NULL
]	NULL
Mizuguchi	NULL
J	NULL
,	NULL
Ji	NULL
YY	NULL
,	NULL
Nakabayaschi	NULL
H	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
activation	NULL
blocks	NULL
anti-IgM-mediated	NULL
signaling	NULL
BAL17	NULL
B	NULL
lymphoma	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
1987	NULL
;	NULL
139:1054-9	NULL
.	NULL

[	NULL
93	NULL
]	NULL
Tewari	NULL
M	NULL
,	NULL
Quan	NULL
LT	NULL
,	NULL
O'Rourke	NULL
K	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Yama/CPP32	NULL
beta	NULL
,	NULL
a	NULL
mammalian	NULL
homolog	NULL
of	NULL
CED-3	NULL
,	NULL
is	NULL
a	NULL
CrmA-inhibitable	NULL
protease	NULL
that	NULL
cleaves	NULL
the	NULL
death	NULL
substrate	NULL
poly	NULL
(	NULL
ADP-ribose	NULL
)	NULL
polymerase	NULL
.	NULL

Cell	NULL
1995	NULL
;	NULL
81:801-9	NULL
.	NULL

[	NULL
94	NULL
]	NULL
Nicholson	NULL
DW	NULL
,	NULL
Ali	NULL
A	NULL
,	NULL
Thornberry	NULL
NA	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Identification	NULL
and	NULL
inhibition	NULL
of	NULL
the	NULL
ICE/CED-3	NULL
protease	NULL
necessary	NULL
for	NULL
mammalian	NULL
apoptosis	NULL
[	NULL
see	NULL
comments	NULL
]	NULL
.	NULL

Nature	NULL
1995	NULL
;	NULL
876:37-43	NULL
.	NULL

[	NULL
95	NULL
]	NULL
Lennon	NULL
G	NULL
,	NULL
Auffray	NULL
C	NULL
,	NULL
Polymeropoulos	NULL
M	NULL
,	NULL
Soares	NULL
MB	NULL
.	NULL

The	NULL
L.M.A.G.E	NULL
.	NULL

Consortium	NULL
:	NULL
an	NULL
integrated	NULL
molecular	NULL
analysis	NULL
of	NULL
genomes	NULL
and	NULL
their	NULL
expression	NULL
.	NULL

Genomics	NULL
1996	NULL
;	NULL
88:151-2	NULL
.	NULL

[	NULL
96	NULL
]	NULL
Zhong	NULL
X	NULL
,	NULL
Schneider	NULL
TJ	NULL
,	NULL
Donohoe	NULL
TJ	NULL
,	NULL
Rothstein	NULL
TL	NULL
.	NULL

A	NULL
novel	NULL
isoform	NULL
of	NULL
Fas	NULL
Apoptosis	NULL
Inhibitory	NULL
Molecule	NULL
(	NULL
FAIM	NULL
)	NULL
--	NULL
cloning	NULL
,	NULL
genomic	NULL
organization	NULL
,	NULL
alternative	NULL
splicing	NULL
and	NULL
restricted	NULL
expression	NULL
.	NULL

Submitted	NULL
2000	NULL
;	NULL
[	NULL
97	NULL
]	NULL
aimondi	NULL
SC	NULL
,	NULL
Dube	NULL
ID	NULL
,	NULL
Valentine	NULL
MB	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Clinicopathologic	NULL
manifestations	NULL
and	NULL
breakpoints	NULL
of	NULL
the	NULL
t	NULL
263	NULL
Inducible	NULL
Fas-resistance	NULL
in	NULL
B	NULL
cells	NULL
(	NULL
8	NULL
;	NULL
5	NULL
)	NULL
in	NULL
patients	NULL
with	NULL
acute	NULL
nonlymphocytic	NULL
leukemia	NULL
.	NULL

Leukemia	NULL
1989	NULL
;	NULL
8:42-7	NULL
.	NULL

[	NULL
98	NULL
]	NULL
Dierlamm	NULL
J	NULL
,	NULL
Rosenberg	NULL
C	NULL
,	NULL
Stul	NULL
M	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Characteristic	NULL
pattern	NULL
of	NULL
chromosomal	NULL
gains	NULL
and	NULL
losses	NULL
in	NULL
marginal	NULL
zone	NULL
B	NULL
cell	NULL
lymphoma	NULL
detected	NULL
by	NULL
comparative	NULL
genomic	NULL
hybridization	NULL
.	NULL

Leukemia	NULL
1997	NULL
;	NULL
11	NULL
:	NULL
747-58	NULL
.	NULL

[	NULL
99	NULL
]	NULL
Petersen	NULL
I	NULL
,	NULL
Bujard	NULL
M	NULL
,	NULL
Petersen	NULL
S	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Patterns	NULL
of	NULL
chromosomal	NULL
imbalances	NULL
in	NULL
adenocarcinoma	NULL
and	NULL
squamous	NULL
cell	NULL
carcinoma	NULL
of	NULL
the	NULL
lung	NULL
.	NULL

Cancer	NULL
Res	NULL
1997	NULL
;	NULL
57:2331-5	NULL
.	NULL

[	NULL
100	NULL
]	NULL
Djerbi	NULL
M	NULL
,	NULL
Screpanti	NULL
V	NULL
,	NULL
Catrina	NULL
AI	NULL
,	NULL
Bogen	NULL
B	NULL
,	NULL
Biberfeld	NULL
P	NULL
,	NULL
Grandien	NULL
A	NULL
.	NULL

The	NULL
inhibitor	NULL
of	NULL
death	NULL
receptor	NULL
signaling	NULL
,	NULL
FLICE-inhibitory	NULL
protein	NULL
defines	NULL
a	NULL
new	NULL
class	NULL
of	NULL
tumor	NULL
progression	NULL
factors	NULL
[	NULL
see	NULL
comments	NULL
]	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1999	NULL
;	NULL
190:1025-32	NULL
.	NULL

[	NULL
101	NULL
]	NULL
Medema	NULL
JP	NULL
,	NULL
de	NULL
Jong	NULL
J	NULL
,	NULL
van	NULL
Hall	NULL
T	NULL
,	NULL
Melief	NULL
CJ	NULL
,	NULL
Offringa	NULL
R.	NULL
Immune	NULL
escape	NULL
of	NULL
tumors	NULL
in	NULL
vivo	NULL
by	NULL
expression	NULL
of	NULL
cellular	NULL
FLICE-	NULL
inhibitory	NULL
protein	NULL
[	NULL
see	NULL
comments	NULL
]	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1999	NULL
;	NULL
190:1033-8	NULL
.	NULL

[	NULL
102	NULL
]	NULL
Balvay	NULL
L	NULL
,	NULL
Libri	NULL
D	NULL
,	NULL
Fiszman	NULL
MY	NULL
.	NULL

Pre-mRNA	NULL
secondary	NULL
structure	NULL
and	NULL
the	NULL
regulation	NULL
of	NULL
splicing	NULL
.	NULL

Bioessays	NULL
1993	NULL
;	NULL
15:165-9	NULL
.	NULL

[	NULL
103	NULL
]	NULL
Cavalier-Smith	NULL
T.	NULL
Intron	NULL
phylogeny	NULL
:	NULL
a	NULL
new	NULL
hypothesis	NULL
.	NULL

Trends	NULL
Genet	NULL
1991	NULL
;	NULL
7:145-8	NULL
.	NULL

[	NULL
104	NULL
]	NULL
Palmer	NULL
JD	NULL
,	NULL
Logsdon	NULL
JM	NULL
,	NULL
Jr	NULL
.	NULL

The	NULL
recent	NULL
origins	NULL
of	NULL
introns	NULL
.	NULL

Curr	NULL
Opin	NULL
Genet	NULL
Dev	NULL
1991	NULL
;	NULL
1:470-7	NULL
.	NULL

[	NULL
105	NULL
]	NULL
Lomedico	NULL
P	NULL
,	NULL
Rosenthal	NULL
N	NULL
,	NULL
Efstratidadis	NULL
A	NULL
,	NULL
Gilbert	NULL
W	NULL
,	NULL
Kolodner	NULL
R	NULL
,	NULL
Tizard	NULL
R.	NULL
The	NULL
structure	NULL
and	NULL
evolution	NULL
of	NULL
the	NULL
two	NULL
nonallelic	NULL
rat	NULL
preproinsulin	NULL
genes	NULL
.	NULL

Cell	NULL
1979	NULL
;	NULL
18:545-58	NULL
.	NULL

[	NULL
106	NULL
]	NULL
Li	NULL
WH	NULL
,	NULL
Tanimura	NULL
M	NULL
,	NULL
Luo	NULL
CC	NULL
,	NULL
Datta	NULL
S	NULL
,	NULL
Chan	NULL
L.	NULL
The	NULL
apolipoprotein	NULL
multigene	NULL
family	NULL
:	NULL
biosynthesis	NULL
,	NULL
structure	NULL
,	NULL
structure-function	NULL
relationships	NULL
,	NULL
and	NULL
evolution	NULL
.	NULL

J	NULL
Lipid	NULL
Res	NULL
1988	NULL
;	NULL
29:245-71	NULL
.	NULL

[	NULL
107	NULL
]	NULL
Frugoli	NULL
JA	NULL
,	NULL
McPeek	NULL
MA	NULL
,	NULL
Thomas	NULL
TL	NULL
,	NULL
McClung	NULL
CR	NULL
.	NULL

Intron	NULL
loss	NULL
and	NULL
gain	NULL
during	NULL
evolution	NULL
of	NULL
the	NULL
catalase	NULL
gene	NULL
family	NULL
in	NULL
angiosperms	NULL
.	NULL

Genetics	NULL
1998	NULL
;	NULL
149:355-65	NULL
.	NULL

[	NULL
108	NULL
]	NULL
Lane	NULL
P	NULL
,	NULL
Traunecker	NULL
A	NULL
,	NULL
Hubele	NULL
S	NULL
,	NULL
Inui	NULL
S	NULL
,	NULL
Lanzavecchia	NULL
A	NULL
,	NULL
Gray	NULL
D.	NULL
Activated	NULL
human	NULL
T	NULL
cells	NULL
expre	NULL
ss	NULL
a	NULL
ligand	NULL
for	NULL
the	NULL
human	NULL
B	NULL
cell-	NULL
associated	NULL
antigen	NULL
CD40	NULL
which	NULL
participates	NULL
in	NULL
T	NULL
cell-	NULL
dependent	NULL
activation	NULL
of	NULL
B	NULL
lymphocytes	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
1992	NULL
;	NULL
22:2573-8	NULL
.	NULL

[	NULL
109	NULL
]	NULL
Noelle	NULL
RJ	NULL
,	NULL
Roy	NULL
M	NULL
,	NULL
Shepherd	NULL
DM	NULL
,	NULL
Stamenkovie	NULL
I	NULL
,	NULL
Ledbetter	NULL
JA	NULL
,	NULL
Aruffo	NULL
A	NULL
.	NULL

A	NULL
39-	NULL
kDa	NULL
protein	NULL
on	NULL
activated	NULL
helper	NULL
T	NULL
cells	NULL
binds	NULL
CD40	NULL
and	NULL
transduces	NULL
the	NULL
signal	NULL
for	NULL
cognate	NULL
activation	NULL
of	NULL
B	NULL
cells	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
1992	NULL
;	NULL
89:6550-4	NULL
.	NULL

[	NULL
110	NULL
]	NULL
Armitage	NULL
RJ	NULL
,	NULL
Fanslow	NULL
WC	NULL
,	NULL
Strockbine	NULL
L	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Molecular	NULL
and	NULL
biological	NULL
characterization	NULL
of	NULL
a	NULL
murine	NULL
ligand	NULL
for	NULL
CD40	NULL
.	NULL

Nature	NULL
1992	NULL
;	NULL
357:80-2	NULL
.	NULL

[	NULL
111	NULL
]	NULL
Ju	NULL
ST	NULL
,	NULL
Panka	NULL
DJ	NULL
,	NULL
Cui	NULL
H	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Fas	NULL
(	NULL
CD95	NULL
)	NULL
/FasL	NULL
interactions	NULL
required	NULL
for	NULL
programmed	NULL
cell	NULL
death	NULL
after	NULL
T-cell	NULL
activation	NULL
[	NULL
see	NULL
comments	NULL
]	NULL
.	NULL

Nature	NULL
1995	NULL
;	NULL
878:444-8	NULL
.	NULL

[	NULL
112	NULL
]	NULL
Brunner	NULL
T	NULL
,	NULL
Mogil	NULL
RJ	NULL
,	NULL
LaFace	NULL
D	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Cell-autonomous	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
/Fas-ligand	NULL
interaction	NULL
mediates	NULL
activation-induced	NULL
apoptosis	NULL
in	NULL
T-cell	NULL
hybridomas	NULL
[	NULL
see	NULL
comments	NULL
]	NULL
.	NULL

Nature	NULL
1995	NULL
;	NULL
878:441-4	NULL
.	NULL

[	NULL
113	NULL
]	NULL
Dhein	NULL
J	NULL
,	NULL
Walczak	NULL
H	NULL
,	NULL
Baumler	NULL
C	NULL
,	NULL
Debatin	NULL
KM	NULL
,	NULL
Krammer	NULL
PH	NULL
.	NULL

Autocrine	NULL
T-cell	NULL
suicide	NULL
mediated	NULL
by	NULL
APO-1/	NULL
(	NULL
Fas/CD95	NULL
)	NULL
[	NULL
see	NULL
comments	NULL
]	NULL
.	NULL

Nature	NULL
1995	NULL
;	NULL
873:4838-41	NULL
.	NULL

[	NULL
114	NULL
]	NULL
Alderson	NULL
MR	NULL
,	NULL
Tough	NULL
TW	NULL
,	NULL
Davis-Smith	NULL
T	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Fas	NULL
ligand	NULL
mediates	NULL
activation-induced	NULL
cell	NULL
death	NULL
in	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1995	NULL
;	NULL
181:71-7	NULL
.	NULL

[	NULL
115	NULL
]	NULL
Ozdemirli	NULL
M	NULL
,	NULL
El-Khatib	NULL
M	NULL
,	NULL
Foote	NULL
LC	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Fas	NULL
(	NULL
CD95	NULL
)	NULL
/Fas	NULL
ligand	NULL
interactions	NULL
regulate	NULL
antigen-specific	NULL
,	NULL
major	NULL
histocompatibility	NULL
complex-restricted	NULL
T/B	NULL
cell	NULL
proliferative	NULL
responses	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
1996	NULL
;	NULL
26:415-9	NULL
.	NULL

[	NULL
116	NULL
]	NULL
Wang	NULL
JKM	NULL
,	NULL
Ju	NULL
ST	NULL
,	NULL
Marshak-Rothstein	NULL
A	NULL
.	NULL

Protection	NULL
of	NULL
T	NULL
cells	NULL
from	NULL
activation-induced	NULL
cell	NULL
death	NULL
by	NULL
Fas+	NULL
B	NULL
cells	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
2000	NULL
;	NULL
in	NULL
press	NULL
.	NULL

[	NULL
117	NULL
]	NULL
Shlomchik	NULL
MJ	NULL
,	NULL
Marshak-Rothstein	NULL
A	NULL
,	NULL
Wolfowiecz	NULL
CB	NULL
,	NULL
Rothstein	NULL
TL	NULL
,	NULL
Weigert	NULL
MG	NULL
.	NULL

The	NULL
role	NULL
of	NULL
clonal	NULL
selection	NULL
and	NULL
somatic	NULL
mutation	NULL
in	NULL
autoimmunity	NULL
.	NULL

Nature	NULL
1987	NULL
;	NULL
828:805-11	NULL
.	NULL

[	NULL
118	NULL
]	NULL
Wolfowicz	NULL
CB	NULL
,	NULL
Sakorafas	NULL
P	NULL
,	NULL
Rothstein	NULL
TL	NULL
,	NULL
Marshak-Rothstein	NULL
A.	NULL
Oligoclonality	NULL
of	NULL
rheumatoid	NULL
factors	NULL
arising	NULL
spontaneously	NULL
in	NULL
lor/	NULL
Ipr	NULL
mice	NULL
.	NULL

Clin	NULL
Immunol	NULL
Immunopathol	NULL
1988	NULL
;	NULL
46:382-95	NULL
.	NULL

[	NULL
119	NULL
]	NULL
Shlomchik	NULL
M	NULL
,	NULL
Mascelli	NULL
M	NULL
,	NULL
Shan	NULL
H	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Anti-DNA	NULL
antibodies	NULL
from	NULL
autoimmune	NULL
mice	NULL
arise	NULL
by	NULL
clonal	NULL
expansion	NULL
and	NULL
somatic	NULL
mutation	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1990	NULL
;	NULL
171:265-92	NULL
.	NULL

[	NULL
120	NULL
]	NULL
Rathmell	NULL
JC	NULL
,	NULL
Cooke	NULL
MP	NULL
,	NULL
Ho	NULL
WY	NULL
,	NULL
et	NULL
al	NULL
.	NULL

CD95	NULL
(	NULL
Fas	NULL
)	NULL
-dependent	NULL
elimination	NULL
of	NULL
self-reactive	NULL
B	NULL
cells	NULL
upon	NULL
264	NULL
Rothstein	NULL
TL	NULL
interaction	NULL
with	NULL
CD4+	NULL
T	NULL
cells	NULL
.	NULL

Nature	NULL
1995	NULL
;	NULL
876:181-4	NULL
.	NULL

[	NULL
121	NULL
]	NULL
Wang	NULL
H	NULL
,	NULL
Shlomchik	NULL
MJ	NULL
.	NULL

Autoantigen-specific	NULL
B	NULL
cell	NULL
activation	NULL
in	NULL
Fas-deficient	NULL
rheumatoid	NULL
factor	NULL
immunoglobulin	NULL
transgenic	NULL
mice	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1999	NULL
;	NULL
190:639-49	NULL
.	NULL

[	NULL
122	NULL
]	NULL
Cooke	NULL
MP	NULL
,	NULL
Heath	NULL
AW	NULL
,	NULL
Shokat	NULL
KM	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Immunoglobulin	NULL
signal	NULL
transduction	NULL
guides	NULL
the	NULL
specificity	NULL
of	NULL
B	NULL
cell-T	NULL
cell	NULL
interactions	NULL
and	NULL
is	NULL
blocked	NULL
in	NULL
tolerant	NULL
self-reactive	NULL
B	NULL
cells	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1994	NULL
;	NULL
179:425-38	NULL
.	NULL

[	NULL
123	NULL
]	NULL
Eris	NULL
JM	NULL
,	NULL
Basten	NULL
A	NULL
,	NULL
Brink	NULL
R	NULL
,	NULL
Doherty	NULL
K	NULL
,	NULL
Kehry	NULL
MR	NULL
,	NULL
Hodgkin	NULL
PD	NULL
.	NULL

Anergic	NULL
self-reactive	NULL
B	NULL
cells	NULL
present	NULL
self	NULL
antigen	NULL
and	NULL
respond	NULL
normally	NULL
to	NULL
CD40-dependent	NULL
T-cell	NULL
signals	NULL
but	NULL
are	NULL
defective	NULL
in	NULL
antigen-receptor-mediated	NULL
functions	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
1994	NULL
;	NULL
91:48392-6	NULL
.	NULL

[	NULL
124	NULL
]	NULL
Ho	NULL
WY	NULL
,	NULL
Cooke	NULL
MP	NULL
,	NULL
Goodnow	NULL
CC	NULL
,	NULL
Davis	NULL
MM	NULL
.	NULL

Resting	NULL
and	NULL
anergic	NULL
B	NULL
cells	NULL
are	NULL
defective	NULL
in	NULL
CD28-dependent	NULL
costimulation	NULL
of	NULL
naive	NULL
CD4+	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1994	NULL
;	NULL
179:1539-49	NULL
.	NULL

[	NULL
125	NULL
]	NULL
Burstein	NULL
HJ	NULL
,	NULL
Tepper	NULL
RI	NULL
,	NULL
Leder	NULL
P	NULL
,	NULL
Abbas	NULL
AK	NULL
.	NULL

Humoral	NULL
immune	NULL
functions	NULL
in	NULL
IL-4	NULL
transgenic	NULL
mice	NULL
.	NULL

J	NULL
Immunol	NULL
1991	NULL
;	NULL
147:2950-6	NULL
.	NULL

[	NULL
126	NULL
]	NULL
Erb	NULL
KJ	NULL
,	NULL
Ruger	NULL
B	NULL
,	NULL
von	NULL
Brevern	NULL
M	NULL
,	NULL
Ryffel	NULL
B	NULL
,	NULL
Schimpl	NULL
A	NULL
,	NULL
Rivett	NULL
K.	NULL
Constitutive	NULL
expression	NULL
of	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-4	NULL
{	NULL
\sl	NULL
in	NULL
vivo	NULL
}	NULL
causes	NULL
autoimmune-	NULL
type	NULL
disorders	NULL
in	NULL
mice	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1997	NULL
;	NULL
185:329-39	NULL
.	NULL

[	NULL
127	NULL
]	NULL
Rathmell	NULL
JC	NULL
,	NULL
Fournier	NULL
S	NULL
,	NULL
Weintraub	NULL
BC	NULL
,	NULL
Allison	NULL
JP	NULL
,	NULL
Goodnow	NULL
CC	NULL
.	NULL

Repression	NULL
of	NULL
B7.2	NULL
on	NULL
self-reactive	NULL
B	NULL
cells	NULL
is	NULL
essential	NULL
to	NULL
prevent	NULL
proliferation	NULL
and	NULL
allow	NULL
Fas-mediated	NULL
deletion	NULL
by	NULL
CD4	NULL
(	NULL
+	NULL
)	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1998	NULL
;	NULL
188:651-9	NULL
.	NULL

[	NULL
128	NULL
]	NULL
DiPiro	NULL
JT	NULL
,	NULL
Howdieshell	NULL
TR	NULL
,	NULL
Goddard	NULL
JK	NULL
,	NULL
Callaway	NULL
DB	NULL
,	NULL
Hamilton	NULL
RG	NULL
,	NULL
Mansberger	NULL
AR	NULL
,	NULL
Jr.	NULL
Association	NULL
of	NULL
interleukin-4	NULL
plasma	NULL
levels	NULL
with	NULL
traumatic	NULL
injury	NULL
and	NULL
clinical	NULL
course	NULL
.	NULL

Arch	NULL
Surg	NULL
1995	NULL
;	NULL
180:1159-62	NULL
;	NULL
discussion	NULL
1162-3	NULL
.	NULL

[	NULL
129	NULL
]	NULL
Klas	NULL
C	NULL
,	NULL
Debatin	NULL
KM	NULL
,	NULL
Jonker	NULL
RR	NULL
,	NULL
Krammer	NULL
PH	NULL
.	NULL

Activation	NULL
interferes	NULL
with	NULL
the	NULL
APO-1	NULL
pathway	NULL
in	NULL
mature	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

Int	NULL
Immunol	NULL
1993	NULL
;	NULL
5:625-30	NULL
.	NULL

[	NULL
130	NULL
]	NULL
Refaeli	NULL
Y	NULL
,	NULL
Van	NULL
Parijs	NULL
L	NULL
,	NULL
London	NULL
CA	NULL
,	NULL
Tschopp	NULL
J	NULL
,	NULL
Abbas	NULL
AK	NULL
.	NULL

Biochemical	NULL
mechanisms	NULL
of	NULL
IL-2-regulated	NULL
Fas-mediated	NULL
T	NULL
cell	NULL
apoptosis	NULL
.	NULL

Immunity	NULL
1998	NULL
;	NULL
8:615-23	NULL
.	NULL

[	NULL
131	NULL
]	NULL
Broome	NULL
HE	NULL
,	NULL
Dargan	NULL
CM	NULL
,	NULL
Krajewski	NULL
S	NULL
,	NULL
Reed	NULL
JC	NULL
.	NULL

Expression	NULL
of	NULL
Bel-2	NULL
,	NULL
Bel-x	NULL
,	NULL
and	NULL
Bax	NULL
after	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
IL-2	NULL
withdrawal	NULL
.	NULL

J	NULL
Immunol	NULL
1995	NULL
;	NULL
155:2311-7	NULL
.	NULL

[	NULL
132	NULL
]	NULL
Peter	NULL
ME	NULL
,	NULL
Kischkel	NULL
FC	NULL
,	NULL
Scheuerpflug	NULL
CG	NULL
,	NULL
Medema	NULL
JP	NULL
,	NULL
Debatin	NULL
KM	NULL
,	NULL
Krammer	NULL
PH	NULL
.	NULL

Resistance	NULL
of	NULL
cultured	NULL
peripheral	NULL
T	NULL
cells	NULL
towards	NULL
activation-induced	NULL
cell	NULL
death	NULL
involves	NULL
a	NULL
lack	NULL
of	NULL
recruitment	NULL
of	NULL
FLICE	NULL
(	NULL
MACH/caspase	NULL
8	NULL
)	NULL
to	NULL
the	NULL
CD95	NULL
death-inducing	NULL
signaling	NULL
complex	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
1997	NULL
;	NULL
27	NULL
:	NULL
1207-12	NULL
.	NULL

[	NULL
133	NULL
]	NULL
Scaffidi	NULL
C	NULL
,	NULL
Schmitz	NULL
I	NULL
,	NULL
Krammer	NULL
PH	NULL
,	NULL
Peter	NULL
ME	NULL
.	NULL

The	NULL
role	NULL
of	NULL
c-FLIP	NULL
in	NULL
modulation	NULL
of	NULL
CD95-induced	NULL
apoptosis	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
1999	NULL
;	NULL
274:1541-8	NULL
.	NULL

[	NULL
134	NULL
]	NULL
Miethke	NULL
T	NULL
,	NULL
Vabulas	NULL
R	NULL
,	NULL
Bittlingmaier	NULL
R	NULL
,	NULL
Heeg	NULL
K	NULL
,	NULL
Wagner	NULL
H.	NULL
Mechanisms	NULL
of	NULL
peripheral	NULL
T	NULL
cell	NULL
deletion	NULL
:	NULL
anergized	NULL
T	NULL
cells	NULL
are	NULL
Fas	NULL
resistant	NULL
but	NULL
undergo	NULL
proliferation-associated	NULL
apoptosis	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
1996	NULL
;	NULL
26:1459-67	NULL
.	NULL

[	NULL
135	NULL
]	NULL
Boussiotis	NULL
VA	NULL
,	NULL
Lee	NULL
BJ	NULL
,	NULL
Freeman	NULL
GJ	NULL
,	NULL
Gribben	NULL
JG	NULL
,	NULL
Nadler	NULL
LM	NULL
.	NULL

Induction	NULL
of	NULL
T	NULL
cell	NULL
clonal	NULL
anergy	NULL
results	NULL
in	NULL
resistance	NULL
,	NULL
whereas	NULL
CD28-	NULL
mediated	NULL
costimulation	NULL
primes	NULL
for	NULL
susceptibility	NULL
to	NULL
Fas-	NULL
and	NULL
Bax-mediated	NULL
programmed	NULL
cell	NULL
death	NULL
.	NULL

J	NULL
Immunol	NULL
1997	NULL
;	NULL
159:3156-67	NULL
.	NULL

[	NULL
136	NULL
]	NULL
Zhang	NULL
X	NULL
,	NULL
Brunner	NULL
T	NULL
,	NULL
Carter	NULL
L	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Unequal	NULL
death	NULL
in	NULL
T	NULL
helper	NULL
cell	NULL
(	NULL
Th	NULL
)	NULL
1	NULL
and	NULL
Th2	NULL
effectors	NULL
:	NULL
Th1	NULL
,	NULL
but	NULL
not	NULL
Th2	NULL
,	NULL
effectors	NULL
undergo	NULL
rapid	NULL
Fas/FasL-mediated	NULL
apoptosis	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1997	NULL
;	NULL
185:1837-49	NULL
.	NULL

[	NULL
137	NULL
]	NULL
Varadhachary	NULL
AS	NULL
,	NULL
Perdow	NULL
SN	NULL
,	NULL
Hu	NULL
C	NULL
,	NULL
Ramanarayanan	NULL
M	NULL
,	NULL
Salgame	NULL
P.	NULL
Differential	NULL
ability	NULL
of	NULL
T	NULL
cell	NULL
subsets	NULL
to	NULL
undergo	NULL
activation-induced	NULL
cell	NULL
death	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
1997	NULL
;	NULL
94:5778-83	NULL
.	NULL

[	NULL
138	NULL
]	NULL
Di	NULL
Somma	NULL
MM	NULL
,	NULL
Somma	NULL
F	NULL
,	NULL
Montani	NULL
MS	NULL
,	NULL
Mangiacasale	NULL
R	NULL
,	NULL
Cundari	NULL
E	NULL
,	NULL
Piccolella	NULL
E.	NULL
TCR	NULL
engagement	NULL
regulates	NULL
differential	NULL
responsiveness	NULL
of	NULL
human	NULL
memory	NULL
T	NULL
cells	NULL
to	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
-mediated	NULL
apoptosis	NULL
.	NULL

J	NULL
Immunol	NULL
1999	NULL
;	NULL
162:3851-8	NULL
.	NULL

[	NULL
139	NULL
]	NULL
Inaba	NULL
M	NULL
,	NULL
Kurasawa	NULL
K	NULL
,	NULL
Mamura	NULL
M	NULL
,	NULL
Kumano	NULL
K	NULL
,	NULL
Saito	NULL
Y	NULL
,	NULL
Iwamoto	NULL
I.	NULL
Primed	NULL
T	NULL
cells	NULL
are	NULL
more	NULL
resistant	NULL
to	NULL
Fas-mediated	NULL
activation-induced	NULL
cell	NULL
death	NULL
than	NULL
naive	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
1999	NULL
;	NULL
163:1315-20	NULL
.	NULL

[	NULL
140	NULL
]	NULL
Panayiotidis	NULL
P	NULL
,	NULL
Ganeshaguru	NULL
K	NULL
,	NULL
Foroni	NULL
L	NULL
,	NULL
Hoffbrand	NULL
AV	NULL
.	NULL

Expression	NULL
and	NULL
function	NULL
of	NULL
the	NULL
FAS	NULL
antigen	NULL
265	NULL
Inducible	NULL
Fas-resistance	NULL
in	NULL
B	NULL
cells	NULL
in	NULL
B	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
and	NULL
hairy	NULL
cell	NULL
leukemia	NULL
.	NULL

Leukemia	NULL
1995	NULL
;	NULL
9:1227-32	NULL
.	NULL

[	NULL
141	NULL
]	NULL
Xerri	NULL
L	NULL
,	NULL
Devilard	NULL
E	NULL
,	NULL
Hassoun	NULL
J	NULL
,	NULL
Haddad	NULL
P	NULL
,	NULL
Birg	NULL
F.	NULL
Malignant	NULL
and	NULL
reactive	NULL
cells	NULL
from	NULL
human	NULL
lymphomas	NULL
frequently	NULL
express	NULL
Fas	NULL
ligand	NULL
but	NULL
display	NULL
a	NULL
different	NULL
sensitivity	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
.	NULL

Leukemia	NULL
1997	NULL
;	NULL
11:1868-77	NULL
.	NULL

[	NULL
142	NULL
]	NULL
Plumas	NULL
J	NULL
,	NULL
Jacob	NULL
MC	NULL
,	NULL
Chaperot	NULL
L	NULL
,	NULL
Molens	NULL
JP	NULL
,	NULL
Sotto	NULL
JJ	NULL
,	NULL
Bensa	NULL
JC	NULL
.	NULL

Tumor	NULL
B	NULL
cells	NULL
from	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
are	NULL
resistant	NULL
to	NULL
CD95	NULL
(	NULL
Fas/Apo-1	NULL
)	NULL
-mediated	NULL
apoptosis	NULL
.	NULL

Blood	NULL
1998	NULL
;	NULL
91:2875-85	NULL
.	NULL

[	NULL
143	NULL
]	NULL
Xerri	NULL
L	NULL
,	NULL
Devilard	NULL
E	NULL
,	NULL
Bouabdallah	NULL
R	NULL
,	NULL
Stoppa	NULL
AM	NULL
,	NULL
Hassoun	NULL
J	NULL
,	NULL
Birg	NULL
F.	NULL
FADD	NULL
expression	NULL
and	NULL
caspase	NULL
activation	NULL
in	NULL
B-cell	NULL
lymphomas	NULL
resistant	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
1999	NULL
;	NULL
106:652-61	NULL
.	NULL

[	NULL
144	NULL
]	NULL
Owen-Schaub	NULL
LB	NULL
,	NULL
Radinsky	NULL
R	NULL
,	NULL
Kruzel	NULL
E	NULL
,	NULL
Berry	NULL
K	NULL
,	NULL
Yonehara	NULL
S.	NULL
Anti-Fas	NULL
on	NULL
nonhematopoietic	NULL
tumors	NULL
:	NULL
levels	NULL
of	NULL
Fas/APO-1	NULL
and	NULL
bel-2	NULL
are	NULL
not	NULL
predictive	NULL
of	NULL
biological	NULL
responsiveness	NULL
.	NULL

Cancer	NULL
Res	NULL
1994	NULL
;	NULL
54	NULL
:	NULL
1580-6	NULL
.	NULL

[	NULL
145	NULL
]	NULL
Natoli	NULL
G	NULL
,	NULL
Ianni	NULL
A	NULL
,	NULL
Costanzo	NULL
A	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Resistance	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
in	NULL
human	NULL
hepatoma	NULL
cells	NULL
.	NULL

Oncogene	NULL
1995	NULL
;	NULL
11:1157-64	NULL
.	NULL

[	NULL
146	NULL
]	NULL
Keane	NULL
MM	NULL
,	NULL
Ettenberg	NULL
SA	NULL
,	NULL
Lowrey	NULL
GA	NULL
,	NULL
Russell	NULL
EK	NULL
,	NULL
Lipkowitz	NULL
S.	NULL
Fas	NULL
expression	NULL
and	NULL
function	NULL
in	NULL
normal	NULL
and	NULL
malignant	NULL
breast	NULL
cell	NULL
lines	NULL
.	NULL

Cancer	NULL
Res	NULL
1996	NULL
;	NULL
56:4791-8	NULL
.	NULL

[	NULL
147	NULL
]	NULL
Ungefroren	NULL
H	NULL
,	NULL
Voss	NULL
M	NULL
,	NULL
Jansen	NULL
M	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Human	NULL
pancreatic	NULL
adenocarcinomas	NULL
express	NULL
Fas	NULL
and	NULL
Fas	NULL
ligand	NULL
yet	NULL
are	NULL
resistant	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
.	NULL

Cancer	NULL
Res	NULL
1998	NULL
;	NULL
58:1741-9	NULL
.	NULL

[	NULL
148	NULL
]	NULL
Hedlund	NULL
TE	NULL
,	NULL
Duke	NULL
RC	NULL
,	NULL
Schleicher	NULL
MS	NULL
,	NULL
Miller	NULL
GJ	NULL
.	NULL

Fas-mediated	NULL
apoptosis	NULL
in	NULL
seven	NULL
human	NULL
prostate	NULL
cancer	NULL
cell	NULL
lines	NULL
:	NULL
correlation	NULL
with	NULL
tumor	NULL
stage	NULL
.	NULL

Prostate	NULL
1998	NULL
;	NULL
36:92-101	NULL
.	NULL

[	NULL
149	NULL
]	NULL
Baldwin	NULL
RL	NULL
,	NULL
Tran	NULL
H	NULL
,	NULL
Karlan	NULL
BY	NULL
.	NULL

Primary	NULL
ovarian	NULL
cancer	NULL
cultures	NULL
are	NULL
resistant	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
.	NULL

Gynecol	NULL
Oncol	NULL
1999	NULL
;	NULL
74:265-71	NULL
.	NULL

[	NULL
150	NULL
]	NULL
Peng	NULL
SL	NULL
,	NULL
Robert	NULL
ME	NULL
,	NULL
Hayday	NULL
AC	NULL
,	NULL
Craft	NULL
J	NULL
.	NULL

A	NULL
tumor-suppressor	NULL
function	NULL
for	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
revealed	NULL
in	NULL
T	NULL
cell-deficient	NULL
mice	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1996	NULL
;	NULL
184:1149-54	NULL
.	NULL

[	NULL
151	NULL
]	NULL
Traver	NULL
D	NULL
,	NULL
Akashi	NULL
K	NULL
,	NULL
Weissman	NULL
IL	NULL
,	NULL
Lagasse	NULL
E.	NULL
Mice	NULL
defective	NULL
in	NULL
two	NULL
apoptosis	NULL
pathways	NULL
in	NULL
the	NULL
myeloid	NULL
lineage	NULL
develop	NULL
acute	NULL
myeloblastic	NULL
leukemia	NULL
.	NULL

Immunity	NULL
1998	NULL
;	NULL
9:47-57	NULL
.	NULL

[	NULL
152	NULL
]	NULL
Davidson	NULL
WF	NULL
,	NULL
Giese	NULL
T	NULL
,	NULL
Fredrickson	NULL
TN	NULL
.	NULL

Spontaneous	NULL
development	NULL
of	NULL
plasmacytoid	NULL
tumors	NULL
in	NULL
mice	NULL
with	NULL
defective	NULL
Fas-Fas	NULL
ligand	NULL
interactions	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1998	NULL
;	NULL
187:1825-38	NULL
.	NULL

[	NULL
153	NULL
]	NULL
Owen-Schaub	NULL
LB	NULL
,	NULL
van	NULL
Golen	NULL
KL	NULL
,	NULL
Hill	NULL
LL	NULL
,	NULL
Price	NULL
JE	NULL
.	NULL

Fas	NULL
and	NULL
Fas	NULL
ligand	NULL
interactions	NULL
suppress	NULL
melanoma	NULL
lung	NULL
metastasis	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1998	NULL
;	NULL
188:1717-23	NULL
.	NULL

[	NULL
154	NULL
]	NULL
Furman	NULL
RR	NULL
,	NULL
Asgary	NULL
Z	NULL
,	NULL
Mascarenhas	NULL
JO	NULL
,	NULL
Liou	NULL
HC	NULL
,	NULL
Schattner	NULL
EJ	NULL
.	NULL

Modulation	NULL
of	NULL
NF-	NULL
Â®	NULL
B	NULL
activity	NULL
and	NULL
apoptosis	NULL
in	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
B	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
2000	NULL
;	NULL
164:2200-6	NULL
.	NULL

[	NULL
155	NULL
]	NULL
Ugurel	NULL
S	NULL
,	NULL
Seiter	NULL
S	NULL
,	NULL
Rappl	NULL
G	NULL
,	NULL
Stark	NULL
A	NULL
,	NULL
Tilgen	NULL
W	NULL
,	NULL
Reinhold	NULL
U.	NULL
Heterogenous	NULL
susceptibility	NULL
to	NULL
CD95-induced	NULL
apoptosis	NULL
in	NULL
melanoma	NULL
cells	NULL
correlates	NULL
with	NULL
bel-2	NULL
and	NULL
bel-x	NULL
expression	NULL
and	NULL
is	NULL
sensitive	NULL
to	NULL
modulation	NULL
by	NULL
interferon-	NULL
v.	NULL
Int	NULL
J	NULL
Cancer	NULL
1999	NULL
;	NULL
82:727-36	NULL
.	NULL

266	NULL

